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ABSTRACT
INTRODUCTION: The burden of Sickle Cell Disease (SCD) in Africa is high; having over
75% of annual global births and mortality reaching 95% in childhood. Introduction of
interventions, which could prevent 70010 of deaths, have been limited because of lack of local
evidence. This study described the clinical spectrum of SCD in Tanzania as the first step in
providing evidence to guide targeted interventions.
METHODS: SCD patients attending Muhimbili Hospital in Dar-es-Salaam, Tanzania were
recruited between 2004 and 2009. Prospective surveillance of clinical and laboratory
information was done at outpatient clinic and during hospitalisation. Specific investigations
included blood cultures on all hospitalised SCD patients, Transcranial Doppler (TCD)
ultrasonography to measure cerebral blood flow velocity (CBFv) and HPLC to measure
levels of foetal haemoglobin (HbF). The outcomes of interest were death, hospitalisation,
malaria, bacteraemia and stroke.
RESULTS: 1,725 SCD patients [mean age 9.7 (SD 7.9) years; 10% below 2 years] were
enrolled with information recorded from 14,000 visits during the study period. 12% of
enrolled SCD patients were lost to follow up and 23% of 86 deaths occurred at the hospital.
'The mortality was 2 deaths/100 person years of observation (pYO); highest under 5 years and
independently associated with low haemoglobin (Hazard ratio 0.7 95%CI 0.6-0.8; p<O.Ol).
504 (29%) of the SCD cohort were hospitalised with pain, fever and anaemia as the
commonest cause of hospitalisation. SCD patients had less malaria than non-SCD patients at
clinic (OR, 0.46; 95% Cl, 0.25-0.94; P = .01) and during hospitalisation (OR, 0.53; 95% Cl,
0.32-0.86; P = .(08). In SCD patients, prevalence of malaria was higher during hospitalisation
and associated with severe anaemia and death. 43 out of 890 hospitalisations had
bacteraemia (4.8%) with Staphylococcus aureus (28%), non-typhii Salmonella (21%) and
Streptococcus pneumoniae (7%) as the most common organisms. The mean CBFv in 372
patients (2 - 16 years) was 132 ern/sec with CBFv > 200crn/sec occurring in 40 (10%)
patients. The incidence of stroke was 0.3 per l00PYO; associated with sickle haemoglobin
and reticulocyte count but not with CBFv. The mean HbF level in 1,669 SCD patients was
6.3 (SD 4.7) % with no association with mortality and hospitalisation.
CONCLUSION: This study has highlighted the burden of disease to individuals and health
system. The findings have important implications for policies to improve healthcare as well
as identifying areas for further research.
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Chapter One
Introduction
INTRODUCTION
Sickle Cell Disease (SCD) is the single most important genetic cause of childhood mortality
world-wide. InMay 2006 at the 59th World Health Assembly (WHA), resolution WHA 59.20
of the World Health Organisation (WHO) was to develop, implement and reinforce integrated
national programs for the prevention and management of Sickle Cell Disease (SCD)I.
Approximately 300,000 children are born every year with SCD in the world, with over 75%
in Africa''. In Tanzania, a low income country (LIe) in Africa, SCD is of public health
significance as the prevalence of the carrier state ranges between 15 - 20%,3 which is
amongst the highest in Africa. The estimated birth incidence of children with homozygous SS
SCD in Tanzania is between 6 to 7 per 1000 children". The majority of these children will
not know that they have SeD and it is estimated that over 5% of infant mortality may be
attributable to SCD5• Although there is a wide variation in the severity of disease in affected
children, these children will require life-long access to hospital care for acute and chronic
complications, with the average cost for managing one patient with SCD ranging between
$4,425 in Jamaica to $7,000 in Canada per year",
Major benefits in the health and survival of children with SCD in high income countries have
been attained through the implementation of a few, simple evidence-based interventions. The
most striking achievements have been as a result of early diagnosis of SCD by newborn
screening (NBS) and the subsequent enrolment of these patients into comprehensive care
I
programmes", These programmes provide interventions which include prophylaxis against
infections, for example with penicillin, early detection and treatment of acute clinical events
such as anaemia, septicaemia, stroke and acute chest syndrome due to infections/infarctions.
These interventions have not been introduced in Tanzania despite the fact that they have been
shown to be highly effective in developed countries. Although there is every reason to
believe that such an approach would have a similar impact in Africa, there are simply no data
on even the most basic problems, such as the common clinical complications and the current
mortality, to support this assertion. In addition, the limitation of resources in LIC mean that
it is essential that proposed interventions are cost-effective and based on a clear defmition of
the problems.
The main objective of this study was to describe the clinical spectrum of SCD in Tanzania by
defining the major causes of morbidity and mortality. This involved the establishment of a
systematic framework for a prospective, descriptive study in a setting with an existing clinical
sickle cell service. This thesis will focus on malaria, bacterial infections and neurological
events, mainly cerebrovascular accidents or stroke, which are thought to cause high morbidity
and mortality in the population of SCD subjects currently forming the clinical load at MNH.
This is probably typical of many hospitals in East Africa (EA). In addition, these three
clinical events have interventional strategies which are effective, could be implemented in
resource-limited settings and would significantly improve the management of African patients.
This work will also describe the clinical epidemiology of foetal haemoglobin (HbF) in the
SCD cohort, as patients with high concentrations of HbF appear to be protected against severe
consequences of SCD. Therefore, study of HbF has the potential both to increase our
understanding of the mechanisms behind SCD and to provide effective therapeutic options in
Africa.
2
This thesis starts with an outline of the scientific and clinical background to SeD, reviewing
pertinent existing literature on malaria, bacterial infections, stroke and foetal haemoglobin.
This is done with an emphasis on defining what needs to be done to improve outcome in an
African setting as the rationale for this thesis. In the second section, I summarise the
methodology and resources that were used to establish the framework for carrying out the
work. The third section initially outlines an overall description of the SCD cohort, followed
by individual chapters on findings in malaria, infections, neurological events and HbF.
Finally, the concluding section summarizes the results as the baseline on which to propose
locally relevant approaches to target resources for appropriate management, intervention and
research. This information has the potential of having a significant impact on clinical course,
quality of life and survival of SCD individuals in Tanzania.
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Chapter Two
Literature review
SICKLE CELL DISEASE
In this section, the biology of haemoglobin, in particular sickle haemoglobin and the genetics
of SeD will be reviewed. This will be followed by an overview of the mechanisms of disease
in SeD and the clinical consequences of SeD. The third section will review the diagnosis,
treatment, prevention and control of SeD, focusing on the interventional strategies that are
pertinent for this study. Finally, there will be a summary of the situation of sen in Africa.
Basic concepts
The function of haemoglobin (Hb) is to carry oxygen and carbon-dioxide between the lungs
and tissues. It is a molecule that is carried within a red blood cell (RBe), a non-nucleated, bi-
concave cell. RBes are produced by the bone marrow, with erythropoietic activity occurring
in almost every marrow cavity in childhood but later activity is limited to the ends of long
bones, axial skeleton, ribs and skull. RBes have a life span of 120 days. An average Man will
have 5xlO12 RBes per litre of blood and the level of haemoglobin ranges between 11.5 -
15.5Wdl in women and 13-18 WdL in men. Anaemia is defined as a decrease in haemoglobin
below the lower limit of reference values for age and sex.
The structure of haemoglobin molecule
The haemoglobin molecule is a protein which consists of four polypeptide globin chains, with
each globin chain containing one molecule of haeme. There are 2 alpha-globin chains and
two non-alpha globin chains. In adults the non-alpha globin chains are beta «(3), gamma (y)
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and delta (5). Therefore, in adults there are three types of haemoglobins - haemoglobin A
(a2 J3z), Haemoglobin A2 (a2 5z) and Haemoglobin F (a2 "(2).
Genetic control of haemoglobin production
There are 2 alpha-like globins [zeta (5) and alpha (a)] and the genes that control the synthesis
of these globins are located on chromosome 16. Similarly for the non-alpha globins (E, 'Y, 5,
J3),the genes are located on the short ann of chromosome II. The J3-g1obingene (HRR) exists
in a region of chromosome 11 called the "beta globin locus control region (LCR)." The
sequence in which they are physically ordered on their respective chromosomes reflects the
timing of their expression during development.
Figure 1 Schematic drawing of gene clusters that regulate haemoglobin molecules in
humans
5' 3'
E
Chromosome 11
V V 6
B-LCR
a a
Chromosome 16
f}-LCR stands for P locus control region
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Distribution of haemoglobins during human development
Since the environment during embryonic, foetal and adult life with respect to availability and
source of oxygen differs, so the properties of the haeme molecule in binding and releasing
oxygen have to differ at each of these stages. This means that the distribution of globin chains
making up the different haemoglobins in individuals gradually changes during development
(Figure 2). During the embryonic period, (up to 6 weeks of gestation), embryonic
haemoglobin is produced consisting of Gower 1 (S2 E2), Gower 2 (U2 1::2) and Portland Hb (S2
Y2). As the embryo develops into a foetus, there is a reduction in the production of zeta and
epsilon globin chains and an increase in the production of alpha chains resulting in a high
concentration of HbF (U2 Y2). This haemoglobin has a high-affinity for oxygen and is
therefore able to bind oxygen more efficiently from maternal haemoglobin, at any given
oxygen concentration. After birth, oxygen is more readily available and therefore there is a
gradual reduction in the synthesis of foetal haemoglobin and an increase in adult
haemoglobin (HbA - U2 rh).
Schematic diagram showing the time course of development of globin genes in man from conception to
adulthood. Sites of synthesis are shown as well as the proportion of different globins at different time
points".
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Sickle Gene
Random mutations can occur in the coding regions of HRR, resulting in abnormal structural
variations in the haemoglobins leading to haemoglobinopathies. Sickle haemoglobin (HbS)
occurs when one amino acid (valine) substitutes another amino acid (glutamic acid) at position
six of the JJ-globin polypeptide chain. This substitution is caused by a single base mutation in
codon 6 within the JJ-globin gene cluster, where the sequence GAG occurs instead ofGTG.
The sickle gene is autosomal recessive and follows Mendelian principles of inheritance.
HbS is one of 3 haemoglobinopatbies which have reached high population frequencies, the
others being haemoglobin C and haemoglobin E, which result from single amino acid
substitution (JJ6 Glu --+Lys ) and (JJ26 Glu --+Lys ) respectively.
Random mutations can also occur in the non-coding region of JJ-globin gene cluster, which
are neither selected for or against. When a gene mutation occurs in the coding region of the
~globin gene, the surrounding non-coding region is not affected. The genetic background of
the surrounding region is called the "haplotype" of that particular mutation. Since the
chance is extremely small that another random mutation will occur in the non-coding region,
the haplotype of a particular gene mutation event is fixed. The haplotypes can be identified
by endonuclease enzymes that isolate the specific polymorphisms by restriction fragment
length polymorphism (RFLP) typing. There are 4 JJs-haplotypes; JJs- Senegal, pS - Benin, pS
- CAR (Central African Republic, also known as Bantu) and JJs - Arab/Indian. Figure 3
shows the HBB cluster with the different haplotypes.
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Figure 3 p-Haemoglobin gene (HBB) cluster of chromosome 11
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Geographic distribution of the sickle gene
The sickJe gene is present in three distinct areas in Africa. The Senegal and Benin haplotypes
occur predominantly in West Africa and the Central African Republic (CAR), also known as
the Bantu haplotype, is predominantly found in East and Central Africa. The Arab/Indian
haplotype is found predominantly in the Arabian Peninsula and the Indian sub-continent.
Epidemiological studies suggest that the number of individuals with ~s gene are higher near
the coast and fall concentrically with progression inland 10,
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Figure 4 Geographic distribution of the sickle gene
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Schematic representation of geographical distribution of Sickle gene. The boxes are DNA
polymorphic sites that determine the HBB-gene cluster haplotype, identified by RFLP. Bantu
haplotype is now known as CARll.
Sickle cell disorders of clinical significance
seD refers to a group of disorders that are characterised by the presence of sickle
haemoglobin. The SCD syndromes which have significant clinical consequences include the
homozygous sickle state (HbSS), known as sickle cell anaemia (SeA), and the compound
heterozygous states, HbSC and HbS~thalassaemia. Within this thesis, SeD refers to the
homozygous state HbSS.
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Epidemiology of SeD
The prevalence of SeD can be objectively determined by calculating the birth prevalence of
affected children, which requires accurate diagnosis and registration at birth. Since this is not
done in most African countries, an alternative method is to use the prevalence of the carrier
or heterozygous states (HbAS) to calculate the expected birth rate of seA based on the gene
frequency and Hardy-Weinberg equation. This has been done in several recent reviews4•l2
and is summarised below. Table 1 and Figure 5 show the global burden of children born with
inherited haemoglobin disorders every year!', Approximately 300,000 children are born
every year with SeD in the world, and countries such as the United States of America, United
Kingdom and Jamaica have a well-documented seD population. However, this SCD
population constitutes only 1% of the global population of SCD, as over 75% are in Sub-
Saharan Africa2•14•
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Table 1 Frequency of heterozygous state, birth prevalence and estimated annual births in
selected areas of the world
Area HbAS Birth prevalence of SeD Annual births
Americas
USA (AA) 9% 0.4 (1:375) 1,531
Jamaica 5.6 302
Bahamas 7.7 46
Europe
UK 0.3 196
France 0.4 220
Africa 15-25%
igena 18 84,636
Tanzania 5.6 7,801
Uganda 6.4 7,821
Kenya 1.2 1,296
4AA - African-American; Source .
Figure 5 Global map showing the birth prevalence of inherited haemoglobin disorders
230,000 births in Africa
307,897 births in the world
• Births with pathological haemoglobin disorder per 1,000 live births
11
Births of individuals with pathological haemoglobin disorders (haemoglobinopathy). The
predominant haemoglobinopathy in Africa is due to sickle cell gene whereas in Asia it is
thalassaemia. Figures are shown in Tanzania, USA and Jamaica for comparison. Source'".
The high birth prevalence of SeD has been successful in highlighting the burden of SeD,
such that in 2006, the World Health Organisation recognised SeD as a public health
priority'. However, the birth prevalence does not provide information about the burden to the
health system and the impact that it has on individuals.
Individuals with seD have high mortality, with reports suggesting that most children with
SeD in Africa die in early childhood. A study done in Nigeria found that the prevalence of
children with HbSS fell from 2.1% at birth, 0.4% at one to four years and to 0.05% over the
age of nine years". Recent estimates suggest that mortality has decreased and is more likely
to be up to 50% by 20 years with the contribution of SeD to under-five mortality in
Africa estimated at 6.4 %17. In the 1960s, the mortality in SeD in USA and UK was estimated
to be over 50% by 20 years but recent reports have shown improved survival in childhood,
with 85.6% surviving to 18 years in the USAl8 and 99.0010 to 16 years in the UKl9. The common
causes of mortality in the USA, UK and Jamaica were infections, acute splenic sequestration
and acute chest syndrome20,2l,22,23, with the highest incidence between 1 to 3 years of age.
Mechanism of disease in SeD
Due to the abnormal amino acid in the J3-g10binchain, sickle haemoglobin (HbS) forms long,
insoluble polymers when deoxygenated, and the RBe containing HbS become less
deformable and form a 'sickle' shape. It was previously thought that the clinical
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consequences were simply due to this abnormal, rigid sickle red blood cell occluding small
blood vessels. However, there is increasing evidence that the pathogenesis of the various
clinical events, both acute and chronic, result from a series of complex mechanisms which are
not limited to the RBC.
The complexity of the pathophysiological mechanisms at play were recently reviewed by
Stuart and Naget24. Although the mechanisms have been broadly divided on the basis of
whether they not they are directly related to RBC (Figure 6), this is an arbitrary division as
the processes are closely linked and are probably even more complex than this simple
classification. However, for purposes of this review, the discussion will outline factors related
to RBC (erythrocyte related) and factors outside the RBC (extra erythrocyte factors).
Erythrocyte related factors
The rate of polymerisation of HbS into the pathogenic pS-globin polymers is determined by
the degree of oxygenation, intracellular pH and the concentration of HbS and HbF within the
RBC. Well-oxygenated HbS remains in solution in RBC in the arterial vessels but in the
venous circulation, with a reduction in the oxygen content, HbS polymerises and becomes
insoluble. This process reaches a point when the RBC loses its capacity to return to its normal
shape even with exposure to oxygen and remains an 'irreversibly' sickled cell (lSCi5. With
regards to the intracellular concentration of Hb, studies have suggested that although the total
concentration of Hb in cells influences the HbS polymerisation, it is the relative concentration
of HbF which is of greater significance as the ability of HbS to polymerise is significantly
reduced by the presence of HbF26,27 and reduction in the concentration ofHbS28• Kinetic studies
of HbS gelation have also been able to demonstrate the role of oxygen concentration" and
acidity in HbS polymerisarion'",
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Under normal physiological conditions, the population of RBC in individuals is
heterogeneous; however this is even more marked in SCD31. Pathological consequences are
related to the wide variation in the density of SS cells32, the most extreme one being the ISC.
The density of RBC is determined by the volume of the RBC which is carefully controlled.
However, there are disturbances in this homeostatic process in SCD which have been linked
to two ion-transport mechanisms in the RBC membrane; the potassium-chloride cotransporter
and the calcium-sensitive gardos channel which result in cellular dehydration':'. In addition to
the abnormalities to the transporter mechanisms in the RBC membrane, there is also
dysfunction in the lipid bilayer, with abnormal exposure of phosphotidylserine components in
the phospholipid layer. This mechanism seems to be independent of HbS polymerisation and
itself causes membrane rigidity, increased RBC-endothelial interaction and pro-coagulation
activi~,3S .
In SCD, vaso-occlusion in both the macro and microvasculature is also thought to result from
increased adhesiveness between different components within the RBC, plasma and
endothelial wall. The sickle RBC has increased adhesiveness to endothelium36,37 as well as to
other cellular components. In addition, within the plasma, there are factors such as
thrombospondin (from platelets) and von Willebrand factor (from endothelial cells) which are
also involved38,39,4O,41.
Extra-erythrocyte factors
The endothelium has been found to be activated from both cell-related (sickle RBC, white
blood cell and platelets) and extra-cellular (inflammatory mediators, coagulation factors)
38,39,40,41,42,43.There is increased inflammatory activity with what appears to be reperfusion injury
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and an increase in free oxygen radicals44. There is also evidence of pro-coagulant activity as well
as activation of haemostasis which may contribute to some of the acute and chronic clinical
events45,46,47. Finally there is compelling evidence of the role of Nitric Oxide (NO) in SCD48.
The increase in haemolysis in SCD results in an excess of haemoglobin which exceeds the
protein-carrying capacity of plasma factors such as haptoglobin. The result is that there is
abnormal 'cell-free' haemoglobin which circulates in plasma, binding to and destroying NO,
so causing a reduction in the concentration of N049. This results in vasoconstriction,
increased adhesiveness of erythrocytes, leukocytes and endothelial cells and platelet
aggregation. The clinical consequences of increased vaso-occlusion are particularly seen in
the lungs and brain.
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Clinical events in SCD
Although seD stems from an abnormality of the RBC, it is essentially a multi-system disorder,
affecting almost every organ-system of the body, as shown in Figure 7.
Figure 7 Selected clinical consequences of SeD
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infection and organ dysfunction.
Haemolysis and haematological complications
At birth, individuals with SCD do not have anaemia, but with the synthesis of adult Hb, they
develop chronic haemolytic anaemia that is present throughout life. This may be interspersed with
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acute episodes of reduction in haemoglobin - .anaemic crises'. The chronic haemolysis in seD
results in gall bladder disease due to high levels of bilirubin. Although the main cause of anaemia in
SeD is chronic haemolysis, there are other types of anaemia. Hyperhaemolysis crises is defined
by a sudden fall in steady state haemoglobin accompanied by increased reticulocytosis and
exaggerated hyperbilirubinaemia. Acute splenic sequestration, when there is rapid onset of
trapping of red blood cells in the spleen, is characterised clinically by a sudden increase in
splenic size, at least 2cm below the left coastal margin, accompanied by a reduction in
haemoglobin or haematocrit by 2oo/oof baseline level has been described in seD and is a
significant cause of mortalityso.sl,52,53.Anaemia may be secondary to infections, notably RBe
aplasia in the bone marrow that has been associated with infection with parvovirus serotype
BI~.sS,S6.
Vaso-occlusion
Vaso-occlusion (vac) is thought to be the underlying cause of painful crises, acute splenic
sequestration and priapism (painful and prolonged penile erection). Painful crises, considered the
hallmark of SCD, are defined as severe pain lasting for 2 or more hours that is attributable to
SeD. The sites that are normally affected include the arms, legs, back, abdomen, chest and head.
Painful crises do not include other causes/types of pain in SCD such as dactylitis, acute chest
syndrome, right upper quadrant syndrome, osteomyelitis and appendicitis. It is the most common
cause of hospitalisation and frequent pain (defined as 2 or more painful events a year for three
years) is associated with poor quality of life and increased risk of death".
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Infection
In the absence of prophylaxis, infections are thought to be the leading cause precipitating
clinical events and associated with increased mortali~,23,58. The role of bacterial infections and
malaria in seD will be reviewed in detail in the respective sections as they are the focus of the
thesis.
End-organ dysfunction
With increase in survival, major organs in individuals with seD are eventually damaged. The
brain and chest are particularly affected, with stroke, defined as an acute neurological syndrome
due to vascular occlusion or haemorrhage in which symptoms and signs last for more than 24
hours, being a well-described event. Acute chest syndrome (ACS) is an acute respiratory
illness characterised by new pulmonary infiltrates on chest X_ray59,60. Both these events have been
reported to occur with high prevalence in SCD and are also risk factors for death23,60,61. The
mechanism of disease in stroke in seD will be reviewed in subsequent section as it is a main
focus of this thesis.
Heterogeneity of clinical events in SeD
The clinical consequences of SeD are extremely heterogeneous in several ways. There is inter-
individual variability with some individuals who are completely asymptomatic while others
have extreme, debilitating illness. There is also variability within an individual, with changes in
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the type and frequency of clinical events with age. Finally, there is variability in clinical events
depending on the geographical location. This is due to the differences in environmental factors
such as nutrition, socioeconomic status, and climate that will influence the natural history of
disease. The general pattern of clinical disease is characterised by quiescent periods
interspersed with acute events, which are referred to as crises.
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Table 2 The prevalence of selected dinical consequences of SCD
Clinical event Prevalence References
Haemolysis
Anaemia Chronic 62,63, 64,65,66,07,68
Cholelithiasis Prevalence is 40% by adolescence 6'1
Aplastic anaemia Associated with parvovirus B 19 infection ";lU,71
Hyperhaemolysis Not common in Africa 72,73,74,75
Vaso-occlusion
Pain More than 60% patients. "J,'~' ,7b,II,71S,7'}
Most common cause of admission
Acute splenic Frequently occurs before the age of 3yrs ·23,50,5T
Leg ulcers Prevalence is 10-25% adults !ro;8T
Priapism Prevalence is 10-40% males IS..
Occurs frequently 5 - 14years age group
Organ dysfunction
Neurological events
Stroke Prevalence is 1()o1o in children !IT
Risk factor for mortality
Cognitive Isilent Prevalence is 20% IS4,IS',ISb,IS7
Risk factor for overt stroke
Leads to impairment of executive function
Retinopathy Prevalence is >30% in HbSC ISIS,!!')
Chest
Acute chest syndrome Prevalence is 40%. ''},bO,bl
Occurs frequently in children,
(ACS)
Has severe uences in adults
Pulmonary hypertension 30% 'JU,'} I,,}:l,,}J,'J4
Risk factor for mortality
Avascular necrosis of Prevalence is 10-50% in adults 95,'16,'17
femoral head
Renal disease Prevalence of chronic renal failure is 5% 20% ,}IS
Infections
Malaria '}'},loo
Bacterial infections 1()o1o children under 5 years 101
Modified from 102.103,
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Diagnosis of seD
The laboratory diagnosis of SCD is based on the demonstration of HbS and the absence of
HbA, with variation in the percentage of the other 2 haemoglobins - HbF, HbA2 - in RBCs.
The tests involve the initial detection of HbS by screening tests which include sodium
metabisulphite sickling test and sickle solubility tests. This is followed by tests to confirm the
sickle phenotype (SS/AS/SC/SIrthalassaemia).
There are three tests that are widely used - haemoglobin electrophoresis (HBE), isoelectric
focusing (IEF) and high performance liquid chromatography (HPLC). DNA-based tests can be
done to precisely describe the genotype. However, for clinical purposes, the diagnosis usually
involves screening (sickling or solubility test) followed by confmnation of phenotype using
one or two of these tests (HBE, IEF or HPLC).
Screening tests
Inmost African hospitals, screening is done, using the 'sickling test', which involves making a
thin blood film which is then put under hypoxic conditions by the addition of sodium
metabisulphite. This will result in RBCs containing HbS forming sickle cells which are seen
under a light microscope. A "positive" sickling test identifies the presence of sickled RBCs,
which occur in both homo (SS) -and heterozygous (AS) states. So to confirm SS-SCD or other
SCD, other tests need to be done. The sickle solubility test is another method used for
screening which is based on the principle that Sickle Hb becomes insoluble when it is
deoxygenated
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Confirmatory tests
These tests are based on the principle that the different haemoglobins have different overall
ionic charge which makes them move with different velocities in an electric field. The
principles and procedures for HBE and HPLC are in appendix III.
HBE can be done under alkaline or acidic conditions,where HbA, HA2, HbF and HbS migrate
towards the anode under an electric field with different speeds. The results are shown
schematically in Figure 8, showing that during alkaline Hb electrophoresis the resolution
between HbS and HbF can be poor, particularly in individuals with high HbF levels e.g.
neonates. Under acidic conditions, HbF moves much faster and is therefore distinct from both
HbA and HbS (Figure 8).
Figure 8 Electrophoresis of common haemoglobin variants under alkaline and acid
conditions
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Isoelectric focusing uses the same principles but is slightly more expensive than HBE.
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However, it is able to identify more Hb variants that would not be detected by HBE. It also has
the advantage that it does not require reagents which are commercially prepared.
HPLC use cation exchange chromatography to identify the various haemoglobins in an
individual. It has the advantage in that it can also accurately quantify the Hb levels. In resource
rich countrie , screening has largely been replaced by HPLC and confirmation is then done by
lEF or HBE. This is mainly because HBE and lEF are labour intensive, time consuming and
would not identify abnormal bands or quantify Hb. Furthermore, the quantification of Hb
fractions by HPLC is used to monitor patients who are on Hydroxyurea therapy or exchange
blood transfu ion.
YTE: to
Figure 9 Chromatogram from high performance liquid chromatography of haemoglobin
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The peaks correspond to the quantity of each haemoglobin component as a fraction of total haemoglobin. Source 104
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The distribution of the different haemoglobins in individuals with different sickle phenotypes
is shown in Table 3.
Table 3 Distribution of haemoglobin fractions in AA, AS and SS individuals
Percentage of total haemoglobin
Foetus Adult(AA) Adult (AS) Adult (SS)
HbA a2 f32 5-10 97 55-70 0
HbA2 a2~ 2-3 2-3 2-3
HbF a212 60-80 0.5-1 0.5-1 2-10
HbS a2BS2 0 30-45 90
Sourcel05
Although detection of the abnormal protein (HbS, HbC, and HbE) is usually adequate for clinical
diagnosis, definitive diagnosis of the genotype requires examination of DNA. This includes
methods such as RFLP, peR and sequencing, which would not only allow the correct
description of the genotype pattern but would also allow further differentiation of the
haplotypes. With recent advances in genomic medicine, genotypic diagnosis has become
readily available and is routinely used in some reference centres for screening and diagnosis of
sen
Interventions in SeD prevention, treatment and control
As a chronic disease, the natural history of SeD is such that it is characterised by quiescent
periods interspersed by acute events, known as crises, leading to patients seeking health care
and frequent hospitalisation. The .crises' range from well characterised syndromes such as
acute chest syndrome (AeS), acute splenic sequestration (ASS), to less well defined symptoms
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that include pain, fever, anaemia, worsening of jaundice and leg ulcers. There are specific
conditions or circumstances when SeD patients require extra care. Peri-operatively, when seD
individuals undergo general anaesthesia and surgery, there is an increased risk of developing
acute sickling complications and sudden death. Other circumstances include pregnancy,
dehydration, and extreme cold weather. With the increased life span of individuals with SeD,
there has been an increasing awareness of the importance of improving the quality of life and
well as preventing damage to organs such as the spleen, heart, lungs, brain, eyes, and kidney.
seD is associated with increased mortality. The causes of mortality in the USA, UK and
Jamaica included infections, AeS, ASS, aplastic crises20,21,22,23. Other events such as stroke,
pulmonary hypertension, and haemolysis have also been reported to be associated with
increased risk of death.
The management of patients with SeD involves interventions that improve survival, prevent
and treat acute events and reduce end-organ damage. Over the past 3 decades there has been an
improvement in the understanding of the different pathogenic mechanisms responsible for
sickle cell events and organ dysfunction. Through a series of clinical trials, effective
interventional strategies have been established. For purposes of this thesis, I will provide a
brief overview of the interventions available, but will focus on interventions that are pertinent to
the situation in East Africa.
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Newborn screening (NBS)
The highest incidence of death occurs in the first 3 years of life20,22,23.106.Therefore,
identification of children at birth by newborn screening (NBS) leads to improved survival'f
107.108.109.Patients who are identified at birth can be given proper counselling and advice about
the course of illness. They can then be enrolled in comprehensive care programmes which provide
prompt and effective interventions as well as providing prophylaxis against complications
which has a positive impact in reducing mortality and improving quality of life. Countries with
large SCD populations and adequate resources have started NBS programmes. These were
initially targeting high-risk populations, but most States in the USA as well as other areas in
Europe are now recommending universal screening'l'',
Comprehensive care including dedicated day care facilities
The identification of SeD at birth has to be accompanied by enrohnent into programmes that
provide comprehensive care. These programmes provide appropriate advice, counselling and
support to parents and affected individuals. This includes advice such as drinking adequate
quantities of fluid to avoid dehydration and wearing proper clothing in cold weather. Specific
health education that will enable them to recognise acute events and seek medical care is also
essential. Teaching mothers to recognise enlargement of the spleen and anaemia was effective
in diagnosing and treating anaemia due to ASS51.53.Patients are also seen on a regular basis
and provided with folic acid supplements. Prompt treatment of crises (fever and pain),
particularly at outpatient or in day-care facilities, has been found to be effective and reduces the
burden of hospitalization to the individual and the health systemlll.1I2.1I3.1I4.This has been found to
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have a significant impact on not only quality of life but also mortality7,1l4,115,116.
This approach that has been found to be effective with comprehensive, multi-disciplinary
teams, with long term care being provided by professionals who have specialised in
haematology and blood transfusion. In settings where there is a low prevalence of SeD or
limited nwnber of health care professionals, seD patients can receive care from general health
care workers. In such a setting, guidelines for management can be provided to general health
care workers with a system of referral to specialised centres.
Prevention and treatment of infections
Bacterial infection in seD is mainly due to Streptococcus pneumoniae, resulting in
pnewnonia, sepsis and meningitis. The highest incidence of invasive disease is in children less
than 6 years of age20,lOl. In a landmark study in the USA, Gaston and colleagues demonstrated an
84% reduction in incidence of pnewnococcal infection with the use of oral penicillin 117and there
has been a significant change in survival with acute treatment of infections 118.
Blood Transfusion (BT)
Individuals with seD have chronic anaemia which is tolerated. However, rapidly worsening
anaemia can occur and this presents as an emergency. It can be caused by ASS, aplastic crises,
hyperhaemolysis or associated with other events such as bacterial infections and malaria.
Under these circwnstances, anaemia is life-threatening and requires prompt treatment with
blood transfusion. The products that are used (whole blood or packed RBes) and the method
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of transfusion (simple or exchange) are determined by the clinical situation, availability of
resources and the capacity to provide the blood product and establish venous access'!". Acute
BT is also effective in other conditions, such as acute strokel2o, Aes121 and peri-operatively'<.
BT works by increasing the level of Hb, thus improving oxygen delivery. It also reduces the
proportion of sickle RBes in the circulation. Exchange or red cell transfusion has also been
shown to be effective in reducing the level of HbS to less than 30%123,124,125,126. This is thought to
reduce the deleterious effects of HbS and improve outcome.
Long term blood transfusion therapy (LTBT) has been found to be effective in the prevention
of brain injury due to cerebrovascular disease 120. Blood transfusion is associated with risks
which have to be weighed against the benefits when considering implementing this is an
intervention. These will be reviewed in the section on stroke.
Prevention and treatment of malaria
It is recommended that individuals with seD who live in a malaria endemic area should
receive prophylaxis against malaria". Furthermore, any clinical suspicion or diagnosis of
malaria in SeD should be treated promptly.
Hydroxyurea
Hydroxyurea (HU) (also known as hydroxycarbamide) has been reported to be effective in
improving survival and reducing morbidity in some SeD patients (Table 4). The clinical
outcomes include reduction in frequency of painful episodes, and hospital admissions I28.
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Hydroxyurea therapy is also monitored by a number of laboratory parameters which include
increase HbF levels, mean corpuscular volume (MCV) and reduction in WBC count.
Hydroxyurea has been found to be effective in the prevention of brain injury due to
cerebrovascular disease 129.
Table 4 Summary of study outcomes for hydroxyurea use in adults and children
Outcome Impact in adults Impact in adolescents
Clinical outcomes
Pain crises Hl H
Hospitalisations lU Hl
Blood transfusion therapy lU +-+ (insufficient data)
Acute chest syndrome lU +-+ (insufficient data)
Laboratory markers
Foetal haemoglobin ttt ID
Haemoglobin tH +-+ (not significantly
Mean corpuscular haemoglobin ttt ttf
White blood cell count Hl m
Prevention of end Ol"2andamage
Brain +-+ +-+
Spleen +-+ +-+
Kidney +-+ +-+
Mortality 1 +-+=
H!=high-grade evidence for decrease; !=low grade evidence for a decrease; jjj=hlgh-grade evidence for
increase; j=low grade evidence for an increase; +-+=not evaluated/not significantly different/insufficient data.
Source 130
Nitric oxide
Lung dysfunction results from a combination of repeated pulmonary infections and infarctions
as well as increased vasoconstriction leading to pulmonary hypertension'" 60. The latter has
recently been shown to be due to reduced bioavailability of nitric oxide", which has resulted
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in therapies such as L-arginine, citrulline and inhaled nitric oxide which is aimed at increasing
NO levels through different pathwaysI31,132,133,I34,135.
Stem ceUtransplant
The only potential cure that is available for SCD is stem cell transplantation (SeT), which
replaces the host's bone marrow with stem cells containing normal p-globin genotype. Since
the first successful transplant reported in 1984136, there has been significant reduction in risks due
to SCT and increasing success, with the best results, of up to 85% event free survival,
occurring with HLA-matched sibling donors and transplantation early in the course of the
disease before end-organ damage occurs137,138,139,140. One limitation of seT is the availability of
sibling donors!", and therefore there have been attempts to improve survival for unrelated
stem-cell donorsI42,143. However, the second limitation is more difficult to address because the
clinical course of SCD is extremely heterogeneous. Despite the knowledge of various genetic
and environmental factors known to alter disease severity, it is still difficult to accurately
identify children with risk of severe disease before extensive damage has occurred. Until such
time that a low-risk, definitive cure is available, the cornerstone of management of SeD is the
prevention of early mortality, prevention of end organ damage and improvement of the quality
of life.
Gene therapy
Since SCD is caused by a defective gene, definitive treatment would involve replacement of
this gene with a normal gene. This has been done successfully in the sickle transgenic
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mousel44 but progress in humans has been limited by identification of appropriate vectors
and efficacy for gene transfer and low level expression of globin genes.
Role of programmes for control and management of SeD
From a public health perspective, the policy for approaching the control of SCD in national
health programmes needs to integrate two main areas: the provision of appropriate medical
care to affected individuals (management) and the prevention of disease. Although, there is
ongoing debate whether care of SCD should be integrated into existing health care services or
whether there should be separate disease-specific programmes for SCD, the WHO
recommends' that for countries where the birth rate of affected infants is above 0.5 per 1,000
births, they should develop separate programmes for these conditions.
Management
The management of SCD involves early diagnosis of affected people, the provision of the most
appropriate basic, cost effective treatment and genetic counselling and psychosocial support.
The long term goal is to ensure appropriate management at different levels of health care with
development of referral centres for specialised diagnosis and treatment. This approach ensures a
cost effective way of effectively dealing with a highly prevalent condition in areas where the
resources are limited. However, it is important that these centres are not limited to urban areas
or centred on academic or research oriented health facilities. In order to avoid this, there must
be active strategies to ensure that appropriate management is built into services at all levels of
health care with adequate support from these specialised centres.
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Prevention
Management of SeD patients needs to be accompanied by strategies aimed at two levels of
prevention: tertiary prevention which involves early diagnosis of SeD and prevention of
complications and more ambitiously, secondary prevention which tries to reduce the number of
children that are born with seD. (Note that primary prevention aims to ensure that individuals
are born free of SeD). Preventative services involves community education, population
screening and genetic counselling that would encourage people to undergo screening before
conception, during the antenatal or postnatal period. There are several issues that need to be
addressed with regards to prevention of seD. The aim of screening is to detect SeD in the
foetus, discuss the consequences of a diagnosis of SeD, options for treatment and prognosis.
Since SeD is a recessive disorder, during pre-conception screening, the chances of getting an
affected child is shown in table below.
Table 5 LikeUhood of children being born with SS SeD from parents with different sickle
pbenotypes
Parent Parent Possible phenotype of offspring Chance of affected children (SS)
AA AS AA,AS Nil
AA SS AS Nil
AS AS AA,AS, SS 1:4
SS AS AS, SS 1:2
SS SS SS 1:1
This illustrates the difficulty in advising a couple not to have children as the risk of getting an
affected child is relatively low (1 in 4), and does not increase with each pregnancy. The highest
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risk would be for two individuals who are SS who wish to have children. This is different from
thalassaemia, where children with the most severe form, thalassaemia major, will inevitably have
severe disease. Therefore, one could argue that this therefore justifies the use of pre-natal
diagnosis as this would identify pregnancies with SeD children and then parents would be
given the appropriate information regarding the consequences and prognosis of SeD.
However, although SeA is the most severe form of the disease (compared to se/sp-
thalassaemia etc), there is still wide variability in disease severity. Therefore, even with the
correct identification and diagnosis of SS with screening, it would be difficult to predict those
who would develop severe disease and have a poor outcome.
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SICKLE CELL DISEASE IN AFRICA
In this section, the importance of SCD in Africa will be reviewed from a public health
perspective, highlighting the burden of disease. This will be followed by an outline of the
rationale in investing in SCD, from a public health as well as from a scientific perspective.
Finally, there will be an overview ofSCD in Tanzania.
Importance of SCD - public health perspective
In May 2006 at the 5gd' World Health Assembly (WHA), resolution WHA 59.20 of the World
health Organisation (WHO) was to develop, implement and reinforce integrated national
programs for the prevention and management of Sickle Cell Disease (SCD). The WHO
identified SCD a problem of public health significance as it is has a high prevalence, causes
significant burden to health systems by having a high morbidity and mortality and relatively
simple, cost-effective interventions can prevent some of the complications associated with this
condition'.
Health burden of SCD - prevalence
In order to determine the epidemiology and health burden of SCD in Africa, the WHO requires
an accurate estimate of the magnitude of the disease and recognised consequences, specifically
mortality and socio-economic burden of the disease to individuals, families and the health
system.
It was previously thought, that although the birth prevalence of SCD is high in Africa, SCD
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was not a significant health burden because the majority of children would not survive the high
childhood mortality. However, there is evidence of increasing population prevalence of
seD81,145,l46,147,l48,149,lSO. Although this may be due to improvement in detection of SeD, this is
more likely due to reduction in mortality due to infectious diseases. Although there is still
much to be done, there is significant success in the control of infectious diseases such as
malaria, lower respiratory tract infections, malnutrition and diarrhoeal diseases.
Furthermore, African countries are becoming increasingly heterogeneous with improvement in
education, health care and socio-economic status particularly in urban areas. This results in a
demographic health transition where the impact of birth defects will increase (Figure 10). Genetic
disorders, which include pathological haemoglobin disorders, account for up to 30% of birth
defects". The proportionate contribution of seD to infant mortality is increasing, with estimates
suggesting that the contribution by SeD to under-five mortality in Africa is 6.4%. However,
without taking into account the inevitable health transition and within the context of
infectious diseases, genetic diseases have a considerable burden on the health care system.
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Figure 10 Effect of demographic health transition in selected countries
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Health burden of SeD: morbidity and mortality
With an increase in detection of SeD children, the previously unrecognised burden of SeD on
the health system will become more apparent. SeD has been estimated to account for up to
14% of general infant mortality rate (4-8% of under-five mortality)", 10West Africa, the under 5-
year mortality rate that can be directly attributed to SeD has been estimated at 20 per
1,000151.In Africa, assuming a mortality of 50 to 80 percent under 5 years of age implies that
there are at least 21,600 to 34,500 deaths per year due to SeD. This is most likely an
underestimate as overall mortality may reach 173,000 per year. This accounts for between 1-
2% of burden of mortality in the under 5-year age group",
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In addition to mortality, because of the chronic nature of the disease, SeD patients require life-
long access to hospital care. Estimates suggest that in high income countries, genetic diseases
account for up to 4()01o of chronic care in paediatric practise". A recent report suggests that 6
million people will be living with SeD in Africa if average survival of affected children
reaches half the African norm 17 (by this we assume, that if the life expectancy in Africa is 50 years,
and average survival of SeD children was 25 years, then there would be 6 million people
with seD in Africa). These individuals will need lifelong care with complications that will
require hospital care. This includes anaemia without any other complications or anaemia requiring
management with blood transfusion. Painful episodes, which are the most common complication
in SeD also causes considerable burden to the individual and to the health system if they
require hospitalisation. Other clinical events, such as orthopaedic complications due to avascular
necrosis of the femoral head. neurological complications due to stroke and seizures, leg ulcers
and retinopathy also contribute to the disability due to SeD6.
The financial burden of SeD has been estimated to illustrate the need to develop and plan
health services for SeD individuals. A report from the WHO estimates that the cost of health
care for SeD in Jamaica is approximately $300 per patient per year'. This is based on
estimates in resource-rich countries or with established seD research programmes. Table 6
shows an estimate of the cost of providing care to 1000 seD patients in Jamaica. Recent
studies have shown that it is possible to provide comprehensive care, with significant
improvement in morbidity and mortality in low income settings 152.
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Table 6 Estimates of cost of care of 1000 SeD patients in Jamaica
cost USDI patient/year* fraction of patients number Total (USD)
Outpatient care 250 1 1,000 250,000
Inpatient care 2,500.00 0.85 850 2,125,000
Transfusion 25,000.00 0.1 85 2,125,000
Exceptional problems 10,000.00 0.1 85 850,000.00
5,350,000
j*ExceptlOnal problems mclude surgery and pregnancy.
Control programmes for SCD in Africa
Most African countries do not have adequate resources to set up national programmes for
control of seD. This is Justified' by the argument that low-income countries do not have the
resources to deal with genetic diseases in the face of pandemics due to infectious disease such
as Human Immunodeficiency Virus! Acquired Immune Deficiency Syndrome (HIV IAIDS),
tuberculosis and malaria.
It is recommended that counties with a high prevalence of SeD, start planning effective
control measures. In this context, control of SeD encompasses two elements: providing best
possible care for affected individuals and preventing the birth of affected individuals. With
regard to providing best possible care, the following are options, depending on available
resources, that have been recommended by Weatherall et al in 20066:
• Option one: best possible patient care with the use of prophylactic penicillin following
diagnosis, together with retrospective genetic counselling.
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• Option two: best possible patient care, together with a newborn screening program and the
use of penicillin for all homozygous babies, together with retrospective screening and
counselling.
• Option three: best possible patient care, together with newborn screening and the use of
prophylactic penicillin from birth for homozygotes, together with population screening and
prospective genetic counselling.
• Option four: as for option three, plus the availability of prenatal diagnosis, bone marrow
transplantation, or both.
Some countries have been able to demonstrate a significant reduction in the birth of affected
individuals by effective public education and screening programmes. Figure 11 below shows
the experience in Sardinia with control of p-thalassaemia, where the number of affected
individuals was reduced from I :250 to I: 4,000 live births"
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Figure 11 Impad of effective control programme on birth rate of P-Thalassaemia in
Sardlala"
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Although there are differences between seD and Thalassaemia, it would not be overly
ambitious to aim for such successful results for SeD. seD has the advantage that the screening
and diagnosis are relatively cheap and easier to do (technologically) and the interventions e.g.
oral penicillin, pneumococcal vaccination) could be integrated into existing programmes e.g.
expanded programme of immunization (EPI), essential drug programme (EDP). However, it is
difficult to justify termination of pregnancy in the event that prenatal diagnosis confirms that a
child has seD. This is because homozygous SeD is extremely heterogeneous and it is not
possible to determine the course of the disease in an individual.
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SICKLE CELL DISEASE IN TANZANIA
Burden of disease
The prevalence of sm in Tanzania is not known. Estimates of the birth prevalence have been
provided by calculating the birth prevalence of SeD from the prevalence of the heterozygous
carriers. The most recent report estimates that up to 8,000 children with SeD are born in
Tanzania every year1S3• This figure makes Tanzania the country with the fourth highest seD
birth rate in the world, after Nigeria, Democratic Republic of eon go and Angola.
The population prevalence of SeD in Tanzania is not known. It is assumed that in the absence
of treatment, up to 95% of SeD born in Africa die in childhood". However, it has been
reported in Tanzania that some SeD individuals survive into adulthood':". Observations in
hospital records (personal observation) suggest that there is an increase in the number of SCD
patients who are hospitalised and who attend the clinic. It is difficult to know whether this
reflects an increase in number as a result of improvement in diagnosis and identification or
whether there is an increase in survival.
Healthcare for SCD inTanzania
The healthcare in Tanzania is mainly provided by the government, through its health facilities
organised in different levels of healthcare. The government has recognised that since
individuals with seD will require healthcare throughout their life, the cost would be a
considerable burden to the individuals. Therefore, the government has a policy that SCD
patients should receive free access to health care in government health facilities. At the level of
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health care facilities, seD patients receive symptomatic treatment for acute events such as
pain, anaemia and infections, and this is normally provided by general health services, internal
medicine or paediatrics. There are limitations in technical expertise to provide a correct
diagnosis of SeD and its complications such as malaria, bacterial infections, and stroke. In
addition, there are few health personnel who are adequately trained to provide care for SeD
patients. There are no health facilities which provide comprehensive care programmes for SeD
patients, despite the fact that this has been shown to have major impact on reducing morbidity
and mortality as well as being more cost-effective. In order to improve the healthcare for SeD
patients in Tanzania, it is critical to get local evidence. This will be used to tailor interventions
that are known to be effective in other populations so that the interventions that are
implemented are appropriate to the individuals, health system and environment.
Within the community, there is little awareness about the prevalence and social and
psychological impact of SeD in Tanzania. Personal observation at the clinic and with
individuals with seD suggests that there is stigma associated with the condition with mothers
being abandoned because of delivering a child affected with SeD. Within the health facilities,
personal observation has highlighted that SeD patients who are hospitalised with pain receive
minimal and inadequate analgesia and are often labelled as being narcotic-dependent or
addicted. Individuals with SeD may have difficult in receiving a good education due to
school absenteeism as a result of illness or some have reported opting not to attend school due
to the stigma of chronic leg ulcers or jaundice. Furthermore, some SeD patients cannot
get employment because of their illness. In order to address the lack of public awareness in
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society, a non-governmental organisation known as the sickle cell foundation of Tanzania
was founded by an individual with an affected child who approached me expressing her desire
to establish an organisation that would raise awareness of SeD in Tanzania. This was registered
in 2008. The foundation will work with other organisations and individuals in Tanzania to
encourage patient advocacy and provide support to individuals and families affected by
SeD.
As Tanzania goes through a health transition, it is expected that there will be reduction in
mortality due to infectious diseases and malnutrition. Therefore, the proportionate contribution
from non-communicable diseases, including genetic diseases, will significantly rise. The
Ministry of Health and Social Welfare has recognized the increasing importance of SeD and
has published a strategy for developing a national policy for the management and prevention of
SeD in Tanzania.
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SICKLE CELL DISEASE AND MALARIA
Introduction
There has been extensive research to understand the complex relationship between sickle
haemoglobin and malaria, based on the evidence that sickle haemoglobin confers protection
against malaria in individuals with AS. This section will review the literature that is available
to support the protection as well as explore the mechanisms proposed for protection. The
second section will look at malaria and SeD, exploring the ways in which the two conditions
influence each other, with particular focus on evidence of protection and susceptibility to
malaria in SeD patients. This will be followed by an outline of the approach to management to
malaria in seD. The final section will review the research questions that need to be explored to
start providing evidence to guide the approach to malaria in seD.
Sickle haemoglobin and protection against malaria
The sickle gene is regarded as the classical example of balanced polymorphism, a theory that
was proposed by Haldane over 50 years ago with regards to thalassacmia'f". Although
individuals with homozygous state for sickle cell (SS) have an increased risk of premature
death, this is balanced by the fact that individuals with the heterozygous state (AS) are
protected from dying from severe malaria 155. The consequence of this is that the sickle gene
has achieved high frequencies in malaria endemic areasl56, 157.
Geographical distribution
The striking overlap of the geographical distribution of the sickle cell gene and malaria is
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compelling evidence of balanced polymorphism. Figure 12 shows that the overlay between the
sickle gene and malaria is almost complete, with the exception of South Asia and Oceania. In
this area, the predominant haemoglobinopathies are haemoglobin E (HbE) and a-thalassaemia
whereas in sub-Saharan Africa it is HbS. This is an example of negative epistasis between
haemoglobinopathies, where the presence of one gene modifies the expression of another,
resulting in the predominance of one haemoglobinopathy in a population II. Recent studies in
Kenya sugge ted a reduced effect of protection by a-thalassaemia or sickle trait when they
occur together, which may account for the predominance of the sickle gene in East Africa I 58.
Figure 12 Global map showing geographical overlap of malaria and the sickle gene
Malaria Sickle Gene
Source: http://www.welJesley.edu/Chemistrv/chem227/bindprotns/malaria.htm
Epidemiology
Although the geographical overlap is striking, the direct evidence for a protective effect was
initially surprisingly limited since the first descriptions by Allison!". There was evidence of
reduced parasite densities in AS individuals in some but not all populations. However, over
the last fifteen years a number of case control and longitudinal studies have shown that
individuals with AS have unequivocal protection against malarial disease, with the most
striking effect on reducing the risk of severe life threatening malariaI58,160,161.
Mechanism of protection
Inparallel with these epidemiological and clinical studies a number of studies in the laboratory
have attempted to define the mechanisms underlying the protective effect of the HbS.
Although, a detailed review of the proposed mechanism of protection will not be included in
this thesis, proposed mechanisms include reduced parasite invasion'Y, reduced parasite
growthl63 as well as increased parasite death and removall64,165,166. Other putative mechanisms
have been proposed, ranging from effects on potassium haemostasis, through effects of
haemoglobin F, to interactions with the immune system. Although the precise mechanisms are
not clear, the sine qua non is that malaria infection causes less severe disease in individuals
withHbAS.
Evidence of protection
The evidence that HbS is protective against malaria is compelling, and one might expect that
the protection is 'dose-dependent', with higher concentrations of the HbS conferring more
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protection. This hypothesis has been explored in another haemoglobinopathy, haemoglobin e
(HbC). Although, HbC involves a mutation at the same position as HbS, i.e. position 6 on the ~
globin gene, the substitution for glutamic acid is with lysine (HbS it is valine). The clinical
phenotype in homozygotes (HbCC) when compared to HbSS has a less severe course of
disease, with less anaemia and reduced prevalence of the other end-organ consequences seen in
SCA23,167,168. HbC has been demonstrated to be protective against malarial69,170, with evidence
that the protection is higher in individuals with homozygous states (CC) than heterozygous
carriers (AC)l7o. The mechanism of protection proposed suggest that it acts by causing reduced
adherence between parasitized RBC and endothelium, reduced rosetting and agglutination, with
higher occurrence of features of RBC senescence. Inall the experiments the effect was greatest in
HbCC with some effects in HbAe and the least effect in HbAAI7I,172.
From the evidence in HbC, it would be possible to hypothesize that individuals with SeD, who
have higher concentrations of HbS, would be even more protected against malaria than
heterozygotes (AS). However, it is widely believed that malaria is associated with severe
morbidity and mortality in seD. Therefore, the recommendation is that all patients with seD
who live in malaria-endemic countries should be on anti-malarial prophylaxis1oo,l27. There have
been significant advances in understanding of the two diseases as well as a reduction in
prevalence of malaria by interventions with insecticide treated bed nets, intermittent
presumptive therapy as well as the effect of environmental and climate change173,174,175.
Therefore as part of these developments, there is a need to re-evaluate the interaction between
SeD and malaria
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Inorder to do this one could look at the current evidence to answer three questions. The first is
whether there is high malarial-related morbidity and mortality in patients with SeD. The
second is whether there is an increased prevalence of SeD amongst patients with severe
malaria. This alternative approach is to look at children admitted to hospital with severe
malaria, where one might expect to see a significant proportion of individuals with SeD, if
severe malaria is a special problem in this group. The third question is whether there has
been an increase in mortality in SeD due to malaria with the spread of chloroquine (eQ)
resistance.
Evidence of role of malaria in SeD
The evidence to determine the role of malaria as a cause of morbidity and mortality in SCD is
conflicting; with some studies suggesting that individuals with SS-SCD have a higher
susceptibility compared to individuals with AA or AS states, while other studies suggest
protection against malaria.
Increased susceptibility to malaria
With regards to malaria as a cause of morbidity and mortality, work done in the Garki district
in Nigeria in 1979, where they followed a cohort of children, found that the prevalence of SeD
was 2.1% at birth which was maintained in the first year of life. However, this prevalence
decreased to 0.4% between 1-4 years and 0.05 above 9 years, suggesting a high mortality
amongst the SeD patients. In determining the cause of mortality, although there was less
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parasitaemia in SS children compared to AS the assumption was that when SeD children did get
malaria, it was fatal and concluded that malaria was responsible for the high mortalityI6.176.
In recent years, two studies in Nigeria also found evidence of increased susceptibility to
malaria in SCD individuals. One study looked at 104 consecutive cases of patients with SeD
presenting with severe anaemia (packed cell volume < or = 15%). They found that the most
common problem associated with SCD patients in anaemic crisis was malaria, which occurred
in 68 (66%) of cases177. Similarly, in 102 adolescents and adults with seD [mean age 20.5
years (SD 13.1)] who presented to an emergency unit in Nigeria, sixty-three per cent had
infection of which 24.5% was malaria'", Other reports suggested that malaria precipitates
crises and admissionI78.179.It is important to note that this is evidence from studies that were
small, with the number of seD patients not exceeding 105.
Increased protection from malaria
The evidence from other studies and case reports suggests a reduced prevalence and density of
malaria in SS patients. The most recent studies in Kenya found malaria prevalence per
genotypic group was 44.1% AA, 36.2% AS and 20% SS, giving a relative risk of malarial
infection of 0.33 in SS (n=20) compared to AA (n=626) and AS (n=120)180.Another study in
Nigeria found no significant difference in malaria parasitaemia (p=0.1) or frequency of malaria
attacks (p=O.06) between SS (n=36) and controls (n=37)181. In another prospective study in
Nigeria, which aimed to explore the relationship between size of spleen and malaria, tests were
done to determine the prevalence of malaria and density of parasitaemia in 100 SeD patients
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and 100 controls; 30% and 34% of the seA patients and controls respectively had
malaria parasitaemia. In SeA subjects, the mean parasite density was significantly
lower (p value<0.05) compared to AA controls [1071.10 ± 895.5 per microlitre (range 33 -
4000) cf 1759±1382.87 per micro litre (range 180 - 5150)]182. Again in 1992 in Nigeria,
malaria parasitaemia was documented in fewer children with SeA (9%) (n=162) compared to
controls (29%) (p<0.000Ii83• Once again, the evidence is from small studies where the
maximum number of SeD patients studied was 162183•
Evidence of role of SeD inmalaria
It is difficult to find convincing evidence on the prevalence of SeD in patients with severe
malaria mainly because in most studies, the sickle status of patients with severe malaria is not
known. In addition, if it is known, most of the seD patients will be on anti-malarial
prophylaxis or will receive prompt treatment (at home or empirically on arrival) because of the
belief that malaria is the cause of hospitalisation. The few studies that have been able to look at
children admitted with a diagnosis of malaria, found that severe cases of malaria had the same
frequency of individuals with AA, AS and AS 184. More recent, epidemiological studies
suggest that SeD individuals are protected against malaria, not only in relation to malaria
parasitisation with reduced parasite incidence, but also protection against severe malaria
anaemia 158,161.
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Lack of evidence of increase in malaria in SeD with ineffective anti-malarial
chemoprophylaxis
It has been generally been accepted that individuals with SCD are susceptible to malaria and
should be on malaria prophylaxis to prevent mortality". Furthermore, there was evidence that
more malaria attacks and deaths were observed in SCD individuals who were not on malaria
prophylaxis I85,186.For many years, weekly chloroquine provided a cheap, effective,
convenient approach to chemoprophylaxis. However, over the past 2 decades, there has been
development of malaria parasite resistance to chloroquine. During this period, when a drug
that was no longer effective was being used to treat a potentially fatal condition, there has not
been any reported evidence of an increase in morbidity or mortality in SCD due to malaria.
The lack of evidence may be interpreted in two ways; that malaria does not have a role in SCD
or it does have a role but studies are needed to illustrate this. A recent Cochrane review of the
effect of malaria chemoprophylaxis in SCA found that only two studies, one conducted in
1962 and one in 2003, met the inclusion criteria of a randomised and quasi-randomised
controlled trials comparing anti-malarial chemoprophylaxis given for a minimum of three
months, compared with placebo or no intervention. The first study done in 1965 in Uganda on
126 children reported a reduction in the frequency of malaria episodes and dactylitis as well as
an increase in mean haemoglobin values187• The second study done in 2003 in Nigeria on 97
children reported a reduction in sickle cell crises (RR 0.17,95% Cl 0.04 to 0.83; 97 children),
hospital admissions (RR 0.27, 95% Cl 0.12 to 0.63; 97 participants), and blood transfusions
(RR 0.16, 95o/oCI0.05 to 0.56; 97 participants)188.From these two studies, with a total of 223
children with SCD, the reviews concluded that it is beneficial to give routine malaria
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prophylaxis in seD in malaria-endemic areas 127.
Current management of malaria in sen in Tanzania
Treatment
In Tanzania, there have been reports of increasing resistance of Plasmodium Jalciparum to
chloroquine treatment189,190.There was a policy change in 2001, which recommended the use of
sulphadoxine-pyrimethamine (SP) for uncomplicated malaria as first line therapy, quinine as
second line drug when SP is contra-indicated or has failed and quinine as the recommended
drug for severe malaria. In 2006, following an increase in parasite resistance to SP of up to
25.5%, it was recommended that first line therapy be changed to artemether and lumefantrine
(ALu), an artemesinin-based combination therapy (AeT)191.
For effective management of malaria, treatment needs to be accompanied by prompt and
diagn . H there i ften di . f mal . 192193194and thi . .correct OSIS. owever, ere IS 0 over agnosis 0 ana" s IS more so m
children with SeDt92, where malaria is perceived as a common cause of hospitalisation and
mortality.
Prophylaxis
In Tanzania, until alternative agents are available or in place chloroquine remains the drug
recommended for use for prophylaxis against malaria in seD patients. The dosage is 300mg a
week for adults and 50 mg/kg for children. However, since 2001, when there was the change in
policy with regards to use of chloroquine for treatment, there has been reduced availability in
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the market. Although, the drug is available in regional and tertiary hospitals, it has become
increasingly difficult for patients to receive an adequate and regular supply, with the result that
patients often do not take any or adequate prophylaxis.
There has been discussion with regards to what agents could be used as an alternative to
chloroquine for prophylaxis that will be effective and affordable. In some countries, the agents
that have been used include proguanil, pyrimethamine and mefloquine183,195. However, the
dosage regime for these agents may not be convenient. In addition, the duration for
prophylaxis is not known. Therefore the usual practise is to continue until at least the age of 15
years and often prophylaxis is used throughout lifel96. Unfortunately, there are few data on the
safety profile of these alternative agents, when used over a long period of time. Furthermore,
the impact of insecticide treated nets (an effective intervention inmalaria prevention) has not
been assessed specifically in the SeD patient group. These factors highlight a real urgency to
determine what agents and interventions should be used for malaria prevention in SeD, and
since prophylaxis may be required for a long period of time, there are issues of patient
adherence and compliance as well as the efficacy and safety profile of the drugs that are used
that need to be carefully explored181,195. Agents such as co-trimoxazole and methotrexate
could be used in SeD as they have both anti-malarial and anti-inflammatory activity. An ideal
way to resolve this would be to conduct a randomised controlled clinical trial, but due to the
presumed relationship between SeD and malaria, it is difficult to justify a placebo-controlled
trial127•
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Conclusion
Although the relationship between malaria and the HbS has been "known" for several decades,
there are still basic questions that remain unanswered. With regards to mechanism of disease, it
is not clear how HbS confers protection against malaria, particularly in SeD patients where
one would expect more protection. However, from a clinical perspective, there is a need to
collect evidence that will first elucidate whether malaria is a cause of morbidity and mortality
in seD. Against this background, this study set out to determine the role of malaria in SeD
patients attending MNH. The purpose was to defme the burden of malaria at outpatient clinic
and during hospitalisation. This study also aimed to determine whether malaria was associated
with adverse events such as severe anaemia and mortality. The evidence would allow the
development of policies to guide the appropriate strategies for prevention and treatment of
malaria in these individuals.
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SICKLE CELL DISEASE AND BACTERIAL INFECTIONS
Introduction
Individuals with seD are reported to be susceptible to infections. Besides malaria which is one
of the specific foci of this thesis, seD patients have increased risk of infection with
encapsulated organisms such as Streptococcus pneumoniae 23,197,198. Gaston et al showed that the
use of oral penicillin in the USA had a significant impact on reduction in mortality'!", and it is
now policy in many high-income countries to give penicillin prophylaxis and anti--
pneumococcal vaccination to SeD patientsl99•
The situation in Africa may be different. Aside from the fact that the data regarding the clinical
spectrum of SeD are limited, there is controversy regarding the role and significance of
pneumococcal disease in causing morbidity and mortality in seD in this setting. Here I will
briefly look at the factors responsible for susceptibility to infections in seD and then review
the epidemiology of bacterial infections in Africa, with particular focus on SeD. I will then
consider the various interventions that have been used to prevent and treat infections in seD.
Increased susceptibility to infections in SCD
The various factors that are associated with increased infections in SeD may be directly related
to the immune system or not. Some infections may be the result of a complication or treatment of
SeD itself. SeD patients are at high-risk of transfusion- transmissible infections particularly
with human immunodeficiency virus and viral hepatitis since they receive frequent, often
unplanned emergency BT2OO,201,202,203,204,205. This is particularly important in Africa, given the
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high prevalence of HIV infection and the operational problems in providing adequate blood-
transfusion services. In addition, long-term transfusion may result in iron overload, which in
itself is associated with infections due to Yersinia Enterocolitica206• SeD causes end-organ
damage to the lung, liver, kidney and skin, making these sites susceptible to infection by unusual
organisms. In addition, skeletal complications, poor perfusion and blood supply to bone tissue are
also thought to contribute to increased susceptibility to infections of the bone, osteomyelitis,
which is often due to salmonella infections207,208,209,21O,211. Other factors include high bone marrow
turnover due to chronic haemolysis which results in increased susceptibility to viral infection
Parvovirus B 19 infections is one of the viral infections that predispose to poor outcome with
erythrocytic aplasia that may lead to life-threatening anaemia54,212,213. However, the
epidemiology of this virus in Africa is poorly defined214,215,216.
Impaired immunity in SCD
Individuals with SeD may have impairment of the immune system, which affects both cellular
immunity and humoral immunity. The most well described immune defect is caused by reduced
function of the spleen. Patients with SeD have repeated splenic infarction due to vaso-
occlusion which causes loss of the splenic vasculature leading to hyposplenism '". Reports
have suggested that 14% patients with ss-seD are functionally asplenic at 6 months of age,
with this number gradually increasing; 28% at 1 year, 58% at 2 years, 78% at 3 years and by 5
years, 94% are affected218• One of the roles of the spleen is filtration of unopsonised bacteria
and remnants of red blood cells from intravascular space219,220 as well as opsonised bacteria'".
Furthermore, the spleen is involved in the synthesis of soluble mediators of immunity.
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Therefore patients with SCD, with a functional asplenia, have been reported to have impaired
antibody responses as well as lacking specific antibodies, particularly against Salmonella
species and Streptococcus pneumoniae222;223. This is thought to be due to deficiency of a
complement factor involved in the activation of the immune system. The classic pathway is
activated by antigen-antibody interaction which causes fixation of complement components
Cl, C2 and C4 which then activate C3, whereas in the alternate pathway the antigen directly
activates C3. Activation of C3, which is an opsonin, results in fixing of antigens on the
microorganism224,225,226 making them susceptible to enhanced phagocytosis by neutrophils and
monocytesimacrophage. Johnston et al illustrated that patients with SCD have an abnormality
in the activation of this pathway with failure of full activation and fixing of C3 to encapsulated
bacteria227• This results in failure of SCD patients to phagocytose invading organisms,
particularly Streptococcus pneumoniae.
The distinction between factors directly related to the immune system or not is somewhat
arbitrary as there is a lot of overlap between the various factors. Although there have been
reports of different patterns of infections in patients with SCD, reviewed above and
summarised in table below (Table 7), for this study the focus is on invasive bacterial
infections as detected by blood culture.
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Table 7 Clinical syndromes and common causative organisms reported in SCD
Syndrome Organisms Reference
Septicaemia S. pneumoniae, H influenza, Salmonella Spp, E U".U".~'V
Pneumonia S pnewnoniae, M Pneumoniae, Chlamydiae
Meningitis S. pneumoniae
Osteomyelitis Salmonella spp, E Coli, Gram negative organisms, zss r, ~V". ~VY.~IV. ~II
Aplastic anaemia Parvovirus :>4.,1,. .llj
AIDS and Hej:>atitis RN Viral hepatitis S,C :lIllI. LU I. 'UL.., Wj, ""'. LIJ)
Abdominal pain Helicobacter pylori, Yersinia enterocolitica ,UD
Epidemiology of bacteraemia inSCD
Streptococcus pneumoniae (SPN) is the most common cause ofbacteraemia, sepsis, meningitis
and pneumonia in children231. The rates of invasive infection with SPN have been summarized
by Overturf32 and have been presented in Table 8.
Table 8 Prevalence of invasive pneumococcal infections in healthy and high-risk children,
expressed as the number per 100,000 population
Population Age Subgroup PrevaiencellOO,OOO Reference
US Under 5 years US 5.7 227.8 .lJJ,2J4
African American 20.6 542.2
Over 5 years US total 5.7 .l-'-' .l-'4
African American
SCD Under 5 years 5,500 -6,500 IUI L-':l,2-'b
Over 5years 600 1,100 1UI,.lJ)
Over 2 years 3,100 3,600 .lJ/,2JIS
Modified from 232
The prevalence is much higher in SCD individuals compared to the general population. This was
first reported by Robinson in 1966, where she looked at 305 SCD patients and found 18 episodes
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of meningitis, 87% of which were caused by SPN239.Since then there have been other reports
that have confirmed that SeD patients have increased susceptibility to SPN and other
encapsulated bacteria208,240,241,242.Studies done in the 1970s and 1980s, reported an annual
iIrideo:e ofSPN septicaemia in sen of7-1Oper 100person-yearslOI, 118,243,244.The rates ofSPN infection
in SeD compared to normal children exceeds 20 - 100 fold, with greatest risk in children
under the age of 5 y~' 101,235,245and the highest risk under the age of 2 years101,245.These bacterial
infections, particularly those caused by encapsulated organisms, are a common cause of mortality
among seD cases20,23,208. The case fatality rate due to SPN infection has been reported to be
between 18 - 35 %101,241,243,246.
Management and prevention of bacterial infection s in SeD
Treatment
The management of bacterial infections in children with SeD involves prompt diagnosis and
aggressive treatment, which results in significant reduction in morbidity and mortality'. As a
consequence, in countries where there are comprehensive programmes for SeD, the
parents and carers of SeD children, usually detected by newborn screening, receive
counselling and support so that they can assess fever and recognise respiratory distress,
splenomegaly and jaundice247.It is recommended that they should receive prompt treatment with
broad-spectnun antibiotics such ceftriaxone or cefotaxime/". However, there are various
factors (Table 9) that are associated with increased risk of mortality. For patients with
these features it is recommended that they are admitted for inpatient care and intravenous
antibiotics, after the appropriate blood and urine cultures and haematological investigations
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are taken.
Table 9 Indications for inpatient care with intravenous antibiotics
Age of child «6 months)
Fever of 40°C
History of prior infections especially SPN bacteraemia
Recurrent abdominal pain with/without severe or increasing jaundice
Persistent pain in an extremity accompanied by acute signs of classic inflammation, increased
Chest pain accompanied by persistently decreased oxygen saturation and/or presence of
Increase in jaundice
Signs of toxicity or meningitis
Evidence of respiratory symptoms such as respiratory distress or dyspnoea
Central nervous system symptoms or signs e.g. severe headache, deteriorating level of
Anaemia and/or enlarging spleen, rapid worsening of anaemia or haematocrit less than 25%
Persistent haematuria orproteinuria
Priapism
Source 248. 249. 2SO
There have been a few studies done to understand the significance of fever in children with
seD, as fever is not always associated with infection. A retrospective study published in 2001,
found that fever was more commonly associated with painful crises (27.3%) and acute chest
syndrome (21.8%) than with bacteraemia (6.1%)198.Both pain and ACS are associated with
increased mortalizy57,59,61.This report highlights the need to take a holistic approach to
management of fever in patients with SeD and not assume that all febrile episodes are
infective in nature.
Since infections are a common cause of hospitalisation, there has been interest in improving
management by determining whether care can be given without hospitalisation. Although this
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would reduce the high costs that would be associated with inpatient care as well as improve the
quality of life of patients, there is concern that outpatient care may be associated with the risk
of severe morbidity or death. An initial study reported in 1990, suggested that selected patients
with SeD could be treated as outpatients'". Another study by Wilimas et al. compared
outpatient therapy and routine inpatient management of fever by conducting a prospective,
randomised trial in SeD children (6 months to 12 years) who were seen in casualty department
in a hospital in the USA with a temperature of 38.5°e and above'!'. Patients who were
considered high risk were admitted; and this group included children with temperature> 40°C,
severe pain, signs of dehydration, severe anaemia with Hb <5g!dL, WBC count <5 or >30
x109IUL and pulmonary infiltrates on chest X-ray. There were 233 febrile episodes in 197
patients. Of these, 98 episodes in 86 patients were randomised. Of the 86 patients, 44 patients
(51%) could safely receive outpatient treatment which was estimated to save $1,195 US
dollars per febrile episode. However, the rate of hospitalisation in this group after 2 weeks was
higher compared to those who received inpatient treatment (22% vs. 2%). The data from this
study on safety and efficacy would be more compelling as it was a prospective study.
In addition to outpatient treatment of infections, efforts have been made to reduce the
number of days patients stay in hospitals. Bakshi et al reported that parenteral antibiotics,
ceftriaxone, reduced the number of days of hospitalisation from 214 (6.3 +/- 1.6
days/patient) to 111 days (2.8 +/- 0.7 days/patient)252.
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Prevention
A prospective randomised trial was carried out in Jamaica, between 1978 and 1983 which
showed effective prevention with penicillin. In this study the intervention was benzathine
penicillin given as an intramuscular injection, once a month with no penicillin given to the
control ann and 14-valent polysaccharide pneumococcal vaccine given to both arms. No SPN
infection was reported in the patients receiving penicillin prophylaxis+',
A landmark study done by Gaston et al was conducted between 1983 and 1985. This was a
multi-centre, double-blind, placebo-controlled trial on children aged 3 to 36 months. 105
children received penicillin V (25Omg bd/day) while 110 children received placebo. All
children under 2 years of age also received pneumococcal vaccination. The study was
terminated early because the incidence of infection in the penicillin groups was reduced by
84% (incidence rate ofSPN bacteraemia per 100 patient years 1.5 vs. 9.5; p= 0.0025)117.
The current recommendation is that all patients with seD should be on oral penicillin
prophylaxis up to the age of 5 years. The recommended dose is 125mg twice a day, for
children from 2 months to 2 years. From 2 to 5 years, the dose in increased to 250 mg. There
have been reports of occurrence of SPN infection in SeD patients on oral penicillin237, 254, 255.
This may be due to lack of adherence or penicillin-resistance strains. Therefore, the concern of
emergence of resistance weighed against the risk of SPN infection caused a debate to arise
about continuing prophylaxis after the age of 5 years. The factors that need to be considered
when debating continuing prophylaxis after 5 years using oral penicillin in SeD include
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patient compliance, cost of the drug, adverse effects and the potential for emergence of
resistance. Various studies found that the compliance after 5 years was difficult with reports
ranging from 50 to 70 %237.256.However, Falleta et al. conducted a study to determine the
rate of SPN bacteraemia on discontinuing oral penicillin. A randomised controlled trial
was conducted with 201 SeD patients continuing with oral penicillin (25Omg twice a day)
and the other groups received placebo. These were patients who had received penicillin for
at least 2 years before their 5th birthday and had received pneumococcal vaccination
between 2 and 3 years. The study found that the rate of invasive disease between these two
groups was not statistically significant (0.33/100 person years vs. 0.67/100 person years;
relative risk 0.5 95%eI 0.1-3.6is7• As a result, it is recommended that prophylaxis should
stop at 5 years of age, after the second dose of pneumococcal vaccination. If there is
occurrence of invasive disease, patients should receive prompt treatment with oral
antibiotics and seek medical attention if the condition worsens and requires inpatient care
with intravenous antibiotics. In one study, 570 patients with seD were reviewed. 33 had
sepsis due to SPN, with 3 dying with the first episode of sepsis. SPN infections recurred in 8
out of 30 with seA who had had a previous episodes of sepsis [(odds ratio 5.2 95% Cl 1.9-
13; p=O.OO2)]258.It is recommended that these patients continue with oral penicillin.
Changing trend of bacterial infections
Since the advent of prevention of SPN infections, using oral penicillin, pneumococcal
vaccination as well as prompt treatment of infections there has been a significant decrease
in the incidence of SPN infection in SeD patientsf". However, although the mortality due
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to SPN infections has fallen from 18-35% in the 1970s and 1980s, to 12.5% in 2001259, it is
still a major cause of morbidity and mortality in SCD patients22• Furthermore, there has been
a reported increase in the frequency of other infections such as Salmonella spp and Haemophilus
Influenza in the USA106.118•
Bacteraemia in SeD patients inAfrica
Epidemiology
InAfrica, anaemia, pain and infections or febrile episodes are the commonest problems
reported in children with SCD; with bacteraemia considered to be an important cause of in-
patient morbidity and mortality. In Benin, a definite or presumed bacterial infection was the
cause of the febrile episode in 76.7% of cases 112. Another study in Nigeria, found that 72%
patients with SCD were admitted with fever or with a history of febrile illness, 63% had
infection of which malaria was reported in 24.5%, bacterial in 17% and viral in 6%76.There
was also an association between anaemia and bacterial infections, reported in 18
(17.3%) out of 104 SCA patients admitted with anaemia 177.
The role of infections in causing mortality in SCD has not been well described in Africa. A
retrospective review of 69 children with SeD hospitalized between 1964 and 1985 in
Kinshasa, Democratic Republic of Congo, reported that 18 children (26%) died,
including 10 with pneumococcal septicaemia (5 cases) and 10 with salmonella
septicaemia (5 casesi60• In 62 Zambian children with SCD, the common causes of death
were infections (29.5%). vasoocclusive crises (22.7%) and splenic sequestration crises
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(20.45%i61 and similarly another study in Central African Republic found that after
anaemia, which was responsible for 47.8% of deaths, infections accounted for 30.4% in
23 children with SCA262• Recently, a study conducted in Angola, reported that bacterial
infections was the most common cause of death accounting for 40.1% of deaths in 64
individuals with SC0263.
However, data regarding the pattern of bacterial infections, particularly the role of
pneumococcal disease, in patients with SCD in Africa are limited and conflicting. There have
been studies reporting pneumococcal isolatesl79, 228, 240, 264, 265, 266. However, other reports from Africa
suggest that in SCD individuals who are hospitalised there is a predominance of organisms such as
Klebsiella spp., Staphylococcus Aureus and non-typhoidal Saimonellae21O, 260, 267, 268. This is
contrary to reports from USA and Europe, where SPN is the commonest organism in blood stream
infections. It is possible that important differences really do exist, in the epidemiology of
invasive bacterial disease in patients with SCD, between Africa and the North. For studies
that have shown a predominance of Staphylococcus Aureus, Salmonellae spp and
Klebsiella spp, it has been argued that there may be high level of carriage of these organisms
in the environmenrf". However, there is compelling evidence from large, systematic studies
showing that in the general population SPN is the commonest cause of childhood bacteraemia in
Africa269, 270, 271, 272. Therefore, considering that seD patients are highly susceptible to SPN
infections, there does not appear to be a plausible reason to explain why this pathogen should
not be important inpatients with SCD inAfrica.
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A study in Uganda, failed to find a high prevalence of SPN infection in seD patients. The
study was conducted on a cohort of 155 SeD with age ranging between 3 months to 15
years. Febrile episodes were documented in 1,265 occurrences and 47 (3.7%) blood
cultures were positive. The pattern of bacteria was as follows: S. Aureus 28 (60%); H.
influenza 9 (19%) and SPN 3 (6%). From this study, the authors questioned whether
prophylaxis was justified in Africa229 considering the lack of evidence. However, a review by
Obaro questioned whether lack of evidence implies evidence of absence273. This is mainly
because the evidence that SPN is one of the leading causes of bacteraemia is compellingr",
270 and there is no reason to doubt that SeD patients would have higher rates of infection.
Therefore, the possibility is high that the absence of evidence is due to limitations in the
design of the studies that have been done to get this evidence. The failure to report SPN in
African SeD studies may be due to three factors. First, studies on SeD patients in Africa are
often conducted in hospitals on patients known to have the diagnosis of SeD. Since most
African countries do not have newborn screening programmes; the diagnosis of SeD is made
when they are older. However, most SeD patients will likely succumb to bacterial infections
between 1-3 years of age, before the diagnosis is known. Therefore, it is highly likely that the
SeD cohorts studied in hospital will not have a high incidence of SPN disease. Second, blood
cultures may be taken after patients had already received prior antibiotic treatment either within the
hospital or within the community due to widespread availability of over-the-counter
antibiotics. Third, is that there may be limitations in microbiology facilities at hospitals in
SSA since SPN is a particularly fastidious organism, and there is often difficulty in isolation of
this bacterium from blood cultures.
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In order to address these limitations, a study design needs to be community based or
include all hospitalised patients. Recently, a research centre in Kilifi, Kenya has established a
robust framework to capture bacteraemia events in all children who are hospitalised270.274.
Although the prevalence of SeD is low in Kenya (birth rate <5 per 1,000 ) compared to the
other countries in east Africa4.275this framework and the low likelihood that the SeD patients
who are hospitalised have received antibiotics before hospitalisation allowed this question to be
answered. A retrospective analysis to determine the phenotype in 1,749 (4.5%) of 38, 866
hospitalised patients in a ten year period was done. The study was able to determine the bacteraemia
rates in 108 SeD patients who had been hospitalised during a 10 year period. S. pneumoniae
was isolated in 44 (41%); non-Typhii Salmonella in 19 (18%) and H. Influenza 13 (12%) of
the SeD patients230. This is compelling evidence that SPN has an important role in causing
bacteraemia in SeD patients during hospitalisation who should receive prompt treatment with
effective antibiotics.
Management
There are few countries in Africa with published national guidelines for management of
fever and infections in SeD. However, due to the high prevalence of infections in these areas,
most SCD patients who are admitted are given empirical antibiotics and antimalarial treatment.
However, the assumed association between seD and malaria is better known than that with
bacterial infections. Therefore, in Muhimbili National Hospital, as is the case in most
hospitals in Africa, SeD patients will receive antimalarial therapy, usually intravenous
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quinine, which is first line treatment for severe malaria. However, they will not receive
antibiotics unless the patient is severely ill or there is an obvious focus of infection or signs
of septicaemia (personal observation). There are now increasing efforts to encourage
health care providers to treat SCD patients who are febrile or have evidence of infections with
antibiotics273, 276, 277, 278. In a study conducted in Benin, West Africa to assess the safety and
feasibility of outpatient management of infections, 60 children with fever received
intramuscular ceftriaxone. 76.6% of these febrile episodes were presumed to be due to
infection. No complications, hospitalisation or death was associated with outpatient treatment
suggesting safety in this approach. In addition, the cost of outpatient management was
estimated to be lower compared to inpatient care ($30 vs. $140 per patient) which is
particularly important as most African counties have limited resources 112.
With regards to prophylaxis, resistance to penicillin is relatively low and therefore there is
justification in using daily oral penicillin as prophylaxis in seD children who are less than
5 years. Pneumococcal vaccines have also been recommendedr ". However, the role of
these vaccines needs to be assessed as the 7-valent conjugate vaccine does not cover the
serotypes which have been reported to be common in Africa27S•
Conclusion
In summary, it is likely that bacterial infection, particularly with pneumococcal disease is an
important cause of morbidity and mortality in SCD patients in Africa. There is a need to
provide evidence that is sufficiently compelling to indicate that preventative measures, such as
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prophylaxis with antibiotics and appropriate vaccines should be implemented in patients with
SCD in Africa. In addition, there is a need to define the most effective antibiotic regimens to
manage febrile episodes in SCD. Therefore, against this background, it remains a high priority
to clearly define the importance of bacterial infections in SeD, identify the common causative
organisms and outline clinical and laboratory features that would identify patients at risk of
bacterial infections and complications and targeting interventions appropriately.
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SICKLE CELL DISEASE AND STROKE
Introduction
The increase in survival of SeD patients has allowed long-term natural history and clinical
observational studies. This has been complemented by an increase in the understanding of the
various mechanisms involved in disease pathology. There are recognised clinical consequences
of SeD which are the characteristic acute complications (crises). However, there are also long
term chronic effects of the disease. This is related to the fact that although SeD is due to a
defect in the haemoglobin molecule, the complex erythrocytic and extra-erythrocytic
mechanisms result in a multi-system disease, where almost every organ in the body can be
affected. The organs which have been most extensively studied are the brain (including the
eye), lungs, kidneys, heart and lung.
Several studies, initially through clinical observation, have described the various neurological
manifestations of seD. The spectrum of disease .includes central nervous system (affecting
both the brain and spinal cord), peripheral nervous system, isolated neurological deficits as
well as less well-defined syndromes. The presentation ranges from seizures, coma, mono- or
hemiplegia, brainstem lesions, visual and hearing disturbances, spinal cord syndromes and
peripheral neuropath~80, 281,282,283,284.
The best described consequences of seD for the neurological system are those involving the
brain285• Although patients with SeD may have infections directly affecting the brain e.g.
meningococcal meningitis and cerebral malaria, the main burden of disease has been due to
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non-infectious complications. Cerebrovascular disease (CVD) refers to disorders which result
from pathology of the blood vessels in the brain. This is the most well-described and common
complication in SCD283, 286. There is evidence of both small vessel and large vessel
involvement, with patients presenting with stroke, transient ischaemic attack, seizures, coma,
focal palsies and a range of other rare manifestations. Cerebrovascular accidents (CVA),
commonly referred to as stroke, are sudden neurological deficits caused by injury to part of the
brain due to lack of blood (infarction). They may also result from rupture of a blood vessel and
subsequent haemorrhage into the brain. Transient ischaemic attacks are reversible, resolving
within 24-48 hours and often result from lack of blood or ischaemia whereas CVAs are usually
irreversible and may be caused by either ischaemia or haemorrhage. With an improvement in
neurological imaging techniques, subtle cerebral damage due to infarction has become
increasingly recognized", 85, 287. These lesions were previously referred to as "silent infarcts
since patients do not have a clinically apparent episode of neurological deficit. However, these
"silent" infarcts have been associated with neurocognitive defects in children with SCD84, 85, 288.
Epidemiology of stroke in SeD
In developed countries, the risk of developing CVA is 250 times higher among children with
SCD than in their non-sickle counterpartsf". In the U.S.A., approximately 25% of patients with
SeD suffer a stroke by the age of 45 years83, the peak incidence being between the ages of 2
and 5 years of age283• There is now evidence of "silent cerebral infarcts occurring in 15 to 20%
of children by the age of 6 years85, 86,290, 291, 292, 293. This causes significant impairment of higher
cognitive and executive function with reduced intellectual and academic performance and is
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thought to be highly predictive of overt stroke84, 85, 86, 291, 294 .
Although, the overall incidence of stroke is estimated at 1.29 per 100,000 per year for children,
the incidence of stroke in children with SeD was estimated at 285 per 100,000 per year 289.
These have been stratified by age with the rates shown in Table 10.
Table 10 Age-related incidence of first stroke in SeD in the USA (modified from [83])
A2e2roup Incidence of stroke
<2 years 0.13 per 100 patient years
2-5 years 1.02_per 100 patient years
6-9 years 0.79 per 100 patient years
10-19 years 0.41 per 100 patient years
20 49 years 0.52.0.74 per 100 patient years
>50 years 1.28 per 100 patient years
Stroke in seD may result from haemorrhage, thromboembolism or infarction. Overall, stroke
due to infarction is more common295 and has two peaks; between 2-5 years and above 30
years. On the other hand haemorrhagic stroke, which is less common, occurs in young adults".
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Figure 13 Hazard rates of infaretive and haemorrhagie stroke in SeD patients by age
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Figure showing hazard rates of stroke in SeD. The solid line shows the rates of infarctive
stroke at different ages while the dashed line shows haemorrhagic stroke.83
InAfrica, the evidence seems to suggest that the incidence of stroke amongst patients with
seD may be higher than in the U.S.A., with reported rates of 1.3per 100 per year296, 297, 298
compared to 0.61/10083• The age-group most affected, 2-5 years is similar in both regions. In
Nigeria, a study looked at neurological events in seD patients over a 12 month period. These
occurred at a prevalence of 1.3% with eVA accounting for 57.5%, meningitis 22.5% and
recurrent seizures 10010 of these events297• InKenya, a larger and longer study was conducted to
assess neurological complications in stroke. This was a retrospective study done at Kenyatta
National Hospital (KNH) which is the main hospital inNairobi, the capital of Kenya. In this 5
year retrospective analysis, 18 SeD patients aged between 7 months and 21, years had
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neurological complications. 12 (76%) of these were eVA, 6 (33.3%) were seizures and other
complications were visual and hearing disturbances as well as confusion and hallucinations 298.
The relatively high incidence of SeD-associated stroke in Africa has been suggested to be due
to the presence of higher rates of some factors in Africa which are associated with increased
risk. These include low haemoglobin, leucocytosis and eAR ~-globin haplotype.
Risk factors
A number of factors have been found to be associated with an increase risk of stroke in seD.
These include age, which as mentioned above, the 2-5 year age group is particularly
susceptible. Although most vascular events occur between the ages of 5 and 10 years, there is
another peak above 50 years. It is thought that stroke may have different pathophysiological
mechanisms which are dominant at different ages; vascular stenosis due to seD in the younger
age group, haemorrhage during adolescents and adulthood and infarction in the older age
group'".
Other risk factors for stroke in SeD children include low red blood cell indices particularly
Hb, HbF, RBe count as well as high nucleated red cell, white cell and platelet counr'", 299, 300.
High homocysteine levels which result from low folate levels are also associated with
increased risk of stroke; folate is required for homocysteine metabolism?".
Some clinical syndromes that have been correlated with prediction of stroke include previous
TIA, a recent history of acute chest crisis, high acute chest syndrome rate, recurrent painful
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episodes (more than 3 a year)23,302,303. Hypoxia, particularly nocturnal hypoxaemia, has been
associated with CVA304.
Table 11 Factors associated with increased risk of cerebral infarction
Clinical factors
Age 2-8 years
Family history - sibling with a stroke
Repeated episode of convulsions
Acute anaemic episode (Hb 2g1dl below normal level)
Bacterial meningitis
Acute chest syndrome
Splenic dysfunction/infarctions near age 1 year
Priapism
Decreasing academic performance
Impaired neurocognitive function
Laboratory factors
Haemoglobin (steady-state concentration <7.5g/dl.
low red blood cell count
high nucleated cell counts
High reticulocyte count
Platelet count
Pitted/pocked RBC
Foetal Hb <13% by 2 years
CAR Beta globin haplotype
No alpha gene deletion
JU:IModified from
Mechanism of disease
Although SCD is often thought to cause small vessel disease, the most common pathology in
the brain is due to large vessel involvement. A complex interplay of different
pathophysiological processes causes a progressive proliferation of endothelial wall, collection
and organisation of mural thrombi, resulting in narrowing or stenosis of the blood vessel.
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These events have been summarised previously in the review of pathophysiology of disease in
SeD. This can occur at any site but commonly affects basal cranial arteries, in the circle of
Willis; predominantly in the distal internal carotid artery (K'A) and the proximal middle and
anterior cerebral artery (MeA and AeA respectivelyi06• As a consequence, eVA frequently
involves the watershed distribution between the AeA and MeA within the frontal lobes=".
Although, one of the consequences of progressive stenosis is eventual occlusion and
ischaemia, the body may respond by the development of small vessel collaterals, which bypass
the stenotic portion of the large blood vessee08. This phenomenon which results in an
angiographic pattern referred to as the Moyamoya syndrome has been reported in seD patients295,
309, 310 and found to be useful in predicting the recurrence of eVA in seD patients'!', The
pathological consequences in small intracerebral vessels are cortical and sub-cortical branch
occlusions, which normally affect the frontal lobe and manifest as subtle higher executive
fimction abnonnalities312,313. The effect of other mechanisms of ev As in patients with SeD is not
known. However it is suggested that hypoxia'?', which has been associated with increased risk of
stroke promotes polymerisation of HbS and adhesion of RBe to endothelium and platelet
and white blood cell adhesion39,313-315.
Diagnosis
Diagnostic techniques such as cerebral angiography, magnetic resonance imaging and
Transcranial Doppler (TeD) ultrasonography are used to detect cerebrovascular disease''".
However, for purposes of this thesis, the focus will be on TeD.
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Transcranial doppler ultrasonography (TeD)
Transcranial Doppler (TeO) ultrasonography is a technique that was devised by Aaslid as a
non-invasive technique for measuring cerebral blood flow velocity (Clsfv) in the basal cranial
arteries'". It uses ultrasound to measure the velocity of red blood cells and by application of
Dopplers' principles can estimate the velocity of blood flowing in large cerebral vessels
through an intact cranium. TeD measures the time-averaged maximum mean velocity of the
blood flowing in large cerebral vessels (TAMMV). Although an increase in velocity may be
due to stenosis or increased cerebral blood flow, studies have determined the abnormalities in
blood velocity that are predictive for stenosis. Studies done in the USA found that a low
haematocrit can increase the velocity up to 150 cm per second in the middle cerebral artery
(MeA), but values greater than this are more likely to be due to stenosis '".
TeD ultrasonography has been found to be highly sensitive and specific in identifying
cerebrovascular abnormalities by detection of arterial stenosis and occlusion in both
symptomatic and asymptomatic SCD patients319, 320, 321. In a study conducted in the USA, 9.7% of
children were found to have eBFv abnormalities, with more children between 2 to 8 years of
age (10.7% i94• The cut-off point that was found to be predictive of risk of stroke was a flow
rate of 200cm per second in the MeA, which was associated with a 40 percent risk of stroke
within three years319• Therefore, this is the cut-off point that is taken to defme seD patients
who are at high-risk for stroke and therefore require more aggressive interventional strategies.
Although Teo ultrasonography has not been used in seD in Africa, it has the advantage of
being relatively cheap, safe, well tolerated, and therefore an ideal investigation in hospitals in
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resource limited countries where cerebral angiography and MRI are not feasible.
Magnetic resonance imaging
Imaging techniques such as high resolution computerized tomography (CT) and magnetic
resonance imaging (MRI) are used for the diagnosis of Cv'A. The latter is particularly good in
the detection of clinically silent infarcts which are associated with increased risk of stroke86•
322. However, neither technique is practical or economically feasible in many of the poorly
resourced areas in sub-Saharan Africa (SSA). In addition, these investigations are mainly
diagnostic of neurological events whereas TeD is used for identifying high-risk patients and
therefore allowing primary intervention. In such circumstances, a combination of TeD
examination and careful neuropsychometric evaluation has been suggested to be helpful in
screening and identifying those children with early eNS pathology or silent infarcts84• 294. 323
which can then be confirmed by more specialised techniques such as MRI or Cf scanning.
Treatment and prevention
There has been progress in the primary and secondary prevention of stroke as there is
improvement in the ability to identify SeD patients who are at particularly high risk of stroke
and therefore require aggressive interventional strategies.
Several randomised controlled trials have shown that initiating aggressive management
strategies such as long-term transfusion therapy in these patients can significantly reduce the
incidence of stroke. In a randomised controlled trial conducted in 1998, 130 children with seD
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who had abnormal CBFv (above 200cm/sec) docmnented on two occasions with no history of
previous stroke were randomised to receive standard care of treatment or blood transfusion 120.
Standard care of treatment included penicillin prophylaxis, pneumococcal vaccination, folic
acid supplementation, surgery for chronic hypersplenism, treatment of acute infections
including blood transfusion when needed for transient episodes but excluding use of
Hydroxyurea. The aim of blood transfusion was to reduce the HbS levels to less than 30%
within a period of 21 days without exceeding a haemoglobin concentration of l2g/dL or a
haematocrit of 36%. There was a 92% reduction in risk of stroke in the patients receiving
blood-transfusion, which led to early termination of the trial'20. It is now recommended that
children with SCD between 2-16 years of age, should have annual TCD ultrasonography to
measure their CBFv, and for those with a CBFv of more than 200cmlsec, which is classified as
abnormal, the recommendation is that they should be started on long term blood transfusion
(LTBT) programmes'". However, there have been difficulties in ensuring compliance and
adherence to LTBr25, 326.1be regime involves blood transfusion every 3-6 weeks and it is not
entirely clear what should be the duration of the regime since there is evidence to suggest that
discontinuation of therapy results in a high risk of recurrence322. Despite this high risk of
recurrence, patients and their caregivers have difficulties complying. This is because of having
to go to hospital every 3-4 weeks as well as venous access'". In addition, there are concerns
with LTBT such as iron overload and alloimmunisation, as well as a risk of transfusion
transmissible infections (TTls)327. These limitations are particularly pertinent in SSA where
there is the added problem of availability of adequate blood supply, with use of replacement
donors and there is often no screening for RBC antibodies before transfusion.
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Alternatives for LTBT for prevention of stroke have been investigated. Hydroxyurea which has
been found to be beneficial for other adverse clinical outcomes in seA 128 may also be a useful
alternative inpreventing stroke in high risk patients328, 329, 330
Conclusion
A more comprehensive picture of the burden of stroke in SeD in Africa needs to be
established. Due to the variability of phenotype and the different pathophysiological
mechanisms for the same event, it is important to establish the associated risk factors in
Africa. This will involve looking at known risk factors as well as looking at factors that can
be established in a cost-effective manner in a resource limited setting. In this context, given
that TeD ultrasonography is relatively cheap, safe and well-tolerated, it should be feasible to
use this technique to determine the spectrum of cerebral blood-flow velocities in African
children with SeD and, subsequently, to define a high-risk group for targeted investigations
such as MRI and CF scanning of the brain with potential interventions with LTBT or
Hydroxyurea.
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SICKLE CELL DISEASE AND FOETAL HAEMOGLOBIN
Introduction
As reviewed previously, there are three haemoglobins in normal individuals HbA, HbAl and
foetal haemoglobin (HbF). This chapter will focus on reviewing the physiology and
measurements of foetal haemoglobin (HbF) followed by a review of its role in SCD and
malaria.
Pbysiology
The main function of red blood cells (RBC), transporting oxygen and carbon dioxide between
lungs and other tissues, is carried out by haemoglobin. Hb has properties that allow it to bind,
transport and release oxygen and carbon dioxide. Since the environment during embryonic,
foetal and adult life with regards to availability and source of oxygen differs the properties of
the haeme molecule in binding and releasing oxygen have to differ at each of these stages.
Therefore, physiologically there are 6 types of haemoglobin, embryonic (Gower I and 2,
Portland); foetal Hb (HbF) and adult haemoglobin (HbA and HbA2). The distribution of these
haemoglobins in individuals gradually changes during development.
During the intra-uterine period, the foetus receives oxygen from the maternal circulation in the
placenta. The main Hb present in foetal RBCs is HbF which has a higher affmity for oxygen
then Hb A, which is the main Hb in maternal RBCs. Since the oxygen saturation of the
maternal blood in the placenta is low, difference in affmity allows effective gas exchange
across the placenta. At birth, HbF constitutes 60 to 80% of total Hb and during the first 2 years
of life, there is gradual transition to adult haemoglobin, consisting of Hb A, with small
amounts of Hb A2 and Hb F (0.5 to I%).The composition of Hb in RBC remains fairly
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constant throughout adult life. The variation in the haemoglobin from embryonic to intrauterine
HbF to adult HbA means that during development there are two switches in the p - like gene
expression from e to 'Y and then to Jl- globin genes. This process of switching from one gene
to another during development has been the focus of a lot of research in order to understand
the factors controlling 'Y-globin gene expression, in order to increase HbF production in SCD.
Factors inOuencing HbF levels
There is a wide variation of Hb F in the population, with 85 - 90 % individuals having HbF
less than 0.6 - 0.7% and F-cells (red blood cells containing any HbF) are less than 4.5%. The
other lO-15% of the population has values above these levels. The factors that influence the
HbF levels include age, sex (females have higher levels), pregnancy and a - globin gene
number. Genetic factors that influence HbF levels mayor may not be linked to the J3 - globin
gene region, with the former associated with the variation in HbF levels with the different
sickle haplotypes. On the other hand, the F-ceU production locus (FCP) on the X-chromosome
account for the difference between 11% men and 21% females who have higher HbF level.
The three factors that determine HbF levels are number of F cells (determined by percentage of
F-reticulocyte), amount of HbF per F-cell and the preferential survival of F-cells over non-F
cells331•
F-Cells (FC), non-F cells and F-reticulocytes: HbF is restricted to a sub-set of specific red
blood cells (RBCs) called F-Cells (FCs) and the rest of the RBCs which do not have detectable
levels of HbF are known as non-F cells. Although, the percentage of FCs within an individual
is stable, there is a wide variation between individuals. The percentage of FCs in normal
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individuals ranges between 0.5 to 7%, while in SCD, the range is broader and levels are higher
(up to 6(010)331.
Hb F per F CeU: To add complexity to the situation, HbF is not evenly distributed in FCs.
Studies have shown that concentration of HbF per FC is not constant, and ranges between 4-6
picograms. The average amount of HbF per FC varies amongst individuals with SCD332, but
the maximum percentage ofHbF in each Fe does not exceed 25% of total Hb.
Survival of F-ceUs: There is selective destruction of Non-F cells compared to FCs. This
preferential survival of F-cells can be calculated by the ratio of FCs to F reticulocyte, which is
known as the enrichment ratio. Although the presence of HbF in FCs, protects it from sickling
and therefore ensures its survival over non FCs, it appears that there may be other factors that
are responsible for the preferential survival ofFCs331,333.
Hereditary persistence of foetal baemoglobin (HPFH)
HPFH refers to a group of conditions characterised by synthesis of HbF into adult life in the
absence of evidence of baematologica1 disease. The distribution of HbF may be pancellular or
heterocellular. In hereditary HPFH, the distribution of HbF is pancellular/even and levels are
higher in African (25-35%) than Mediterranean (12-25%) populations+". In heterocellular
HPFH, the distribution of HbF is uneven between the cells and levels are often less than 10%,
having been described in Swiss and Northern European populations.
84
= 8 0~~ 0 0
=
..... .....
= 0 -+~ II") ~~ ~ ~ 0 ~ 0 ..... '"'00 0 "R I 0 I 0= v II") ..... .....I M ..... ZIIJ
r=.
~
0 II'! ~ 0 s M NI M M CV I ..... ..... -+I /I. 0 IIIJ 00 II") /I. II") II") 0\
l II") 0 0 0 ~~ \0 0\00 0 M 00 N cb ..... I -+/I. /I. V \0 r-I II")
IIJ
0 0 ~
CI'l ~ II") 0 0 \0 ~ ~ 00 '"'0 .....IIJ CI'J M 0\ I cb II") I I 0V N II") II") \0 ZII") N
0 II") N e- ~
CI'l CI'J r-- M ,. I I II") ..... Z.( < I I II") ..... III") N 0 II") .....
II") M 0 0 .....
N r- ~
~ ~
e-- M I I II") ..... Z0\ I 0 II") II") ..... IN 0 .....0 .....
r.rJ 0 II")= 0... ..... 00 NQ,I I 0 0e II")
~ \0 N
~
I~
'3
I~ I~
~
o.~
I~
rIl
~ ~ ~
a:: I~ e.
~ I~ ~ I~ 'i) ;0 I~ .9 0-g es le.... ~
~
;j u
g ~ ~ ~ I~ ~ ~
.g
~
I~
N I~ 1--= -.;;;i11 ]I~ I~ les ~ ~ j ;j~ ~ CI'J ~ II) 8~ ffl ffl rt ~ 0~ ~ >
...:
Laboratory measurement of foetal haemoglobin
Quantification of HbF
The quantification of HbF can be done using a number of methods. Betkes method uses
an acid-elution technique which allows the estimation of HbF per ce1l336• This is
normally reported as a percentage of total haemoglobin. However, this method is limited
because the laboratory procedures are complex and require diligent, labour-intensive
skills.
The second method is done by initially performing haemoglobin electrophoresis and
identifying the HbF bands which are then measured by densitometry. A third method uses
radial immunoprecipitation to quantify HbF levels. However, the HbF levels using radial
immunoprecipitation have been reported as being higher and this could be misleading=".
The quantification of HbF by high performance liquid chromatography (HPLC) uses ion-
exchange chromatography to identify the different haemoglobins in blood, and determine
the levels of Hb in each individual+". This method is increasingly becoming more
widely used as it is automated and not user-dependent and is therefore the gold-standard
for Hb quantification. With the increase of availability of HPLC, it will be possible to
accurately describe the range of HbF in normal and SCD individuals in resource limited
settings.
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Detection of F-ceUs
The Kleihauer - Betke method has been used to stain and count the number of FCs
present in individuals and is reported as a percentage of RBC28. This method is slide
based and requires microscopy and is therefore labour intensive, time consuming and
prone to methodological errors. The use of fluorescent-labelled anti-F antibody allows the
detection of FC on fixed smears. However this method cannot measure the HbF
concentration per cell. Flow cytometry using anti-Hbf antibody, is a simpler method of
counting the number of FCs, and flow cytometry, both simple and fluorescence activated
cell separator (FACS) systems have been used to accurately and rapidly detect and
quantify FCs332, 339, 340.
FOETAL HAEMOGLOBIN AND SICKLE CELL DISEASE
Physiology of HbF inseD
In individuals without SCD, the levels of HbF are between 0.5 and 2%. Most patients
with SeD have elevated levels of HbF compared to normal individuals, with marked
variation within individuals, and has been found to be up to 20- fold in some populations
9. The factors responsible for this variation include age, sex and a-globin gene number.
The j3-globin haplotype have also been associated with different HbF levels, with the
Arab - Indian haplotypes having higher levels of HbF followed by Senegal, Benin and
CAR haplotypes. This probably explains the findings that the levels of HbF go up to
10% in Africa ISO, 341, 342, 343, 344, 345; and 30% in the Arab region346• However, there are genetic
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factors that are not linked to the J3-globin gene, one of which is an area located on the X
chromosome known as the F-cell production locus (FCP). Although the FCP locus is
thought to be the most important determinant identified, more than 50% of the
variation cannot be explained by known factors. These other factors are thought to act
by varying the levels of FCs, HbF concentration per cell and preferential survival of FCs.
Amelioration of severe disease by HbF in SeD
There is a wide variation in the clinical severity of disease in individuals with seD and
this has been attributed to various genetic and environmental factors. High levels of HbF
is one of the more important factors that has been associated with modifying clinical and
laboratory features, reducing the severity of disease and mortality 57,61.Furthermore,
epidemiological studies have reported that certain populations have milder forms of the
disease, attributable to high HbF levels346,347,348,349..
There has been considerable debate regarding the levels of HbF required to ameliorate
disease. In 1980, Powars et at specifically looked at 14 clinical and haematological
parameters in a cohort of 272 patients with SCA in the USA and were unable to establish
the effect of HbF on their phenotype35o. This led to studies that suggested that for HbF to
be associated with mild disease, the levels have to be above a 10% to prevent major
organ failure e.g. stroke and above 20% to prevent recurrent clinical events e.g. painful
crises351,352. InAfrica, there are few studies, mainly in West Africa to evaluate HbF and its
association with disease severity. The results from these studies have been conflicting
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with some reporting association with severe disease and others not showing any
sig)1ificmt ~15O,341,342,343,344,345.
Mechanism
As previously mentioned, the rate of polymerisation of HbS depends on the total
concentration of Hb, as well as the relative composition of HbS and non-HbS Hb within a
RBC. The ability of HbS to polymerise is significantly reduced by the presence of
HbF 10, 26, 27. In addition, the high level of HbF "automatically" reduces the amount of Hb
S in the RBC28• The result is fewer irreversibly sickle cells, reduced rates of haemolysis
and preferential survival of FCs. However, even with high HbF levels, there is evidence
that suggests that other factors such as Fe production, concentration of HbF per FC and
FC survival, may also influence the ameliorating effect of HbF33I.
Therapy
Since high levels of HbF are associated with protection from severe consequences of
SeD, interventions that would increase the levels of HbF have been used in the treatment
of SeD. These interventions include pharmacological agents that are known to augment
HbF levels and other interventions involving the manipulation of genetic switching to
ensure that HbF levels are produced at high levels, similar to the intrauterine, foetal
period.
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Pharmacological augmentation of HbF
There are two groups of drugs which have been found to be associated with an increase in
HbF levels: cytotoxic drugs which interfere with DNA synthesis such as Hydroxyurea, 5-
azacytidine & its analogues and short chain fatty acids. The second group are agents that
stimulate the production of erythropoiesis such as erythropoietin.
Hydroxyurea
Hydroxyurea (HI) has been studied extensively and found to increase the number ofF-
reticulocyte, F-cells and HbF levels353354.A series of clinical trials have found that the use
of HI is associated with improvement in various clinical and laboratory events in seD
(Table 13).
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A landmark double-blind, randomised control trial was published in 1995 which was stopped
after a mean follow-up of 21 months. Amongst 148 men and 151 women studied at 21
clinics, the 152 patients assigned to hydroxyurea treatment had lower annual rates of crises
than the 147 patients given placebo (median, 2.5 vs. 4.5 crises per year, P < 0.001). The
median times to the first crisis (3.0 vs. 1.5 months, P = 0.01) and the second crisis (8.8 vs. 4.6
months, P < 0.001) were longer with hydroxyurea treatment. Fewer patients assigned to
hydroxyurea had chest syndrome (25 vs. 51, P < 0.001), and fewer underwent transfusions
(48 vs. 73, P = 0.001)128. The effect of HU on mortality was shown by Steinberg et af in
2003, where they reported a 40% reduction in mortality (P =.04). However, patients with
reticulocyte counts less than 250 000/mm3 and haemoglobin levels lower than 9 g/dl, had
increased mortality (p =.(02)363.
However, there are limitations with HU therapy. In about one third of patients, HU does not
seem to have any effect on HbF levels, and the reason for this is not entirely clear'?". It is
therefore important to identify very early on the patients who are likely to respond in order to
avoid patients being on a cytotoxic drug that will have no benefit. Attempts have been made
to identify factors that may be predictive of a good response; and these include plasma
hydroxyurea level, initial white blood count and initial HbF concentration. Others include
high baseline counts of reticulocytes, two or more episodes of study-defmed myelotoxicity
(note that myelosuppression is target of therapy and this has to be balanced with
myelotoxicity), and absence of a CAR haplotype354,364.
HU is also associated with toxicity including gastrointestinal disturbance (nausea), hair loss,
skin rash and the most significant being myelosuppression. The latter is reversible on
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stopping HU intake, and therefore patients on HU require monitoring to be done on a
monthly basis. A long term side affect of HU is that as a cytotoxic drug that interferes with
DNA synthesis, it has the potential of causing DNA mutation. Although there is a suggestion
that prolonged use of HU may be associated with an increase risk of carcinogenesis, in
particular with acute leukaemia, there has not been such an increase risk seen when HU was
used in other conditions365-367.
Othn agents tluU increase HbF levels
Azacytidine and its analogues
Decreased HbF production is associated with DNA methylation (by DNA methyltransferase
[DNMT]) at the gamma-globin (HbF) gene promoter. Therefore cytosine analogs such as 5-
azacytidine and 5-aza-2'-deoxycytidine (decitabine) hypomethylate DNA by inhibiting
DNMT, resulting in an increase in HbF levels368.Clinical trials with Azacytidine showed a
consistent response in increasing HbF levels369. Other azacytidine analogues such as
decitabine are being tried for use in patients who do not respond to HU370,371.The further
development and use of azacytidine was stopped due to concerns of toxicity and increased
risk of cancers. However, there is currently interest in use of decitabine as it has been found
to be useful in preventing certain cancers372,373.
Short chain Fatty Acids
Butyrate and other short chain fatty acids have been found to also increase HbF levels374-377.
However, the limitation of this group of pharmacologic agents is that in order to achieve
adequate HbF levels, a continuous intravenous infusion is required. Moreover, this increased
is not sustained with continuous therapy, requiring an intermittent dosing schedule377, 378.
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Orally administered butyrates have been tried but are again limited by the formulation;
requiring an intake of over 30 tablets a day75.
Erythropoietin
Studies in animal models, showed that HbF production could be induced by the use of
erythropoietin'I" 380. Although some studies suggested that use of erythropoietin in seD
patients may not be of measurable benefit53, Rodgers et al showed that if it is used with HU,
the effects ofHU are augmented, more so than ifHU is used alone381.
Switching
Although the mechanism of switching of globin gene expression resulting in production of
HbF in foetal life to adult haemoglobin in the first year of life is beyond the scope of this
thesis, it is worth mentioning that there is extensive research into understanding the
mechanisms responsible for controlling the switching. This is because by understanding the
mechanisms responsible for production of foetal haemoglobin in adult life, this will provide
alternative routes for therapeutic manipulation.
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FOETAL HAEMOGWBIN AND MALARIA
Protection against malaria in SeD
There is now substantial evidence that individuals with seD have resistance against malarial
infection per se. Such protection has been shown in a number of epidemiological studies 159-
161 and is supported by the results from in-vitro studies that indicate a range of potential
mechanisms, including reduced invasion of HbAS erythrocytes by malarial parasites, reduced
parasite multiplication, and accelerated parasite clearance by the spleenl64, 382, 383. The
protective role of HbS in malaria has been studied extensively and is covered in detail in
chapter 5 in this thesis. In this section, I will concentrate on the role of foetal haemoglobin
(HbF) in malaria, particularly in seD.
The protection that is described in SeD has been attributed to HbS. However, SeD
individuals possess HbF, which has properties that may contribute to malaria resistance. The
epidemiological evidence of protection of HbF against malaria can be seen in the first year of
life. During this period (birth to 9 months) children have been reported to have few episodes
of malaria, and they have not developed immunity384. The protection during this period is
partially thought to be due to maternal antibodies, but HbF may also contribute to immunity
during this period as it is the only Hb present in circulation. (Note Hb in neonatal period is
almost 100% HbF) and has been shown to be protective against malaria. The proposed
mechanism of protection by HbF is backed by evidence from clinical, in-vitro and studies in
animal models is as follows: there is preferential invasion of young RBes by the malaria
parasite over HbA containing RBes385. Therefore, parasites are "directed" to invade HbF
containing cells (foetal, F-cells). However, HbF has been shown to be resistant to parasite
digestion with malaria parasites showing slow rates of growth in HbF containing cells386, 387.
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Therefore parasitised, HbF-containing RBes will have a retarded growth, shortened life span
and will be rapidly cleared from the bodi88• This model seems plausible, as in the first 6-9
months the main Hb is HbF, and it is only after this period that the protective effect of HbS
starts having a role384•
Conclusion
Foetal haemoglobin has an important role in ameliorating disease severity in patients with
SeD, with agents that increase HbF levels being effective options in treatment of SeD. In
addition, the role of HbF in protection against malaria has not been entirely elucidated. In this
thesis, I will examine the spectrum of HbF levels in patients with SeD and explore the
relationship with disease morbidity and mortality, with particular focus on malaria, bacterial
infections and stroke.
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CONCLUSION
On reviewing the literature on SeD, I conclude that although the single gene mutation in
SeD has allowed extensive research to understand the role of sickle Hb in clinical disease, it
is now apparent that there is a complex interplay between the genotype and the extremely
heterogeneous phenotype. From a public health perspective, there is a high prevalence of
SeD in Africa and it causes considerable burden to individuals, communities and the health
system. Therefore, Tanzania needs to develop a policy that will guide interventions that can
be used in the short-term, and start planning a more detailed management plan for the long
term. In the medium to long-term, with economic development in low income countries such
as Tanzania, there will be a demographic transition, making chronic, non-communicable
diseases such as SeD have increasing importance. Research in high income countries has
shown evidence of reduction in disease morbidity and mortality with the application of
relatively simple interventional measures. There is every reason to believe that the
application of some of these interventions would have similar results in Africa.
Model for control of genetic disorders
Within the past 10 years, there have been significant advances in the field of genomics,
marked by the publication of the human genome sequence. Since then, various technologies
which were previously confmed to academic or research oriented centres, have become
available in health care. Although the growth of the field of medical genetics (which deals
with the application of genetics to medicine) has rapidly expanded in resource-rich countries,
it is inevitable that developing counties will need to engage with medical genetics' 389. It is
therefore important that within developing countries there is a strategy that is formulated to
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form the basis of the introduction of medical genetic services for care and control in these
countries". SeD could be considered the most important public health genetic disorder
because it is common and severe, causing considerable burden to the health system. The
problems that hinder establishment and implementation of a control programme of genetic
disorders include lack of awareness (of prevalence and significance) and lack of organisation
which can be addressed by strategic advocacy to key policy makers, patient/parent support
groups and community education' 3. Once this is done, there is compelling evidence that
SeD could be reduced because it can be diagnosed by simple, cheap tests and the care and
treatment can be incorporated into the primary health care system, with only one "central
reference laboratory/treatment centre!". For these reasons, SeD would be an "ideal disease
that could be used as a good model for developing a frame-work for delivering cost-effective
genetic services to the community in developing countries390.
Understanding disease mechanisms, population and evolutionary genetics
Since the discovery of SeD as a molecular disease in 1949 and the subsequent
identification of the single gene defect in 1956, there has been extensive research in trying to
understand the relationship between genotype and phenotype, resulting in significant
progress in our understanding of disease mechanisms and factors modifying disease severity.
SeD is also a disease that could be used to understand population and evolutionary genetics
by studying recent selection pressures, like malaria, on the development of the human
genome. Therefore, it is thought that by using the tools and techniques that are now available
and with the appropriate investment, it is possible that major leaps in scientific knowledge,
would most likely happen with a simple monogenic disorder like seD.
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RATIONALE FOR THE STUDY
This thesis will describe the clinical and laboratory characteristics of SeD patients in
Tanzania. The focus will be on malaria, bacterial infections, neurological events and foetal
haemoglobin as these are considered to have a significant role in causing disease morbidity
and mortality. In addition, these areas have various interventional options that can be applied
to the magnitude of illness and death in individuals with SeD. Unfortunately these
interventions have not been used in Africa probably due to the limited resources available in
most of the countries in sub-Saharan Africa. The aim is to provide an evidence-base that is
locally appropriate which will guide the development of policies for the management and
control of SeD in Tanzania.
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Chapter Three
Materials and Methods
STUDY AREA
Tanzania
Tanzania is situated on the eastern coast of Africa between longitude 290 and 410 East,
Latitude 10 and 120 South covering 940,000 square kilometres. It has a population of 40
million with a population growth rate of 2.1 %. 36% of the population lives in an urban area.
Tanzania is a low income country which has one of the lowest gross national income (GNI)
per capita in the world at 730$, with 36% of the population living below the national poverty
line. Note the GNI is converted to international dollars using purchasing power parity rates.
An international dollar has the same purchasing power over GNI as a U.S. dollar has in the
United States391•
The national expenditure on health is 4% of gross domestic product (GDP). This covers the
total health expenditure and is the sum of public and private health expenditures figured as a
percentage of a country's GDP. It covers the provision of health services (preventive and
curative), family planning activities, nutrition activities, and emergency aid designated for
health but does not include provision of water and sanitation. The physician to population
ratio is 0.04 per 1,000 people. The annual birth rate is 1,400,000 per year with a life
expectancy at birth of 52 years. The infant and under five mortality rates are high at 104 and
125.6 per 1,000 live births respectively'". Tanzania mainland is divided into 21
administrative regions which are further divided into 106districts (Figure 14).
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Figure 14 Map of Tanzania showing administrative regions
Source http://www.tanzania.go.tz/census/census/map2.htm. The shading denotes
population density.
Organisation of health services
The health services in Tanzania are organised into three levels with health centres and district
hospitals at primary level, regional hospitals at secondary and tertiary level hospital services
being provided by national, referral and specialised hospitals. Tanzania is divided into 4
geographical zones, each with one referral hospital. MNH is the national hospital and also
serves as the referral hospital for the eastern zone. The other hospitals are Kilimanjaro
Christian Medical Centre (KCMC) based in Kilimanjaro region and serving the northern
zone, Bugando referral hospital ba ed in Mwanza region and serving the Western Zone and
Mbeya Referral Ho pital, ba ed in Mbeya region and serving the southern zone.
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Dar-es-Salaam
Dar-es-Salaam is the main administrative region of Tanzania, with a population of 2.5
million. It occupies an area of 1,392 square kilometres and at 1,800 persons per square
kilometre has the highest population density in Tanzania. Dar-es-Salaam region has 3
districts (population in brackets) - Ilala (640,000), Kinondoni (1,100,000) and Temeke
(780,000). The socio-economic status of these three districts is heterogeneous with
Kinondoni having a more affluent population and Temeke having the highest concentration
of low income households. The study was carried out in Muhimbili National Hospital
(MNH), which is located in Ilala district. This district has the lowest population density in
Dar-es-Salaam and has areas of the most intense malaria transmission'?'.
Figure 15 Map showing the three districts in Dar-es-Salaam
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Muhimbili
Muhimbili consists of the Muhimbili University of Health and Allied Sciences (MUHAS)
and Muhimbili National Hospital (MNH). MUHAS is the only public higher learning
institution in health sciences in Tanzania and is responsible for training all cadres of health
care workers (including doctors, nurses, laboratory technologists and pharmacists). It is
closely affiliated to MNH. MNH serves approximately 1,000 outpatients every day (Monday
to Friday) and 1,000 admissions a week for inpatient care.
Clinical Services/or SCD in Muhimbili
The clinical services for patients with SCD require a multidisciplinary approach and are
therefore shared between three departments; haematology and blood transfusion, internal
medicine and paediatrics and child health. There is no system in place for screening and
diagnosis of SCD and therefore most of the patients are diagnosed when they present with
symptoms and signs suggestive of illness. There are two outpatient clinics a week providing
outpatient services to SCD patients. The department of paediatrics and child health provides
services to children under 13 years of age who are seen in a clinic that is specifically
dedicated to SCD. Adults are seen in a clinic conducted by the department of haematology
and blood transfusion which is not exclusively dedicated to SCD but also provides a service
to patients with other haematological disorders.
Since SCD patients are thought to have a high risk of morbidity and mortality due to malaria,
the policy in Tanzania is provide chemoprophylaxis against malaria and prompt diagnosis
and treatment of malaria. The recommendation for chemoprophylaxis is chloroquine despite
the high resistance. This was because of a failure to identify and propose another agent that
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would be affordable, effective and had a known safety profile. All patients attending the
paediatric clinic were prescribed chloroquine at a dose of 5mglkg once a week. During the
period of the study, first line therapy for malaria changed from monotherapy with
chloroquine to sulphadoxine pyrimethamine (SP), with the current recommendation being
artemisinin-based combination therapy (ACT), artemether lumefantrine (ALU)191For
patients enrolled in the study management continued as recommended by the policy and
followed hospital guidelines. SCD patients do not receive chemoprophylaxis with oral
penicillin V or vaccination with pneumococcal vaccination to prevent infection against
Streptococcus pneumoniae.
For patients who require inpatient care, children below the age of 8 years are admitted under
the care of the department of paediatrics and child health whereas older children and adults
are admitted in the department of internal medicine. The haematology department provides
additional care in collaboration with these two departments. The management of SCD
patients who were hospitalised followed hospital guidelines. Patients who were hospitalised
with pain received hydration with oral fluids (water) and intravenous fluid (1 to 2 litres of
normal saline alternating with dextrose-saline over 24 hours depending on the weight and
degree of dehydration). The analgesia included paracetamol, diclofenac and pethidine
following recommended dosage regimes. Pethidine was often limited to the first 24 hours.
SCD patients who were hospitalised with fever were investigated for malaria by a blood slide
for malaria parasite. Following this, they received presumptive treatment for malaria
following national recommendations mentioned above; uncomplicated malaria was treated
with chloroquine, SP or ALu due to changing treatment therapy during the course of the
study. Severe malaria was treated with quinine. Patients who were suspected to have bacterial
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infections from symptoms and signs (such as a focus of infections e.g. abscess; signs of
septicaemia) received antibiotics. The hospital recommendation which was followed for the
SCD patients includes a combination of benzylpenicillin and chloramphenicol in children. In
adults the same combination was used although in some cases, ceftriaxone was used as ftrst
line, presumptive treatment of septicaemia including meningitis. The indication for blood
transfusion (whole blood 20mls/kg or packed red blood cell lOmls/kg) included a
haemoglobin level of <5g/dL or clinical features of severe anaemia including symptoms of
anaemia and the presence of pulmonary oedema and/or right heart failure. Severe
pancytopaenia that was not transient (>1 month) and occurred in the presence of evidence of
active erythropoiesis (high reticulocyte count above 2%) was discussed with the surgeons to
make a decision about splenectomy. Osteomyelitis and avascular necrosis of the femoral head
were managed after consultation with the orthopaedic surgeons.
DESCRIPTION OF STUDY
Study design
This thesis is based on an observational study which consisted of systematic longitudinal
surveillance of clinical and laboratory events in a cohort of SCD patients recruited at
Muhimbili National Hospital. Cross sectional analysis was done to describe pattern of clinic
attendance, recruitment and hospitalisation.
In order to explore the pattern, cause and outcome of hospitalisation during the study period,
a series of approaches were used. The first was a case-control approach, where cases were
patients within the SCD cohort who were recruited into the study and hospitalised at MNH
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during the course of the study. Controls for this analysis, were SCD patients who were
recruited into the study and never hospitalised at MNH during the course of the study. The
second approach was a cross-sectional study, looking at risk factors and outcome for seD
patients hospitalised at MNH. In this analysis, the outcome was survival and therefore
comparison was between patients who survived and did not survive during hospitalisation at
MNH.
In order to address the role of malaria in precipitating hospitalisation, we used a case-control
approach with cases defined as SCD and controls were non-SflD individuals. Details of the
analytical approach have been outlined in chapter five, SCD and malaria.
In order to determine the role of bacterial infections in SCD during hospitalisation, this was a
prospective cohort study. All SCD patients who were hospitalised at MNH were identified
and blood cultures were done to identify the rates and risk factors of bacteraemia. Some
patients were identified during hospitalisation and therefore their first contact and recruitment
into the study was during hospitalization. In this case, patients were advised to return to clinic
after discharge from hospital. For the majority of patients, they were identified and recruited
at outpatient clinic. Therefore, events that occurred during hospitalisation could be compared
to outpatient visits.
To establish the association of increased CBFv and CVA in SCD patients, the study had two
components; the first phase was a cross sectional, observational study to determine the
spectrwn of CBFv using TeD in sen patients in MNH. The second phase was a cohort study
exploring the relationship between clinically evident CVA, confirmed by CT scan of brain,
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and eBFv. Other risk factors for stroke, including hypoxia, frequency of painful crises,
hospitalisations etc were also to be assessed Further details of analytical approach have been
outlined in chapter seven, SeD and stroke.
The study design to determine HbF levels in SeD was a cross-sectional survey on all SeD
patients who had been recruited into the study. The HbF data were then used to explore
association with clinical events collected as part of the longitudinal surveillance of the cohort
study.
Study population
sen population
Estimates suggest that there are approximately 5.6 to 9.9 per 1000 children born every year in
Tanzania with SeD4. With an annual birth rate of up to 1,500,000 this means that
approximately 7,800 to 14,600 children are born with SeD every year. Due to the magnitude
of the disease and a reported high rate of mortality in childhood, the Ministry of Health and
Social Welfare in Tanzania has a policy that all individuals with seD should have access to
free health care. However, there are no national guidelines for specific comprehensive care or
regular follow up at outpatient clinic. Therefore, individuals who are known or suspected to
have SeD are diagnosed only when symptomatic and are often seen when they have an acute
clinical event or require inpatient hospital care. Outpatient care is offered as part of general
medical or paediatric care. MNH is the only hospital which provides specialised health care
services for seD.
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Study population
Study population: The study population was patients with seD who came to MNH for
health services and had an entry visit as defmed below. Recruitment was done twice a week
from patients attending the pre-existing OPD clinics. In addition, patients who were admitted
during the study period were also advised to come to the clinic when they were discharged. A
patient was considered to be in the SeD cohort if they fulfilled the following criteria:
• Entry visit at outpatient clinic.
• Laboratory diagnosis of SeD. This was defined as SS on haemoglobin
electrophoresis and on HPLe their haemoglobin levels were as follows: HbS>70%; HbAo
= 0%. The assumption was made that the contribution of patients with S-
pOthalassaemia and those with S and hereditary persistence of foetal haemoglobin into
this cohort of seD patients would be minimal. This was based on the supposition that the
clinicalphenotype of S-HPFH is mild and it is unlikely that these individualswould come to
the clinic. Individuals with S-pOthalassaemia would also present with SF on
haemoglobin electrophoresis and HbS of above 70%, similar to SS individuals.
Although, microcytic hypochromic indices may be used to distinguish SS from S-
pOthalassaemia, the high prevalence of iron deficiency anaemia in our setting
would make it difficult to use this parameter. The definitive diagnosis of S-HPFH
and S-p°thalassaemia requires family studies and genotyping for Beta globin
mutations which was not done as part of this thesis. Co-inheritance of (1-
thalassemia, which would also result in low MeV, also requires genotyping for
confirmation.
• Patients who had conflicting results or had a history of blood transfusion had a repeat
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investigation to confmn the sickle phenotype. If a repeat investigation was not possible,
either because the patient died or was lost to follow-up, the patient was not considered to be
in the SCD cohort.
The following patients were not considered to be part of the main SeD study population:
• Laboratory diagnosis of AS or AA. These patients were considered to be controls.
Further details are included below in section of control population.
• Failure to confmn the diagnosis of SeD. These are patients who had equivocal
laboratory results either due to blood transfusion and a repeat laboratory test was not
possible either due to death or loss to follow-up.
• No entry visit at outpatient clinic. This includes patients who were identified in the
wards during hospitalisation or who were found to have SeD but did not return to
clinic for an entry visit.
Hospitalised SeD population: Clinical surveillance was done every day to recruit all patients
known or suspected to have SeD who were admitted to the hospital. They were given a
unique admission number for each hospitalisation. Since recruitment and the issuing of
unique SCD cohort number was only done at the clinic, there were some seD patients who
were identified at hospitalisation but had not been recruited into the study. In this case their
hospitalisation date preceded the date of recruitment into the study. Therefore, they were not
included in analysis of the rates and risk factors for hospitalisation of the cohort. However,
these patients were included in the risk factors for death during hospitalisation.
TeD population: In order to establish the cerebral blood flow velocity using Transcranial
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Doppler ultrasonography, SeD children who were aged between 2-16 years were selected
during scheduled clinic visits. Between November 2004 and June 2005, all consecutive seD
patients who attended the clinic were given an appointment to retwn to the hospital for TeD
ultrasonography.
Control population
There were two groups of individuals who were recruited into the study as the "control"
population. The first population consisted of siblings and relatives of SeD patients attending
clinic who were requested to enrol into the study as family members would have similarity
with regards to environment as well as some genetic factors. In addition, individuals who
came to hospital requesting investigation to exclude seD were also recruited. Individuals
who were found to have a diagnosis of AS or AA were used as the control group for
individuals with SeD.
The second population was patients who were recruited from those hospitalisations to the
paediatric wards at MNH between 2005 and 2007. These were patients who were not known
to have SeD and were screened for malaria using malaria rapid diagnostic tests (ROT) and
microscopy to provide data of the background prevalence of malaria parasitaemia during the
study period. It is acknowledged that ideally this control population should have included
adults. I decided to focus on the paediatric population as from an epidemiological point the
prevalence, morbidity and mortality of malaria is highest in children. This was acknowledged
as a limitation of the study.
1I0
PROCEDURES
Clinical procedures
Procedures at the outpatient clinic
Three types of visits to the outpatient department resulted in the collection of clinical
surveillance data.
1) Recruitment: this was the clinic attendance during the study period (25th March 2004
to March 2009) when patients were recruited and enrolled into the study. This is also
referred to as the baseline or entry visit.
2) Follow-up visit: three monthly visits, which were scheduled for all SCD patients who
were well.
3) Acute visit: unscheduled visits, when the patient attends due to a problem or the
attending clinician gave the patient an appointment for review earlier than the
scheduled visit.
Baseline visit (entry)
At the first clinic attendance during the study window, patients were enrolled into the study.
This visit was referred to as the entry visit. All patients who fulfilled the inclusion criteria
were recruited into the study after informed consent was obtained from the patients or
relatives. All the information was recorded onto standardized proformas that were
specifically designed for the study. Clinical information collected included demographic
details, past and current symptoms. Physical examination was performed which included
general anthropometric measurement and thorough systematic examination. Detailed
neurological evaluation was done if clinically indicated as well as assessment of cranial and
peripheral nervous system for focal deficits.
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Patients were given a SeD number which was their unique identifier that would be used for
all subsequent SeD visits. In addition, patients were given SeD booklets where their
haemoglobin levels and any other pertinent details were recorded. These books were also
used to record details of visit to any health care facility outside Muhimbili.
For patients who were identified as having SeD during hospitalisation, data was collected
during this event but recruitment into the study was only done when the patient came to the
clinic after discharge from the hospital. Therefore some patients will have hospitalisation
events which precede recruitment into the study. This information was collected as it was
thought that important data regarding causes of hospitalisation or mortality may not be
captured. Therefore, the data were used to determine the rates and risk factors for mortality
during hospitalisation. It was not used in the analysis of the rates of hospitalisation for the
cohort.
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Figure 16 Flow chart for procedures at baseline visit
Patient arrives at OPD clinic
Registered into hospital and SeD study system
~
Informed consent, demographic information, residence form
~7
Specimen collection where Blood sample is taken
~
General examination including anthropometry done
recording in SeD questionnaires and hospital files
~
medical history and physical examination
recorded in SeD questionnaires
~
laboratory results return to the clinic
~7
notes written in hospital file, prescription and appointment given
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Scheduled (Follow up) visit
Patients with SCD were scheduled to come to the clinic every three months. During this visit
information was collected on a follow-up proforma. This included clinical history with
symptoms as well as any acute events between scheduled clinic visits. In addition, physical
examination was performed. Investigations that were done included full blood picture and
examination for malaria parasites. Additional investigations were done as clinically indicated.
During the course of the study, there was an increase in the number of SCD patients.
Therefore, the outpatient visits were scheduled between 3 to 9 months.
Unscheduled (Acute) visit
Unscheduled visits were precipitated by an event that required patients to seek health care.
During this visit patients were handled as during scheduled visits with particular attention
paid to precipitating event. In the event that the patients required in patient care, they were
admitted and subsequently handled as an admission. Doctors were also able to ask patients to
return to clinic before the 3 month period to follow up a particular problem. This was also
regarded as an acute outpatient visit.
Procedures for hospitalisation
Clinical surveillance of the adult and paediatric admitting wards to identify individuals
admitted with known or suspected SCD was maintained throughout the period of study. On
arrival to the ward, SCD patients were admitted following normal hospital procedures. A
general examination was performed that included a record of temperature, weight, blood
pressure, peripheral oxygen saturation pulse and respiratory rate. Detailed clinical history and
physical examination were undertaken to determine the events leading to hospitalisation.
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Blood samples were collected for the following investigations; FBC, reticulocyte count,
malaria parasitaemia and blood cultures, serum creatinine, lactate dehydrogenase [LDH],
bilirubin total and direct and alkaline phosphatase [ALP]. Additional examinations such as
chest X-rays were performed as clinically indicated. All this information was recorded in
the "admission questionnaire.
Procedures for neurological events
For patients admitted with suspected neurological events, a more detailed history and
examination was taken focusing on the neurological system and the information was recorded
in a specific questionnaire for CNS events. Additional investigations that were done included
a computerised tomogram of the head for patients suspected to have a cerebral event. Similar
procedures were followed at outpatient if a seD patient was suspected to have a neurological
event as an outpatient.
Procedures for TeD ultrasonography
From November 2004 to June 2005, SeD patients who were between 2-16 years of age were
recruited during scheduled clinic visits and given appointments to return to the hospital for
TeD Ultrasonography. On the day of the TCD examination, patients were registered on
arrival. Information was given about the procedures and consent was given to allow TeD
examination. Personal and demographic details were recorded and a general examination was
done with recording of temperature, weight, blood pressure, peripheral oxygen saturation
pulse and respiratory rate. Following this, a detailed history and examination was taken
focusing on the neurological system and the information was recorded in a specific
questionnaire for CNS events. TeD examination was then done on the patient to measure the
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eBFv. Patients with abnormal results were informed of the high readings and this
information was documented in their seD books so that they were identified as high risk for
eVA. All the patients were then advised to return to the OPD clinic on the day of their
scheduled appointment.
Procedures for control populations
Siblings and relatives of SeD patients were invited to attend the OPD clinic where after
informed consent, history and examination was taken. This included a detailed family history.
Physical examination was done followed by blood sample collection. All the information was
recorded in a questionnaire for control patients. Other individuals who were recruited as
control populations were patients who attended the hospital requiring screening for SeD. The
individuals received their results after 2 weeks. For those who were found to have SeD, they
were given an appointment to attend OPD clinic. For those whose results were AS were
advised that they had sickle trait but would not require hospital care. However, they were
informed of a risk of having children with SeD. These patients were not followed up.
The control population for malaria parasitaemia was recruited from hospitalisations to
general paediatric wards. All hospitalisations were seen daily and screening information that
included age, sex, presenting complaint was collected. Malaria testing was done by rapid
diagnostic testing and microscopy. The results of the malaria test were immediately made
available to guide clinical management. Note that any discordant results were read by another
laboratory technologist. In the event that the two reports were discordant, a third independent
technologists read the slides.
116
The ideal control population should have been adults and children hospitalised during the
study period. This was not possible during this study and is acknowledged as a limitation. For
pwposes of this sub-study, recruitment was done for all consecutive hospital admissions into
the paediatric ward from July 2006 to July 2008.
Procedures for tracing patients who were lost to follow up
In a cohort study, it is imperative that one tries to have complete data on all patients who
have been recruited. Therefore, tracing patients who were lost to follow up was an integral
part of ensuring completeness of data.
Definition of loss to follow up
Lost to follow up was defined as any seD patient after recruitment into the study, who did
not come to clinic for a follow up visit for a period of at least 6 months. This definition did
not include patients who were identified to have SeD during hospitalization but had not yet
been seen at the OPDclinic and therefore did not have a unique seD number.
Tracing patients who were lost to follow up
The procedures for tracing patients who were lost to follow up consisted of 3 stages: I)
identifying from the database patients who were lost to follow up; 2) telephone tracing for
those who had telephone numbers 3) physically tracing the patients by going to their place of
residence.
Identifying patients who were lost to follow up from database: All patients who were
recruited into the study were identified by analyzing the entry database. Two timelines were
117
identified: date of recruitment and date of last visit to the clinic. For some patients who had
only been recruited and never returned to the clinic, this date would be the same. Patients
who did not have SeD were excluded, as were those who had been recruited within the last 6
months. From this list, patients who were known to have died either in hospital during
hospitalization or when death was known or was reported were identified and excluded. In
addition there were a few patients who were known not to attend the clinic for a specific
reason e.g. migration. Therefore a list was generated with 3 groups of patients: those with
telephone details, those with no telephone but with physical details and those who had no
details at all. This information was verified by checking in the profonnas in the case notes to
confirm the following details: attendance at clinic implying that they are not really lost to
follow up but there was an error in the database. Telephone and residence details were also
checked to identify if additional information had been provided on other visits. All
information was recorded in a new form that was specifically designed with detailed
residence information (appendix).
Telephone tracing: A list of lost to follow up for telephone tracing was generated. A new
variable was inserted, telephone tracing (available/not available). This information was
verified for the second time to ensure that all the information was available. Patients were
then telephoned and information was recorded as to whether they were available. For those
who were available, a specially formulated proforma known as LTF was completed and
entered into LTF database. Traced patients were given an appointment to come to the hospital
where a follow up proforma was completed. For those who were not traced by telephone,
they were then moved to the list of patients who were going to be physically traced.
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Physical tracing: a list of patients who had to be physically traced was generated which
included those without telephone numbers, or those with telephone numbers but who had not
been found by telephone. The residence information was clustered in the following manner:
District>Division>ward>street>ten cell unit leader>school>health post>bus stop so as to
make it logistically easy for patients to be traced in the same geographical location. This
follows the administrative hierarchy of local government organisation within districts in
Tanzania. Before going to the community, information was verified for the third time to
confirm that all information is most current.
Procedures in the field: The physical tracing of patients was limited to patients living in Dar-
es-Salaam. This has the administrative divisions outlined with local government officers
starting at street level with an executive officer who is responsible for "streets which may
have several ten cell units. The ten cell unit leaders are "political leaders but often are
responsible and know individuals in the households within their units. Therefore, the tracing
followed the administrative system, with households being visited with the ten cell unit
leader. On finding the patient a previously designed questionnaire for non attenders was
completed. This included a verbal autopsy for patients who were reported to have died.
Laboratory procedures
Procedures for collection of samples
Procedures for collection of samples at outpatient clinic
At the baseline visit a total of 6 mIs of blood was drawn in all individuals, irrespective of age
2 mls of blood was collected in a tube with EDTA anticoagulant. 2 vacutainers were filled
with 1mI of blood each. The vacutainers were either empty sterile containing no additive or
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had an additive that separated the serum. One thick blood slide was made for malaria
microscopy and a thin blood film was made for reticulocyte staining. All the samples were
labelled with SeD number and date when sample was collected. For follow up visits, whole
blood was collected and a malaria film was made, with additional specimens being collected
as clinically indicated.
Procedures for collection of samples during hospitalisation
During hospitalisation, following informed consent and aseptic procedures, 8 mls of blood
was collected: 2 m1s into an EDTA container, 2 m1s into an empty sterile or serum separator
container and 4 mls taken for blood culture. Before 2006, the blood culture samples were
collected in bottles that were prepared with appropriate media in the hospital laboratory but
after 2006, samples for blood culture were collected in commercially prepared BacTec®
bottles. In addition, a urine sample was collected in an empty sterile bottle. All the samples
were appropriately labelled.
Procedures for collection of samples for the control population
For siblings and other individuals who came to the outpatient department, the procedures for
sample collection were similar to those for patients at baseline visit. For paediatric
hospitalisations, following informed consent and explanation of procedures, a capillary blood
sample was taken from a finger prick. The blood drop was used for malaria ROTs and an
additional sample was used to make a thick film for malaria microscopy.
Procedures for processing of samples
All samples from outpatient clinics were taken during normal working hours and were
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transported to the laboratory. The specific investigations were done as outlined. Samples
from patients admitted out of working hours were processed within 24 hours.
Processing and separation of samples
Processing of EDTA sample: Two films were prepared from whole blood. A thick film was
stained for malaria parasites and a thin film was stained for reticulocytes. A full blood count
was then performed using the remaining sample. This included peripheral blood cell count,
both total and differential white cell count as well as red blood cell indices. For samples from
baseline visits or control individuals, haemoglobin electrophoresis was done using the
alkaline cellulose acetate method. The sample was then centrifuged and aliquoted into
plasma, which was stored for immunological studies; buffy coat for DNA extraction and
subsequent sickle genotyping.
Processing of serum separated samples: Biochemistry analysis was done on the serum and
the sample was then stored for processing for RN and viral hepatitis at a later stage. This is
not part of the thesis. The summary of processing of samples is outlined in appendix.
Archiving of samples; There were some investigations that could not be performed
immediately. In this case, the appropriate samples were stored for analysis at a later stage.
The following components were stored in IOxlO boxes, and stored at -20 degrees centigrade.
Buffy coat, packed red blood cells, serum and plasma were also stored. A template for
archived samples was written and filed.
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Procedures for laboratory investigations
Malaria
Microscopy for malaria parasitaemia: Thick films for malaria diagnosis were made from
whole blood at the time of collection from the patients or from EDTA bottle in the laboratory.
Thick films were stained using Giemsa and examined by microscopy for the presence of
malaria parasites using standard methods. The number of parasites (trophozoites) was
counted against 200 white blood cells. A slide was reported negative for malaria parasites
after at least 100 high-powered microscopic fields were examined. Note that counting malaria
parasites against 200 white blood cells may have resulted in underestimating malaria density
as the white cell count in SS patients is higher due to inflammation and haematology
analysers counting nucleated RBC as neutrophils. Therefore ideally, the white cell count
should have been corrected and "normal" reference values for SS and non-SS individuals
calculated and used. For purposes of this thesis, the parasite density was not used The quality
assurance process involved the following: all positive slides were read by a second person. If
there was a discrepancy between the two readings, then a third person read the slide. For the
negative slides, one out of every ten slides was reread by a second person.
Rapid diagnostic testing for malaria: Rapid diagnostic testing (RDT) to detect malaria
Histidine rich protein (HrP-2) antigen was conducted using the Parahit test (Parahit, Span
Diagnostics, India or Paracheck, Orchid Biomedical Systems, India). This was reported as
positive or negative. These tests come with a commercially-prepared quality assurance
method for positive and negative results.
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Haematology
Full blood count: Full blood counts were performed on an automated haematology analyser
(Pentra 60, Horiba ABX, Kyoto, Japan) was used. Quality assurance was done using
commercially prepared reagents that were run on a daily basis with the readings documented
and acted on, following the laboratory protocol. On a regular basis, samples were run on 3
different haematology analysers in the university to ensure that the results were valid. The
comparison was made with haematology analysers which were part of an external QA
programme.
Reticulocyte count: Reticulocyte counts were performed using the new methylene blue
method as outlined in appendix III. Using a high-powered lens, the number of reticulocytes
was counted against 1,000 mature red blood cells and the results were reported as a
percentage of total red blood cells. One in ten slides was read by a second person and the
results were compared.
Haemoglobin electrophoresis: Haemoglobin electrophoresis was done for all patients to
determine the sickle phenotype using the cellulose acetate method (Helena, Sunderland, Tyne
& Wear, UK). (See appendix IT!).The cellulose acetate membranes were stored and filed for
references. The results were reported as SS, AS or AA. For some patients, the results were
reported as SF. These results were considered to be SS. Quality assurance was done using
commercially prepared controls that were run on for each electrophoresis gel.
The quantitative analysis of haemoglobin sub-types by HPLC: From June 2005, haemoglobin
was analysed quantitatively using the Beta thalassaemia short programme on a Variant
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Classic HPLC machine (BioRad, Hercules, CA, USA). This machine uses ion-
exchange high performance liquid chromatography (HPLC) to identify the different
haemoglobins in whole blood. The haemoglobins of interest were haemoglobin Ao, A2, F and
S and the results were used to confirm the diagnosis of sickle haemoglobin as well as to
determine the levels of HbF in each individual. The chromatograms and results were
photocopied and filed. The data for the corrected area percentage of the different
haemoglobins were entered using FoxPro (TM) and subsequently into MySQL database.
Patients were considered SS if HbS>70%; HbA=O%; HbA2<3.5%2. For a definitive
differentiation of SS from S/J3°-thalassaemia and S/HPFH, DNA and/or family studies are
required. HPLC (Hb Fractions and value with units in percentage), however, are extremely
useful in distinguishing the 3 genotypic groups as outlined below.
• SS: HbA = 0; HbA2<3.5; HbS >70; HbF 0 - 25
• SI J3°-thalassaemia: HbAo = 0; HbA2 >3.5; HbS >70; HbF <20
• SI HPFH: HbAo = 0; HbA2 <2.5; HbS >70; HbF >30
The following patterns were labelled as non-SCD and were distinguished further as follows:
• AS: HbA >50; HbA2 2-3; HbS 30-40%; HbF 0 -2
• AA: HbAo>90; HbA2 2 - 3; HbS 0%; HbF 0-2
For purposes of this thesis, the analysis was assumed to predominantly include individuals
with SS genotype based on Table 12. It is acknowledged that this cohort may include
individuals with S/J3°-thalassaemia and SIHPFH. Quality assurance was done using
commercially prepared reagents that were run for each batch of reagents with the readings
documented and acted on, following the laboratory protocol.
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DNA diagnosis for haemoglobinopathies: The diagnosis of SCD and other
haemoglobinopathies particularly S/fJo-thalassaemia and SIHPFH is made by DNA studies.
DNA was extracted and stored for all individuals recruited into the study, but DNA studies
were not part of the thesis.
Chemistry
Blood: The following parameters were assayed using a chemistry analyser (Roche Cobas
Mira, New York. USA or Abbott Architect, New York, USA) - bilirubin (total and direct);
lactate dehydrogenase, (LDH) alkaline phosphatase (ALP), gamma glutamyl transferase
(GGT) and creatinine. Quality assurance was done using commercially prepared reagents that
were run on a daily basis with the readings documented following laboratory protocol.
Microbiology
Blood cultures
From the start of the study until July 2005, blood cultures were processed using standard
hospital laboratory procedures. Culture media was prepared in the hospital microbiological
laboratory and identification followed conventional routine techniques. The organisms that
were identified were archived in -70°C freezers. The hospital laboratory is part of a project
known as Network for Surveillance of Pneumococcal Disease in the East African Region
(netSPEAR). netSPEAR (http://www.aboutus.org/NetSpear.org) supported laboratories to
improve the quality of microbiology techniques, particularly in hospital laboratories where
resources were limited and the yield of positive microbiology culture was low. This was done
by providing reagents, reviewing standard operating procedures and providing a quality
assurance system. The organisms that were identified were archived in -70°C freezers and
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sent to Nairobi, Kenya for re-identification. The re-identification was done in a laboratory
that has accreditation at international standards for good laboratory practise. The results from
the re-identification revealed that the differences in the results between the two laboratories
were more than 70%. This was discussed in detail with the laboratory and strategies were
proposed to address the potential causes of the differences in the results. Some of the
strategies included using commercially-prepared horse blood instead of human blood to make
blood agar media plates, use of automated blood culture machines and regular positive
quality assurance method to ensure that the media supported the growth of fastidious
organisms such as SPN.
For purposes of this thesis, it was felt that in order to ensure scientific rigour in achieving this
objective, it was necessary for blood cultures to be done in an environment where I would be
able to achieve the standards required to answer the question. Therefore, from July 2005,
blood cultures were processed using the BACTEC 9050 system (BACTEC, Becton Dickinson,
Franklin Lakes, NI, USA). Positive samples were examined under Gram staining and sub-
cultured to standard media plates (chocolate agar, blood agar and CLEO). Isolates were
identified using routine microbiological techniques which included microscopy and Gram-
staining, API biochemical testing, catalase and specific identification for streptococcus and
staphylococcus. Isolates were stored in freezing media which was specifically prepared and
stored at minus 700C for identification in the laboratory in Kenya. When this was done, the
results that were obtained were accurate. All batches of blood culture bottles and agar media
plates were tested by inoculation with known organisms suspended in transport media the
blood culture bottle was then inserted into the BACEC machine to check that positive
growth would be identified. For agar media plates, organisms were inoculated, grown and
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identified to ensure that the media supported microbial growth and resulted in correct
diagnosis.
Cultures of other samples
Samples from other sites such as wounds, urine etc were collected as clinically indicated.
They were processed using routine microbiological procedures. These results will not be
presented in this thesis.
Procedures for TCD ultrasonography
TeD ultrasonography
I conducted Teo examination following intensive training for 3 months in Kilifi, Kenya.
TeO examination was conducted to measure eBFv using a Nicolet EME companion II
(Nicolet, Warwick, UK). This instrument uses pulsed ultrasound at a frequency of 2MHz
generated by a transducer that is held against the temporal portion of the scalp to assess
velocities of middle cerebral artery (MeA), anterior (AeA) and posterior cerebral arteries
(peA) on the left and right hand side. The basilar artery (BA) was assessed using the
suboccipital approach. Additional signals were obtained from the internal carotid artery
(K'A) in the neck. The highest time-averaged maximal mean velocities (Vrnean), depth at
which the artery was insonated, pulsatility index (PI) and resistance index (RI) were
recorded.
Quality assurance of TeO: The blood vessels were identified by depth, waveform pattern,
sample volume, direction of blood flow and angle of insonation. The quality of the TeO
measurements was done by ensuring that the eBFv that was recorded came from the
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waveform with the best audiovisual signal and envelope. Before recording, the vessel was
"tracked" up and down by 2mm increments to ensure that the best waveform was identified.
Snapshots of all the recordings were taken and saved. The results were saved on the TCD
machine. The data were backed up on an external hard drive which was stored in a different
physical location from the TCD machine. The results were independently reviewed by a
consultant neurologist, Fenella Kirkham, Institute of child health, to ensure that the readings
were accurate.
Reference ranges for the parameters were derived from studies done in Kilifi, Kenya392•
These were calculated from CBFv from individuals who were well and not known to have
SCD. The range was defined as -2 standard deviation (SD) as the lower limit and +2SD as the
upper limit around the median value of CBFv readings.
Computerised tomography
For patients who presented with features suggestive of a neurological event due to a
cerebrovascular accident, computerised tomography of the head was done. The scans were
reported by a radiologist and the results were ftled. The CT scans were also digitised. These
results will not be presented in this thesis.
Radiography of chest, bones and other sites
X-rays were taken at Muhimbili National Hospital when clinically indicated. The results were
documented in the patients file notes. These results will not be presented in this thesis.
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Other radiological and imaging investigations
Other radiological investigations including ultrasonography and echocardiography were
conducted as clinically indicated. The results of these investigations were documented and
filed in the patients records.
Personnel
Clinical personnel
The clinical-epidemiological information from the hospital visits was collected by the author
with the assistance of two medical officers. Additional assistance was increased during the
course of the study to take into the account the higher number of study participants than
anticipated. Supervision and monitoring was done through daily meetings, reviewing of
questionnaires as well as reviewing hospitalised patients. For the TCD, I was responsible for
performing all the procedures of neurological and TCD examinations.
Laboratory personnel
I was responsible for setting up and performing the following laboratory tests: haemoglobin
electrophoresis, reticulocyte staining, and malaria microscopy. These tests were subsequently
done by a laboratory technician with a Diploma in Medical Laboratory Sciences, under my
supervision. Microbiology procedures were similarly set up following a period of training at
the KEMRI-Wellcome Trust programme in Kilifi, Kenya. This site has established laboratory
systems and has received accreditation for international good laboratory practise standards.
The microbiology procedures were consequently supported jointly with experienced
microbiologists inboth Muhimbili and Kilifi.
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I was responsible for interpretation of the results and troubleshooting problems that arose
with equipment or procedures. Investigations using automated machines such as
Haematology and chemistry analysers were done following standard operating procedures for
the machines. The tests were performed by hospital laboratory personnel. The author was
responsible for ensuring that quality assurance procedures were put in place as well as the
interpretation of normal and abnormal results. Once the procedures were in place and
functioning adequately, they were performed by 2 laboratory technologists under the
supervision of the author.
Data personnel
I was responsible for development of the proformas, coding of the variables, and design of
the database (both the FoxPro and MySQL). The data were entered by data entry clerks who I
supervised.
DATA MANAGEMENT
Data collection
Clinical data
All clinical information was collected in pre-formatted questionnaires or proformas that were
designed specifically for the study. There were specific proformas for different visits or
events. During outpatient visits a baseline/entry or follow up visits proforma was completed
and during hospitalisation an admission proforma was completed. A CNS proforma was
completed in the event of a suspected neurological event. For the control population, a
control proforma was completed. Information for paediatric hospitalisations was recorded in
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a log book. For patients who were lost to follow up, a proforma was completed and in the
event of death a verbal autopsy section was completed. Residence information was collected
into residence proformas. Profonnas were reviewed annually to amend variables and improve
the quality of data collected. All profonnas are attached in appendix.
Laboratory data
Laboratory data were collected from different sources. For haematology data, the results were
printed from haematology analysers. For the results that were generated from hospital
laboratory, the printed results were photocopied and the copy was stored in the study patient
file. For other laboratory results, this was recorded into pre-printed laboratory results forms
and filed with the patients' case notes.
Other data
Teo data were automatically generated during Teo examination. These data were entered
into FoxPro and subsequently into the MySQL database.
Data entry
From 2004 to 2007, clinical and laboratory data were entered in FoxPro (version 6 (Microsoft
Corp., Seattle, WA, USA). In 2007, due to the increase in data that were being collected, a
new database system was designed that used a web-based system known as MySQL (Sun
Microsystems Inc, Santa Clara, California, USA). The data that had already been entered
were transferred into the new database system.
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Data cleaning
Data verification and cleaning was done following double entry and inconsistencies were
corrected. Missing data, that was independent of time of collection, was collected at
subsequent visits.
Data security
The questionnaires were stored in filing cabinets and locked, with access only to personnel
involved in the study. Access to the data was limited to a few key personnel who were
authorised by the author. Data were backed up on a weekly basis onto CDs which were stored
in a different physical location.
STATISTICAL METHODS
Introduction
An analysis plan was formulated during proposal development. This was refmed after 18
months of data collection to outline an approach to the data. An initial description of the
cohort was made. In order to address the four specific objectives, regarding malaria,
infections, stroke and HbF, a series of different analytical approaches were used to take into
account the complexity of the study design and magnitude of the data. Details of the analyses
conducted will be described in the methods section of each chapter. The analysis was done
using STAT Av 10 (StataCorp, College Station, TX).
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Definition of variables
Outcome variables
SS Sickle cell disease: This was defined as any patient who had sickle cell phenotype SS as
detected by Hb Electrophoresis and HPLC. Patients who were SS were defined as sickle cell
disease, those with phenotype AS as sickle cell trait and AA as normal, This was generated
into binary outcome variables where I=SS was sickle and 0= Non-sickle and included AA or
AS.
Hospitalisation: This was defined as hospitalisation during the study period and included any
patient who was admitted for inpatient hospital care. A binary variable was generated from
hospitalisation or no hospitalisation during the study period where O=no hospitalisation and
1=hospitalisation. At entry into the study patients were asked if they had ever been admitted
and this was defmed as history of hospitalisation where O=no history and I=history of
hospitalisation.
Malaria: Malaria was defmed as positive malaria rapid test or the presence of malaria
trophozoites on microscopy.
Stroke: A neurological deficit caused by injury to part of the brain due to either lack of blood
(infarction) or rupture of a blood vessel and subsequent haemorrhage into the brain. This was
characterized by a combination of symptoms (weakness of limb or part of body, loss of
consciousness, seizures) and signs (loss of muscle bulk; either decrease or increase in muscle
tone; loss of muscle power) lasting for more than twenty four hours.
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Bacterial infection: Bacterial infection was defined as binary variable with presence or
absence of bacteria on blood culture during hospitalisation (bacteraemia). Further
categorisation ofbacteraemia was done according to the species isolated.
Exposure variables
Demographic variables This included the gender, age and place of birth. Ethnic origin was
defmed by coding the tribe of mother. The residence at time of recruitment was coded
according to the frequency of occurrence of a place.
Clinical variables This included the presence or absence (coded 0 absent 1 present) of any of
the following features during surveillance. Symptoms included any history where the
individual or parent reported the presence of fever, pain, anaemia, jaundice, cough, difficulty
in breathing and CNS event (weakness (hemiplegia), seizures, transient ischaemic attacks,
cranial nerve deficit and gross cognitive impairment) Physical signs were categorised as
follows: fever was axillary temperature > 37.5°C; hypertension was blood pressure> 150/100
mmHg and hypoxia as peripheral oxygen saturation <95%.
Laboratory variables: Haematological variables included red blood cell indices
[haemoglobin (Hb), red blood cell count (RBC), and mean corpuscular volume (MCV)],
white cell indices {total white blood cell count (WBC» and platelet count. In addition,
reticulocyte count and HbF levels were also defined. Clinical chemistry variables included
bilirubin (total and indirect), lactate dehydrogenase (LDH), alkaline phosphatase (ALP),
aspartate transaminase (AST) and creatinine.
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The laboratory variables were analysed as continuous variables. They were then categorised
using cut-offs from published international reference values. I decided to use the cut - off
values from published reference values as this would allow me to compare the results from
this study with the normal population. The level of haemoglobin below 5g/dL was defined as
severe anaemia. The details of cut-off points that were used to define abnormal CBFv and
high HbF as generated from this study are presented in their respective chapters.
Patient level variables
Variables that remained constant for each individual throughout the study were sex and sickle
status. Sex was recorded as female=O, male=l, with female used as the reference category.
Sickle status has been defined previously.
Time dependent variables
Variables that were known to change their value over time were age of individuals, clinical
and laboratory variables and month in study.
Age: The age was calculated at date of visit from the date of birth. The age was calculated in
years rather than months. Age was then examined as a continuous variable with increments of
1 year. Three collapsed age groups variables were defined with categories as follows: <2, 2-4,
5-9, 10-14, 15-19, 20-29, 30-39 and >40. The second age group was: <2, 2-4, 5-9, 10-19,
>20. The third age group was <5, 5-10 and >10 years. Different age groups were defmed to
allow comparison with published data.
Steady state: although the clinical and laboratory variables changed with each visit, it was
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assumed that when well there would be minimal variability within an individual. The values
during this "steady-staten were determined from visits at outpatient clinic where patient was
well and there was no hospitalisation event within the preceding or subsequent 3 months.
These data were not used in the thesis.
Date and month of visit: month of visit was categorized into a variable that included month
and year of study, beginning with March 2004 and ending in March 2009 for recruitment.
Descriptive analyses
Description of study populations for analyses
The initial analyses involved an overall description of the study outlining the total number of
seD patients and control individual recruited into the study. This was followed by a
description of the SCD patients at two different time points - at recruitment into the study
and during hospitalisation.
Description of SCD cohort during recruitment: This was a description of the clinical and
laboratory features of SCD patients at the time of recruitment into the study. This group of
patients was compared with patients who did not have SCD.
Description of SCD cohort during hospitalisation: A number of cohort members were
hospitalised during the study period. A description of the rates and risk factors for
hospitalisation was examined by comparing the admitted and non-admitted patients. A
separate analysis was done on all SCD individuals hospitalised during the study period to
determine risk factors that determine adverse outcomes during hospitalisation.
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Description of seD cohort during follow-up visits (longitudinal surveillance) : There was
initial analysis of the pattern and factors that determine follow up visits. This included
examination of adherence/compliance to follow up. Major clinical events that were known to
be a cause of morbidity and mortality in SeD were then examined. This included mortality
and hospitalisation. The three events that were the specific aims of the study - malaria,
infection and stroke are examined in their individual chapters. Longitudinal analysis of
specific clinical events such as pain, anaemia, jaundice and any other event that had a high
occurrence will not be included in this thesis.
Disease estimates
Prevalence: The unit of observation was at the visit level i.e. the clinical and laboratory
results from one individual during a visit. The visit was either recruitment, follow-up,
hospitalisation or tracing during lost to follow up. The prevalence estimates for any outcome
represent the outcome prevalence (number of positive outcome/total number of outcomes in
the relevant population).
Incidence rates: Incidence rates were calculated for the following disease outcomes;
mortality, hospitalisation, malaria and stroke. An incident case was defined as a case in any
individual at that particular visit. Therefore incidence rate estimates included recurrent cases.
The exception was for stroke, where clinical examination had to determine whether the
neurological deficit was due to a new event. Incidence rates were expressed as number of
events per patient years of observation.
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Calculation of incidence using STATA
All the data from outpatient clinic visits and hospitalisation were combined to make one
dataset. The data therefore comprised of records of individuals with prospectively collected
observations at different time points. In order to do longitudinal analysis, the data need to
look at events at different time points. This analysis is referred to as survival analysis and
involves the event of interest and time. The event is referred to as a 'failure' and the time
until 'failure' is 'survival time'. In order to do longitudinal analysis, the data has to be set so
that the analysis focuses on times until the event of interest occurs. In order to do this, the
following command was used: stset datetod. id (demographic jd) failure(death) exit(time
end date) scale(365.25) where datetod is the date that the individual was seen, id is the
unique identifier of the individual, which in my data base was coded as 'demographic id'.
Failure is the event under analysis. The event was the outcome for which the incidence was
being calculated. This was death, hospitalisation, malaria and stroke. Exit is the time at which
the individual exited the study and scale gives the time scale in years.
Following this, the incidence was calculated with the outcome expressed in person years of
observation. This was done by using the STATA command stsum to calculate the overall
incidence of the event and stsum, by (agegp), provided the incidence rate stratified by age at
which the event occurred. The result was expressed per 100PYO.
UDivariable analyses
Univariable analyses of exposure variables were conducted to assess the strength and
direction of association with the outcome of interest. The statistical significance of
univariable associations was determined using i or Fisher's exact contingency table analysis.
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The level of statistical significance was set at 0.05 with values between 0.05 and 0.09
considered to be marginally statistically significant. Crude odds ratios were determined with
ordinary logistic regression and reported with 95% confidence intervals (95% Cl) around the
odds ratios (OR).
Multivariable analyses
Multivariable analyses was done using logistic regression which assumes that exposure
variables are independent of each other. This allows one to determine the effect of exposure
factor on the risk of disease outcome after controlling for the effect of another exposure
factor. Exposure factors that had a level of significance of:::;0.05 during univariable analysis
were included in a multivariable model. A stepwise procedure was used to arrive at a fmal
multivariable model. The level of significance and confidence interval was reported as above.
Accounting for clustering of data
Multivariable analyses assumes that exposure variables are independent of each other.
However, the design of the study is such that there was clustering of data at different levels
leading to a multi-level hierarchical dataset which is shown below (Figure 17)
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Figure 17 Hierarchical structure of data
Clinic
Family
Patient
Clinic is defined as visit to hospital clinic. Family: members of one family who share one or
both parents.
Individual: data were clustered within an individual, as a patient could have data from
different visits during the study period.
Family; There were observations that were clustered within families as there were siblings and
twins who may have either SCD or were controls. Family was defmed as individuals who
shared one or both parents.
Visits: It was likely that there would be unmeasured factors that were specific for a particular
visit. For example, haematology variables from Thursday and Friday clinic would be
different as they use different haematology analysers on each day. Results from the different
analysers were compared to ensure that they were comparable to ensure that the use of
different analysers did not affect or account for the differences. Therefore there was
clustering of individuals within visits.
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Cross classification: although there was clustering within visits, an individual could have
measurements from different visits, therefore visits could be said to cluster within an
individual. For example, an individual could have 2 hospitalisations and four follow up visits.
This type of data would require modelling to take into account such a complex data structure.
For purposes of this thesis, the analysis used the building of models with 2-level mixed
effects logistic regression, with visit included as a fixed effect and individual as a random
effect. This would account for clustering at visit and individual level. The clustering within
families was not taken into account.
ANAL YSIS PLAN
Baseline description
This included a description of pattern of clinic attendance and recruitment. This was followed
by a detailed description of the clinical and laboratory features of patients at the time of
recruitment into the study. The group used as a control population was individuals with
sickle phenotype AA and AS.
Hospitalisation
This included a description of the pattern, cause and outcome of hospitalisations during the
study period. On determining risk factors of hospitalisation, the association of the clinical and
laboratory features of the SCD patients at baseline visit was explored with the risk of
hospitalisation during the course of the study. For this analysis, a comparison of
characteristics at baseline visit between the individuals in the SCD cohort who were
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hospitalised at MNH during the course of the study and those individuals who never
hospitalised at MNH during the course of the study. The aim was to identify factors that will
identify patients at the first visit with a likelihood of hospitalization
A second analysis looked at risk factors for mortality during hospitalisation by analysing the
association between clinical and laboratory factors at hospitalisation with mortality. The aim
was to identify factors at hospitalisation that could identify those with a higher risk of
mortality during hospitalisation. In this analysis, all SeD individuals hospitalised during the
study period were included. Therefore, this included SeD individuals who were identified in
the ward, but may not have returned to clinic and may not have been recruited into the seD
cohort.
Longitudinal data (follow up)
This is a description of pattern of follow-up visits and rates of patients who are lost to follow
up. There is a description of key events which include death, hospitalisation, malaria, stroke
and bacteraemia during the course of the study. The aim was to identify the rates of these
events during the study period and identify the risk factors associated with these events.
Malaria
The analysis for this section was to answer the question; is malaria a common cause of
morbidity and mortality in seD? To do this a description of the prevalence of malaria in SeD
compared to non-Sf'D population was made. Further analyses were done to assess malaria in
SeD patients and control during hospitalisation. Further details of analytical approach are
covered in the individual chapter.
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Infections
The analyses in this section were to describe the major bacterial pathogens in blood
associated with all seD patients on hospitalisation. The objective was to determine the
magnitude of bacteraemia in SeD patients and to describe the major pathogens identified.
Further details of the analytical approach are covered in the relevant chapter.
Stroke and other eNS events
This includes a descriptive analysis of prevalence of stroke and other neurological events at
entry into the study. This was followed by a description of the spectrum of eBFv in seD. For
longitudinal analysis, the incidence rate of stroke and risk factors associated with increased
risk was determined. This is covered in detail in the relevant chapter.
Foetal haemoglobin
Initially there was a description of the spectrum of levels ofHbF in seD. Analysis was done
to look for demographic, clinical and laboratory factors that could be used to identify
individuals with high HbF levels. This was followed by analysis to determine whether HbF
levels were associated with specific clinical events including death, hospitalisation, malaria
and stroke. Details of further analyses are included in relevant chapter.
Study design and statistical analysis
Study design
During planning the study, I contacted individuals and centres considered to be experts in the
field of SeD research and healthcare. Therefore, I visited and discussed the most appropriate
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study design for the questions that I wanted to answer. The centres and people I discussed
included David Weatherall, Swee Lay Thein, David Rees, and Fenella Kirkham in the UK;
Graham Sergeant, Terrence Forrester in Jamaica and in the USA Martin Steinberg, Mohandas
Narla, Griffin Rogers, Thomas Wellems, Alan Schechter, Kwaku Ohene-Frempong. The
statistical methods for planning the study were done with the statistician of the KEMRI
Wellcome research programme, Kilifi, Kenya. This included estimating sample size, advice
on the size of control populations as well as statistical methods for analysis.
Data analysis
Developing skills in clinical epidemiology and statistical analysis was part of the PhD
training programme. I attended two courses at the London School of Hygiene & Tropical
Medicine, UK; the intensive course in epidemiology and medical statistics and the advanced
course in epidemiological analysis. During the course, I acquired skills in analysing data
using STATA. As part of the course, the course organisers provided study clinics, where they
provide advice regarding strategic approaches to data analysis. Since I had already been
collecting data for over 12 months when I attended the course, I had several discussions and
advice during the data clinics. Following these discussions, I reviewed and modified my
analysis plan.
The analysis of the data was done under supervision of Greg Fegan, the statistician of the
programme. The analysis of the malaria chapter was done in collaboration with one of the
PhD supervisors, Thomas Williams. For analysis of survival data, the approach followed the
methods used by Platt et al. This was supervised by Greg Fegan with advice from Ian
Hambleton (Jamaica) and Emelda Okiro (Kenya). Both have expertise in longitudinal
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analysis of cohort data.
Analysis of longitudinal data requires time-series analysis and advanced statistical techniques
in handling data with multiple levels of hierarchy and clustering. This was noted, discussed
and agreed that for purposes of this thesis, the analysis would be limited to approach
described. In order to further utilise the data that has been collected, I would pursue further
analytical skills during the post-doctoral period.
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Chapter Four
General Results
INTRODUCTION
The prospective, cohort study at Muhimbili started on 25th March 2004. In this chapter, the
first section will be a description of pattern of recruitment, comparison between seD patients
and controls and characteristics of main study population at recruitment. Section two will
include the rates and risk factors of hospitalisation during the study period. Section three will
describe the rates and risk factors for mortality in SeD patients. Within each section, there
will be a brief introduction of the objectives of the section, methods and results. The
discussion of the three sections will be covered at the end of the chapter.
DESCRIPTION OF STUDY POPULATION
Introduction
In Tanzania there are no screening programmes to identify seD individuals at birth or in the
community. Therefore, it is likely that seD individuals who are symptomatic visit several
health facilities and receive symptomatic treatment for clinical events such as fever, pain,
anaemia and stroke before a diagnosis is suspected and the appropriate laboratory
investigations are done. Recognising that most SeD individuals will visit a health facility
which may not have expertise and resources for diagnosis of SeD, we wanted to identify
symptoms and signs that could be used in areas with limited resources to identify those
individuals likely to have SeD. These individuals would then be prioritised to be sent for
further investigations. Therefore, in this study, the aim was to compare clinical and laboratory
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characteristics of SeD and non-Sf'D individuals at OPD clinic.
Methods
SCD patients
This is the main SeD population with the following inclusion criteria:
• An entry visit at the outpatient clinic at MNH between March 2004 and March 2009.
• Confirmed laboratory diagnosis of SeD.
seD individuals who were identified during hospitalisation but did not return to the clinic for
an entry visit were not included in this analysis.
seD patients who did not live in Dar-es-Salaam were included in the main study cohort. This
is because most of these patients would travel to Muhimbili once or twice a year for follow-
up clinics. Furthermore, those patients who lived outside Dar-es-salaam agreed to be
contacted by telephone.
Non-SCD individuals
The ideal control population for this study would be age-matched individuals, recruited in the
same period and from the same community as the seD population. This would have required
considerable resources (including a demographic surveillance system) that were not available
during the course of my study. At the beginning of the study it was agreed following
consultation with my supervisors and statisticians, that the control population should have a
minimum of a 100control patients in each age band < 2 years, 2 - 4 years, 5 - 9 years, 10-
19 years and over 20 years. A decision was made to recruit siblings and relatives of seD
patients attending the MNH. The assumption was that family members would have similarity
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with regards to environment as well as some genetic factors. Therefore, the differences would
be due to the diagnosis of SCD. Therefore, family members of SCD patients were invited to
enter the study. After 3 months of recruitment, the number of individuals who were identified
was small. Therefore, after discussion with my supervisors, a decision was made to include
individuals who came to hospital requesting investigations for SCD. These were referred
either because they were symptomatic or because the attending clinician wanted to exclude a
diagnosis of SCD.
This group consisted of individuals who had the following criteria:
• A visit at the outpatient clinic between March 2004 and March 2009.
• Confirmed laboratory diagnosis of AS or AA.
Statistical methods
A general outline of descriptive statistics, univariable and multivariable analyses is provided
in the methods chapter.
In this analysis all individuals who fulfilled the inclusion criteria for SeD and non-SCl) as
defmed above were included in one dataset. Individuals where the laboratory diagnosis of
seD status was equivocal or was not available were excluded. The outcome was SeD status.
Descriptive analyses were run to determine the mean, median and range of individuals
recruited per month during the study period. The non-Sf.D individuals were then separated
into AS and AA individuals to determine the composition of the non-SCl) population.
To explore the clinical and laboratory characteristics of the SeD and non-Sf'D populations
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the two groups were compared. The initial comparison was done by stratifying the two
populations into the 5 age bands. Following this, clinical and laboratory characteristics were
compared between the two groups.
Continuous variables were compared using two sided t-tests while categorical variables were
compared using the i test and results presented as odds ratios (DRs) with 95% confidence
intervals. Multivariable logistic regression was used to identify independent associations with
malaria, using all variables that were significantly associated (p<0.05) on univariable
analysis.
Results
Patients were recruited serially from the paediatric seD clinic and adult general haematology
clinic. The study is ongoing, but the analysis is limited to patients recruited from March 2004
to March 2009, giving a total period of follow up of 60 months. 2,487 individuals were
recruited into the study with the sickle phenotype as follows: ss 1,725 (69.4%); AS 455
(18.3%) and AA 307 (12.3%) (Figure 18). The pattern of recruitment is shown in the figure
below (Figure 19). The mean number of individuals recruited per month was 41.4 (SD 35.9)
with a range of 2 to 209 individuals seen per month. For individuals with SCD, a mean
28.7 (SD 36.5) number of patients were recruited every month with a range of 2 to 206
patients. For non-SflD individuals, the mean number of individuals seen every month was
13.1 (11.9) patients with a range of 1 to 71 individuals every week.
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Figure 18 Summary of individuals recruited into the study
Total number of individuals
N=2,487
I
j_ I
Patients with SCD Patients without SeD
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Characteristics of SCD and non-SCD individuals at recruitment
The composition of SeD and non-Sf'D patients stratified by age group is shown in Table 14.
seD patients were younger than controls (9.7 vs. 14.4 years; p<O.Ol). There was a
significant difference in the two groups, SeD and non-SflD, in children under 2 years and
adults over 20 years. For the age group under 2 years, SeD patients were older compared to
Non-Sf'D patients (0.81 vs. 0.59 years; p<0.01). For the individuals over 20 years, the SeD
group was younger (26.8 years vs. 34.9 years; p<0.01). The difference between the groups
from 2 years to 19 years was not statistically significant.
Table 14 Number, mean and median age of different age groups in SCD and non-SCD
individuals.
Non-SCD SeD
Mean (SD) p::w Mean (SD) p:m QR p
<2 104 0.59 (0.49) I 166 0.81 (0.39) I 3.05 (1.75-5.29) <0.01
2-4 114 2.96 (0.86) 3 368 3.06 (0.81) 3 1.16 (0.89-1.49) 0.26
5-9 139 6.98 (1.39) 7 478 6.7 (1.44) 7 0.89 (0.79-1.02) 0.11
10-19 193 13.3 (2.76) 13 518 13.59 (2.8) 13 1.02 (0.96-1.09) 0.49
20+ 195 34.9 (56.4) 30 195 26.8 (6.0) 25 0.92 (0.89-0.95) <0.01
Total 745 14.4 (31.6) 10 1725 9.7 (7.9) 8 0.96 (0.95-0.97) <0.01
Pso is the median. QR is the interquartile range.
The clinical characteristics of SeD patients compared to individuals who are non-Sf.D are
shown in Table 15. On univariable analysis, more SCD patients than controls reported to
have been born in Dar-es-Salaam (71.3% vs. 62.8%; p<0.01). On measurement of vital signs,
SCD patients had lower diastolic and systolic BP; lower saturation and higher pulse rate. On
examination, they were more likely to have jaundice and a palpable spleen.
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Table 16 shows the laboratory characteristics ofSCD patients compared to individuals who are
non-SCD. With regards to haematological factors, SCD individuals had lower Hb; but higher
levels of WBC, Reticulocyte count, RDW and MCV. With regards to biochemical tests for
markers ofhaemolysis and liver function, SCD patients had higher levels of bilirubin, AST,
ALP, LDH and creatinine.
Multivariable analysis
On multivariable analysis, factors that were independently associated with likelihood of
having SCD were low diastolic blood pressure [(OR 0.97 (95% Cl 0.94 - 0.99); p=O.Ol] and
jaundice [2.77 (1.66 - 4.64); p=<O.Ol] on examination. Laboratory factors that were
independently associated with SCD status were high WBC count [1.27 (1.19 - 1.30); <0.01]
and RDW [1.17 (1.08 - 1.27); <0.01] and low haemoglobin [0.75 (0.63 - 0.89); <0.01]. For
the laboratory markers of haemolysis and liver function, individuals with SCD had lower
ALP [0.99 (0.99 - 0.99); 0.01] and high total bilirubin [1.01 (1.00 - 1.01); 0.02].
Table 17 Multivariable analysis of clinical and laboratory features associated with SCD
status n=991
Factor OR P
Age (years) 0.99 (0.96 - 1.02) 0.41
Pulse rate (beats per minute) 0.99 (0.98 - 1.01) 0.52
Systolic blood pressure (mmrlg) 1.01 (0.99 - 1.03) 0.19
Diastolic blood pressure (mmHg) 0.97 (0.94 - 0.99) 0.01
Peripheral oxygen saturation (Percent) 0.94 (0.87 - 1.02) 0.12
Jaundice 2.77 (1.66 - 4.64) <0.01
White blood cell count (XI o-VIL) 1.27 (1.19 - 1.36) <0.01
Haemoglobin (gldl) 0.75 (0.63 - 0.89) <0.01
Red blood cell count (x 10121L) 0.79 (0.56-1.12) 0.19
Mean corpuscular volume CtL) 1.02 (0.99 - 1.05) 0.23
Red cell distribution width (%) 1.17 (1.08 - 1.27) <0.01
Platelet count (xl0Y/l) 1.00 (0.99 - 1.00) 0.84
Aspartate transaminase (Itl/L) 0.99 (0.99 - 1.01) 0.53
Alkaline phosphatase -(lUlL) 0.99 (0.99 - 6.99) 0.01
Bilirubin - total (~ol/L) 1.01 (1.00- 1.01) 0.02
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For the second model, we limited analysis to laboratory factors to determine whether there
were any parameters that could be used to identify individuals who were more likely to have
seD. The results are shown in table below (Table 18).
Table 18 Multivariable analysis of laboratory features associated with SeD status
(0=1,805)
Factor OR P
White blood cell count (xl091l) 1.25 (1.19 - 1.32) <0.01
Haemoglobin (g/dl) 0.79 (0.69 - 0.91) <0.01
Red blood cell count (x lOJ~IL) 0.64 (0.49 - 0.82) < 0.01
Mean corpuscular volume (fL) 1.01 (0.99 - 1.04) 0.33
Red cell distribution width (%) 1.18 (1.10-1.00) <0.01
Platelet count (xlO~/l) 1.00 (0.99 - 1.00) 0.55
Aspartate transaminase (lUlL) 0.99 (0.99 - 1.00) 0.86
Alkaline phosphatase (lUlL) 0.99 (0.996 - 0.998) <0.01
Bilirubin - total (umol/L) 1.02 (1.02 - 1.03) <0.01
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STUDY POPULA nON
Baseline characteristics of SeD patients
During the study period, 1,725 patients with SCD were recruited into the study and 209
(12.1 %) were lost to follow up as 31st March 2009. In the SCD cohort, there were 856
(49.6%) male. Figure 20 shows the age distribution at time of recruitment into the study.
Figure 20 Age distribution of SeD patients at time of enrolment
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When age was grouped, the distribution was as shown in Figure 21, with 166 (9.6%) below 2
years and the majority of patients (79.3%) between 2 years and 20 years, which would be
considered children and adolescents.
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Figure 21 Age distribution, grouped into 5 age groups, of SeD patients at time of
recruitment
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For 1,661 patients with available data on place of birth, 1,185 (71.3%) of SeD patients had
been born in Dar-es-Salaam with 1,158 (72.5%) patients reported to be living in Dar-es-
Salaam, at time of recruitment. Although the patients were born and resident in Dar-es-
salaam, the ethnic origin was heterogeneous; 418 (24.7%) were from the 2 main tribes on the
coast; Zaramo and Ndengereko. 379 (22.4%) were from North Tanzania, around the region of
Lake Victoria. 121 (7.0%) were from Zanzibar or had Indian or Arab origin. The rest were
from tribes from different parts of Tanzania.
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HOSPITALISATION IN sen
Introduction
The burden of disease as a result of being affected by SeD can be estimated determining the birth
and population prevalence of disease. These estimates do not capture the disability that SeD
patients face due to chronic illness, characterized by recurrent episodes of acute clinical illness.
Weatherall et al recently estimated that up to 20, 194 disability adjusted life year (DALY) losses
occur every year due to SeD, with 13,856 (68.9%) from death and 6,338 (31.4%) due to chronic
anaemia, pain and other clinical events" The clinical severity within a SeD population is extremely
heterogeneous, ranging from patients who have asymptomatic or mild disease to severe forms.
However, if I was able to provide evidence that would aid in identifying individuals who were at
high-risk of hospitalisation, this would help in targeting interventions towards these individuals.
Acute clinical events such as pain, fever and anaemia may require visits to a health facility or
hospitalisation. In this thesis, I wanted to focus on those individuals who were hospitalized. The
aim was to determine the outcome of hospitalisation and to determine whether there were any
clinical or laboratory features at the time of at hospitalisation that could be used to identify those at
risk of having an adverse outcome.
Therefore, in this section, I set out to do the following; 1) determine the pattern and incidence of
hospitalisation in SeD; 2) determine factors associated with likelihood of hospitalisation in SeD;
3) identify factors associated with mortality during hospitalisation.
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Methods
Patients
In order to determine the rates and risk factors of hospitalisation in SCD, the study population
consisted of SCD patients who were part of the main study population i.e. individuals who had an
"entry visit" at outpatient clinic as described previously and were part of prospective surveillance.
For this analysis, SeD patients who had been hospitalised but did not have a clinic visit were not
included.
In order to determine the factors associated with death during hospitalisation, the study population
consisted of all SCD individuals who were hospitalised during the study period. In this analysis,
individuals who were identified as having SCD in the wards but did not have an entry visit were
included.
Procedures
At the first clinic attendance during the study window, patients were enrolled into the study. This
visit was referred to as the entry visit. All patients who fulfilled the inclusion criteria were recruited
into the study after informed consent was obtained from the patients or relatives. Clinical
information collected included demographic details, past and current symptoms. Physical
examination was performed which included general anthropometric measurement and thorough
systematic examination. Detailed neurological evaluation was done if clinically indicated as well as
assessment of cranial and peripheral nervous system for focal deficits. Patients were given a SCD
number which was their unique identifier that would be used for all subsequent visits to MNH. For
patients who were identified as having SCD during hospitalisation, data was collected during this
event but recruitment into the study was only done when the patient came to the clinic after
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discharge from the hospital. Therefore some patients will have hospitalisation events which precede
recruitment into the study. This information was collected as it was thought that important data
regarding causes of hospitalisation or mortality may not be captured.
Statistical methods
Rates and risk Jactors Jor hospitalisation
Data were analyzed using STATAvlO (StataCorp, College Station, TX). The SCD cohort was
defined to include patients who had an enrolment visit. The overall and age-specific incidence of
hospitalisation was estimated for the cohort. This was calculated from the ratio of number of
hospitalisations divided by the number of person years of observation (PYO), expressed as
hospitalisation rate according to age. The analysis did not include SCD patients who were identified
at hospitalisation, but had not returned to outpatient clinic for enrolment into the cohort. Data were
summarized as means, medians or proportions.
In order to determine the factors at enrolment associated with hospitalisation, I grouped the
individuals in the cohort into two groups; those who had never been hospitalised at MNH and those
who had been hospitalised at MNH (once or more) during the study period. Individuals with
multiple hospitalisations during the course of the study were classified in the latter group. Logistic
regression analysis was used to analyze factors at enrolment associated with hospitalisation, with
results presented as odds ratios (ORs) with 95% confidence intervals (95%CIs). Multivariable
logistic regression was used to identify independent associations with hospitalisation, using
variables that had significant association (p<O.05)on univariable analysis.
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Risk factors for mortality during hospitalisation
This analysis included all SeD individuals who were hospitalised at MNH during the course of the
study. This included some seD patients who were not included in the main cohort population.
Therefore this was a cross-sectional study of all hospitalised SeD patients with comparison made
between those who survived during hospitalisation and those who died. Logistic regression
analysis was used to analyze factors at hospitalisation associated with death, with results presented
as OR with 95% confidence intervals (95%els). Since some individuals may have multiple
hospitalisations, Ihad to take this into account during the analyses. There are two approaches;
accounting for clustering using the following command in Stata; logistic death_inp var cl(
demographic_id). The other approach would be using a random effects model (xi: xtlogit
death_inp var re i(demographic_id) or nolog). I analysed the data using both approaches and
following statistical advice, the results presented are from the first model. Multivariable logistic
regression (accounting for clustering as done during univariable analysis) was used to identify
independent associations with death, using variables that had significant association (p<O.05) on
univariable analysis.
Results
During the course of the study, of 1,725 SeD patients who had a baseline visit, 504 (29.2%) were
hospitalised at MNH during the five year period. The mean number of hospitalisations per month
was 15 (SD 7.2) with a minimum of 3 and maximum of 38 hospitalisations per month. The
hospitalisation pattern during the course of the study is shown in Figure 22.
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Figure 22 Number of hospitalisations per month during course of the study
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The x-axis shows the number of months with 1 being March 2004.
For the 572 patients who were admitted, the range of number of hospitalisations (Figure 23) was
1 10 times, with a mean of 1.6 (1.1) hospita1isations. 398 (69.6%) of patients were admitted only
once during the course of the study; 149 (28.7%) admitted between 2-5 times and 6 (1.2%) patients
were admitted between 6-10 times.
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Figure 23 Frequency of hospitalisation for 572 patients hospitalised during the study
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Rate of hospitalisation during the study
During the course of the study, the incidence rate of hospitalisation was 0.15 per 100 PYO. This
rate was calculated from 1,496 of 1,725 enrolled SCD patients with 620 hospitalisation events. This
gave 4,167 PYO.
Table 19 Rate of hospitalisation for SeD patients during study
Age (Group) Patients I Observation(yrs y~ Events.1 Incidence" (/100 PYO)
<2 100 49.3 24 0.49 (0.33-0.73)
2-4 361 453.4 109 0.24 (0.19-0.29)
5-9 584 1182.9 186 0.16 (0.14-0.18)
10-19 698 1871.9 195 0.10 (0.09-0.12)
20+ 256 610.5 106 0.17 (0.14-0.21)
Total 1,496 4167.9 620 0.15 (0.14-0.16)
Note: includes 1,496 out of L,725 SCD patients with complete data. I Number of patients in that age
group 2 Person-years of observation 3 events or hospitalisation 4 Incidence of hospitalisation per 100
PYO
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Factors associated with hospitalisation during the study
The clinical and laboratory features at baseline were analysed to explore whether there was an
association with risk of hospitalisation during the course of the study. At the baseline visit, patients
who were subsequently admitted were more likely to report having a febrile episode or being
hospitalised during the 12-month period preceding the baseline visit. There was also a higher
proportion in this group who reported to have noticed worsening of jaundice. The duration or
period of time over which this occurred was not docwnented.
On physical examination, patients who were subsequently admitted had lower diastolic blood
pressure and a higher proportion of jaundice, pallor and bossing of frontal bone of skull was noted
Furthermore, this group of patients had a higher proportion of individuals with palpable liver and
spleen.
Table 21 shows laboratory features at baseline, comparing patients who were hospitalised at least
once during the course of the study and those who were never hospitalised. The group of patients
who were likely to be admitted had lower Hb, wider RDW and higher LDH.
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Table 20 Clinical features at baseline visit associated with hospitalisation during the study
Total No Hospitalisation OR P
Total 1725 1221 (70.8' 504 (29.2'
Male 856 602 (49.3\ 254 (50.4' 1.04(0.85-1.29) 0.68
Age (years) 1725 9.8 (7.9) 9.5 (8.1) 0.99 (0.99-1.01) 0.49
BominDar 1185 823 (70.3\ 362 (73.9\ 1.19(0.94-1.52) 0.14
Clinical events reported in past 12 months
Hospitalisation 678 405 (50.8\ 273 (70.0' 2.26 (1.75-2.92) <0.01
Blood transfusion 548 374 (30.9\ 174(34.8 1.19 (0.95-1.48) 0.12
Pain 743 523 (43.3\ 220 (44.2' 1.04(0.84-1.28) 0.73
Fever 480 320 (27.4\ 160(32.7 1.29 (1.02-1.62) 0.03
Chest symptoms 14111 90 (7.5\ 51 (10.2) 1.41(0.98-2.03) 0.06
Seizures 1720 8 (0.7\ 1 (0.2) 0.3 (0.04-2.41) 0.26
Symptoms at baseline visit
Fever 1650 69 (5.9\ 40 (8.3' 1.44 (0.96-2.15) 0.08
Pain 1651 120(lO.3 52 (10.8) 1.05(0.75-1.49) 0.77
Anaemia 1628 22 (1.9\ 14 (2.9 1.55 (0.78-3.05) 0.21
Jaundice 1630 9 (0.8\ 11 (2.3 2.98 (1.23-7.24) 0.02
Cough 1648 81 (6.9' 43 (8.9) 1.31 (0.89-1.93) 0.17
CNS event 1645 6 (0.5\ 3 (0.6 1.21 (0.30-4.85) 0.79
Physical examination
Temperature (OC) 1575 36.5 (0.5) 36.5 (0.5) 1.04 (0.84-1.28) 0.70
Febrile (?37.5uC) 1575 19 (1.7 8(1.8 1.03 (0.45-2.37) 0.94
SBP (rrunHg) 1321 105.8 (15.8) 105.7(15.8) 0.99 (0.99-1.01) 0.94
DBP(rrunHg) 1187 67.4 (11.2) 65.7 (10.7) 0.95 (0.97-0.99) 0.02
Sp02 (%) 1008 97.2 (3.3) 97.6 (2.7) 1.04 (0.99-1.09) 0.09
Sa02<95% 1008 23 (3.2) 4 (1.4) 0.42 (0.14-1.23) 0.11
Jaundice 1587 581 (52.1 276 (58.5) 1.29(1.04-1.61) 0.02
Pallor 1622 422 (36.8) 213 (44.8) 1.39(1.12-l.74) <0.01
Frontal bossing 1576 255 (23.0 145(30.9, 1.49(l.18-l.90) <0.01
Palpable spleen 1608 146(l2.8 86 (14.4) 1.54 (1.15-2.06) <0.01
Palpable liver 1522 42 (3.9) 37 (8.3) 2.23 (1.42-3.53 <0.01
Death 1516 45 (4.2) 41 (9.1) 2.27 (1.47-3.53) <0.01
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Multivariable analysis
On multivariable analysis, two models were built. For the first model all variables that were
significant at 0.05 during univariable analysis were included. 703 events, with complete data were
included in this analysis. The factors that were independently associated with hospitalisation during
the course of the study were hospitalisation and RDW (Table 22).
For the second model, we did not include LDH which was available for only 640 (37.1 %)
hospitalisation events. 238 events were included in this analysis. In this case, hospitalisation, febrile
episode in past 12 months and RDW were independent risk factors for hospitalisation during the
course of the study (Table 23).
Table 22 Multivariable analysis: Factors at baseline visit associated with hospitalisation during the
study (n=703)
Factor OR P
Hospitalisation in past 12 months 2.64 (1.85-3.76) <0.01
Febrile episode in past 12 months 0.88 (0.60-1.31) 0.56
Reported worsening jaundice 2.29 (0.57-9.19) 0.24
Diastolic blood pressure (mmHg) 0.99 (0.98-1.02) 0.99
Jaundice on examination 1.13 (0.80-1.61) 0.48
Pallor 1.31 (0.92-1.88) 0.13
Bossing 1.22 (0.82-1.80) 0.32
Palpable spleen 0.78 (0.49-1.26) 0.31
Palpable liver 1.95 (0.93-4.12) 0.08
Haemoglobin (g/dl) 0.97 (0.85-1.10) 0.62
Red cell distribution width (%) 1.05 (1.01-1.10) 0.02
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Table 23 Multivariable analysis: Factors at baseline visit associated with hospitalisation during the
study (n=238
OR P
Hospitalisation in past 12 months 2.92 (1.41-6.07) <0.01
Febrile episode in past 12 months 0.37 (0.15-0.94) 0.04
Reported worsening jaundice 1.62 (0.21-12.75) 0.65
Diastolic blood pressure (mmHg) 0.99 (0.97-1.02) 0.73
Jaundice on examination 1.65 (0.90-3.03) 0.11
Pallor 0.94 (0.49-1.77) 0.85
Bossing 2.29 (0.96-5.50) 0.06
Palpable spleen 1.02 (0.40-2.58) 0.97
Palpable liver 4.65 (0.60-36.05) 0.14
Haemoglobin (g/dl.) 0.92 (0.72-1.18) 0.5
Red cell distribution width (%) 1.13 (1.04-1.24) <0.01
Lactate dehydrogenase (lUlL) 1.00 (0.99-1.00) 0.29
The factors that were independently associated with likelihood of hospitalisation during the course
of the study were history of hospitalisation in previous 12 months and ROW.
Description of events during hospitalisation
There were 885 hospitalization events identified from 572 SCD patients (note that this includes
SCD patients who did not have a baseline visit), and the analysis included all these events. For 3 of
these events, the outcome (death or discharge) was not known. Death occurred in 20 out of 882
(2.3%) hospitalizations.
From 882 hospitalisation events, 40 1 (46.5%) events were from male patients; with no difference
between the two groups (gender was not available for 3 events). The mean age at hospitalisation
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was 10.9 (SD 8.72) years, with 78.9% below the age of 18 years. 605 of 849 hospitalisation s
(73.3%) were from people who were born inDar.
The commonest clinical event in the 12 months preceding hospitalisation was pain, occurring in
226 of 865 events (26.1%) and fever (24.3%) . 99 of 865 (11.5%) reported to have received blood
transfusion.
The most common symptoms at hospitalisation were pain, occurring in 667 of 885 events (76.1%)
fever in 520/871 (59.6%) and anaemia in 191/868 (21.9%). 110/804 (12.4%) events reported
worsening of jaundice.
On physical examination, 246/868 (28.3%) were febrile, with body temperature above 37.7°C
with 9 out of 755 patients (1.2%) having peripheral oxygen desaturation. 77% were jaundiced
with palpable spleens and liver in 23.5% and 12.9% respectively.
Factors associated with mortality during hospitalisation
For 882 hospitalisation events, 862 (97.4%) were discharged and 20 (2.3%) died. The age group
with the highest proportion of deaths was 10 - 19years (3.9%), followed by over 20 years (2.7%).
the proportion of deaths in the other 2 age groups was 2 - 4 years (2.4%) and 5-9 years (0.8%). No
deaths were recorded in the 62 children admitted who were below 2 years of age at hospitalisation
(OR 1.38(0.94-2.02); p=O.09).
Univariable analysis
For this analysis, the association between clinical and laboratory features at hospitalisation and
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whether the outcome was survival or death was explored. There were no statistical differences
between those who survived and those who died with respect to history of clinical events in the 12
months neither preceding each hospitalisation nor presenting symptoms. Although, jaundice was
reported to occur in more patients who died (23.5%) compared to those who survived (12.3%), this
was not statistically significant (OR=2.21; p=O.18).On physical examination at hospitalisation, the
group of patients who died had higher temperatures, lower systolic blood pressure and palpable
liver at hospitalisation.
Comparing patients who survived to those who died, there were differences between the laboratory
values of these groups at hospitalisation. The laboratory factors that were associated with increased
risk of death were haemoglobin level, reticulocyte and platelet count. Individuals who died had a
lower haemoglobin (5.1g1dL) compared to those who survived (6.5g/dL; OR-O.88; p<O.OI).Those
with severe anaemia, haemoglobin <5g1dL, had a higher risk of death compared to those without
severe anaemia (Hb>5g/dL) but this was not statistically significant (OR 2.46; p=O.07).For the other
laboratory parameters, bilirubin, AST and creatinine were significantly higher in the group of
patients who died.
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MuItivariable analysis
On multivariable analysis, two models were built to identify the factors that were independently
associated with mortality. For the first model, 405 events were included (388 individuals) with
complete data. From this model, total bilirubin was independently associated with mortality.
Table 26 Multivariable analysis: Risk factors for mortality during hospitalisation n= 405 (388
individuals)
Factor OR p
Temperature (OC) 1.6110.47-5.51) 0.45
Systolic blood pressure (mmHg) 0.99 (0.92-1.07) 0.89
Palpable liver 1.64 (0.19-13.641 0.65
White blood cell count (x1091l) l.02i_0.97-1.1~ 0.46
Haemoglobin (g/dl) 0.67 JO.39-1.16) 0.15
Reticulocyte count (%) 1.02 (0.90-1.16) 0.70
Platelet count (x1091l) 0.99 (0.99-1.00) 0.22
Bilirubin - total (umol/L) l.01 i_1.00-1.0ll 0.04
Aspartate transaminase (lUlL) 1.01 (l.00-1.0ll 0.39
Creatinine (umol/L) 1.00 (0.99-1.02) 0.58
For the second model, the following variables were excluded because they had more than 25 % of
variables missing; reticulocyte had 616 (69.7%) with available data and total bilirubin had 637
(71.9%) with available data. From this model, haemoglobin was independently associated with
mortality during hospitalisation. Temperature, platelet and creatinine showed an association but this
was not statistically significant.
Table 27 Multivariable analysis: Risk factors for mortality during hospitalisation n= 532 (388
individuals)
Factor OR P
Temperature eC) 2.13 (0.94-4.81) 0.07
Systolic blood pressure (mmHg) 0.97 (0.92-1.02) 0.24
Palpable liver 1.47(0.37-5.77) 0.58
White blood cell count (xl091l) 1.00 {0.97-1.04} 0.81
Haemoglobin (g/dl) 0.66 (0.44-0.99) 0.05
Platelet count (x109/l) 0.99 (0.99-1.00) 0.11
Aspartate transaminase (lUlL) 1.00 (0.99-1.01) 0.24
Creatinine (umol/L) 1.00 (0.99-1.02) 0.09
Reticulocyte and total bilirubin excluded from this model.
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MORTALITY IN sen
Introduction
Estimates suggest that 50-80% of SCD children born in Africa patients will die before adulthood".
The World Health Organization estimate that up to 70% of these deaths are preventable with
simple, cost-effective interventions such as early identification of SCA patients by newborn
screening (NBS) and the subsequent provision of comprehensive care. Identification of risk factors
has led to improved survival through targeted interventions. In the West, reported risk factors for
death include infections, low haemoglobin and foetal Hb (HbF), high white blood cell count and
hemolysis22, 61,73. Therefore comprehensive care includes prompt treatment of acute events and
prophylaxis against infections, mainly with oral penicillin and vaccination against Streptococcus
pneumoniae and hydroxyurea Countries that have introduced these interventions have achieved
significant reduction in mortality; with up to 94% surviving to 18 years in the United States of
America (USA)18 and 99% to 20 years in the UK19. In most African countries, the lack of an
evidence-base has led to inertia in terms of implementation of these interventions, such as penicillin
prophylaxisr". One of the first steps in addressing this lack of knowledge is to provide an estimate
of mortality rates to highlight the burden of disease due to SCA. The ideal approach is to establish a
cohort of SCA patients, diagnosed at birth, and follow them up to determine rate and cause of
death. However, most countries in Africa do not have NBS programs, therefore such evidence will
rely on hospital-based studies. Information from such cohorts is biased, as it will consist of healthy
survivors or those with severe disease, who seek health care. This situation is similar to that in
Jamaica and USA in the early 1970s, when NBS for SCA was not established and evidence relied
on prospective studies in hospital-based cohorts, where most of the patients (92% and 65%
respectively) were not identified at birth. Despite the limitations of hospital-based studies, these
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studies provided important evidence on morbidity and mortality due to SCA. The aim of this
analysis was to determine the rate and risk factors of mortality in SCD patients.
Methods
Individuals were enrolled at outpatient clinics when they were stable without evidence of acute
illness. Those patients with acute illness were seen in casualty or hospitalized. All the SCA patients
attending the clinic followed the existing clinical practice of referrals and diagnosis on the basis of
clinical suspicion or family history. There is no NBS programme in Tanzania. The methods have
been described previously''". A detailed history and examination was recorded onto standardized
proformas. Blood samples were collected for a full blood count, haemoglobin electrophoresis,
HPLC and biochemical analysis. Nucleated RBC could not be differentiated from neutrophils by
the haematology analyzer.
SCA patients who did not attend clinic for more than 12 months were defined as defaulters and
were actively contacted by telephone or, for those residents in Dar-es-Salaam, home visits. Patients
who were not found after three attempts of tracing were considered to be lost to follow-up.
Statistical analysis
Data were analyzed using STATAvlO (StataCorp, College Station, TX, USA). The study period
started at enrolment clinic visit and the end was date of death or date last known to be alive. For
patients who died outside the hospital where date of death could not be ascertained, I used the date
of last hospital attendance. The Cnaan and Ryan approach to data analysis was used394, which
takes into account patients entering and leaving the study cohort with the observation beginning
after disease onset, which in this case was at birth. According to this method, a patient contributes
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to the population at risk for a given death only if that patient is enrolled in the study at the age at
which death occurs. Data were set using the stset command in STATA; stset date_end,
fail( death) origint dob ) enter(date_recruit) exit (date_end) id( demographic_id) scale(365.25).
This command takes into account three time points; origin which is the date of birth; enter which is
the date that the patient was enrolled into the study (in this case this is the entry visit at outpatient
clinic) and exit which is the date of censoring. This was date of death or date last known to be alive.
The overall and age-specific incident rate of mortality was estimated. This was calculated from the
ratio of number of deaths divided by the number of person years of observation (PYO), expressed
as mortality rates. In STATA, the command strate, per(J 00) generated the overall mortality rate
and the command strate age_exit _5y _grp, per(J 00) gave the age-specific incident rate, with age in
3 years; < 5 years, 5 - 9 years and above 10 years. The results are presented as incidence per 100
PYO.
To determine life expectancy, I modelled age at death rather than the length of time from enrolment
to death, similar to method used by Platt et atl. This was done using the stci command in STAT A
to determine the median survival after the data were set as described above and the survival curve
was drawn using the sts graph command in STAT A The data were summarized as means, medians
or proportions. Cox regression was used to analyze factors at enrolment associated with death, with
results presented as hazard ratios (HRs) with 95% confidence intervals (95%Cls). STATA
command stcox 'var' where var is the clinical or laboratory characteristic that is being analysed.
Multivariable Cox regression was used to identify independent associations with death, using
variables that had significant association (p<0.05) on univariable analysis. For the SCA patients
who died in hospital, the clinical and laboratory fmdings were reviewed and likely cause of death
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was ascertained.
The cause of death could only be ascertained in the SCD patients who died in hospital. For these
patients, the hospital notes, profonnas and laboratory results were reviewed. I classified possible
cause of death into infection if the patient presented with fever; presence of malaria or bacterial
infection and marked increase in white cell count. Cause of death was anaemia if the patient
presented with anaemia and haemoglobin was <5 g/dl. or there was a drop of haemoglobin level of
more than 2 g/dl, from the nearest clinic visit when patient was not unwell.
Results
Mortality rate
From March 2004 to March 2009, 1,725 SCD patients were recruited into the cohort. Two hundred
and nine were lost to follow up. Therefore, longitudinal information was available for 1,516 (80%)
patients with 4,295.9 person years of observation (P'r'O) [median: 2.9 (range: 0.02 - 5.14) years].
Death occurred in 86 (5.7%) patients, with only 20 (23.3%) occurring in MNH. The overall
incidence of death was 2.0 (95%CI 1.6, 2.5) per 100 PYa, with the highest rate below 5 years
(Table 28).
Table 28 Mortality rates stratified by age at exit from study
Age at exit or death*
A2e(group) Patientsl Observation" Deaths" Incidence"
<5years 252 285.4 23 8.1 (5.4.12.1)
5-9 years 1017 3,212.5 48 1.5(1.1 1.9)
>10 years 247 797.9 15 1.9 (1.1 3.1)
Total 1,516 4,295.9 86 2.0 (1.6 2.5)
*Date begin is date of birth and date of entry is date of enrolment into the study at outpatient clinic.
~atients; 'Number of individuals in each year group; 2person-years of observation; 3Deaths;
incidence of death per 100pya
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Survival of patients enrolled into the study
The estimated median survival of patients enrolled into the study was 32.7 (95%CI 25.9, 43.9)
years, with no difference between genders (p=O.8). The survival of patients enrolled in the study
was above 85%, during the period of observation.
Figure 24 Survival estimates of SeD patients enrolled into study.
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The survival curve takes into account that patients were identified and recruited into the study after
onset of disease. Using the Cnaan and Ryan approach", a patient contributes to the population at
risk for a given death, only if that patient is enrolled in the study at the age at which death occurs
(p=O.8)
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Risk factors for mortality
The characteristics of 1,516 patients at the visit when they were recruited into the cohort were
compared for those who were alive at last contact and those who died to explore whether any of
these factors could be used to identify high-risk individuals. Older age at exit from the study,
frontal bossing, and pallor on examination were significantly associated with increased risk of
mortality (Table 29).
On examination of laboratory features at baseline visit, lower haemoglobin, higher direct bilirubin
and higher alkaline phosphatase were associated with increased risk of death on univariable
analysis (Table 29).
Multivariable analysis
On multivariable analysis, low haemoglobin (HR 0.693, 95%CI 0.580, 0.829; p<0.OOO5),and high
direct bilirubin (HR 1.004, 95%CI 1.001, 1.007; p=0.018) were associated with death
independently of age at exit from the study and the other variables, including indirect bilirubin.
Cause of death
Of the 20 deaths that occurred in hospital, 5 (20%) were likely due to anaemia, 3 (15%) due to
infections and 12 (60%) were difficult to ascertain. No post-mortem studies were done.
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Table 29 Clinical and laboratory features at baseline visit associated with survival in SeD patients
Survived Died HR(95% Cl) p
n=I,430; n=86 (5.7%)
n (%) or n (%) or
Male (n %) 696 (48.7) 44 (51.2 1.02 (0.66, 1.57) 0.92
Age at entry (years) 7.9 (0.25-47.7) 9.3 (0.8-42.3) 1.003 (0.975, 1.032) 0.83
Agem~t(years)M~ 11.2 (0.7-49.0) 12.0 (l.5-44.0) 0.965 (0.933, 0.997) 0.03
CHnicai symptoms and signs
Pain 145 (10.6) 8 (9.4 0.97 (0.46 . 2.02) 0.93
Symptoms of anaemia 25 (1.9 5 (5.9) 2.44 (0.98 6.12) 0.06
Jaundice 692 (52.6 50 (60.9 1.23 (0.77 1.95) 0.38
Pallor on examination 525 (38.9 44 (53.7 2.04 (1.31 3.16) <0.01
Bossing 306 (23.5 32 (39.0) 1.59 (1.012.51) 0.05
Palpable spleen 189 (14.1 16 (20.0\ 1.49 (0.84 . 2.66) 0.17
Palpable liver 60 (4.8 8 (10.3 1.69 (0.79 3.59) 0.17
HbF 6.3 (4.7) 6.7(5.0) 1.044 (0.991, 1.099) 0.11
White blood cell count 15.9 (7.0) 15.7 (7.3) 1.014 (0.98 . 1.049) 0.45
Haemoglobin (g/dl) 7.5 (1.3) 6.9 (1.6) 0.678 (0.578, 0.794) <0.01
RBC 3.0 (0.8) 2.8 (0.8) 0.729 (0.519, 1.024) 0.07
RDW 23.1 (4.3) 24.4 (5.1) 1.039 (0.993, 1.088) 0.09
MCHC 32.9 (2.9) 33.1 (2.5) 0.902 (0.804, 1.011 0.08
Total bilirubin 69.7 (56.7) 87.5 (81.4) 1.002 (0.999, 1.005) 0.14
Direct bilirubin 20.9 (34.2) 33.1 (57.6) 1.003 (1.000,1.006) 0.05
Aspartate transaminase 50.1 (28.4) 49.3 (24.1) 0.997 (0.987, 1.006) 0.43
Alkaline phosphatase (lUlL) 266 (124) 277 (153) l.002 (1.000, 1.004) 0.05
Creatinine 40.8 (19.9) 43.3 (22.8) 1.003 (0.992, 1.013) 0.62
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DISCUSSION
This study presents data from one of the largest cohorts of SeD patients from a single centre
in the world. Although the prevalence of SeD is high in African countries, the largest cohorts
have been established outside of Africa where the prevalence is much lower (estimated
annual birth prevalence of SeD: Tanzania 7,800; USA 1,531 and Jamaica 302)4. The reasons
for this are threefold; first, for many low income countries (LIe), it is reported that there are
few individuals with SeD who survive and require health care as the assumption is that there
is high mortality in childhood. Since there is a high incidence of infections such as malaria,
lower respiratory infections, diarrhoeal diseases, the focus and priority has been on
addressing these conditions. Second, as a genetic disorder it is assumed that management
(diagnosis and treatment) would require resources that are beyond the means of health
ministries in LIe. Third, prospective surveillance of patients for clinical and research
purposes requires considerable resources in terms of personnel, time and funding. However,
the situation is changing, with SCl) having been recently recognised as a public health
priorityl12 and reports that show how cost-effective interventions can be introduced in LIe277•
Finally, identification of 1,725 SeD patients from one centre and without active
surveillance in the community or health facilities illustrates the magnitude of disease in this
setting.
The SCD population
Previous reports from Africa suggest that most children with seD die in early childhood with
prevalence of SS reported to fall from 2.1% at birth, 0.4% at one to four years and to 0.05%
over the age of nine years". In our study, 70% of the SeD population was above 5 years,
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suggesting that although there is no active intervention, SCD patients are surviving. More
recent estimates suggesting that Hb disorders contribute the equivalent of 6.4% of under 5
mortality in Africa". Although almost 9()01o of our study population were paediatric (under
18years), only 11.3% were < 2 years. This is of particular significance for SCD, because this
is the period of highest incidence of mortalityr'. In order to address this information gap of
spectrum of disease in first 2 years of life, natural history and survival of SCD, accurate
information on the birth and population prevalence as well as the age-specific mortality rates
is required.
In this study, we wanted to determine clinical and demographic features that could be used to
identify patients likely to have SCD as well as describe the clinical and laboratory features of
SCD patients in this setting. Clinical features classically described in SCD were seen in our
SCD populations, but were not found to be useful in identifying SCD patients. The finding
that hypoxaemia, measured by Sp02, was associated with SCD is interesting as it has been
reported to be a marker of disease severity 315 and has been associated with pulmonary'? and
neurological events304 314. This study also found that enlargement of the spleen was
independently associated with SCD status. The detection of a spleen can be easily taught and
could be used to identify patients who should be screened for SCD. In addition, teaching
SCD patients parents and carers to recognize splenic enlargement is of relevance with regards
to early detection and treatment of acute splenic sequestration. This is one of the common
causes of death in scn20 53 58 and recognition of splenic enlargement has been reported to
improve survival106•
The haematological and biochemical parameters in both SCD and the control population in
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Tanzania have been described, which would be locally-appropriate reference values of SCD
as well as non-SCD individuals in this setting. Comparison with SCD populations from other
geographical areas (fable 30) suggests that there are differences52, 63, 68,114,395-398. In addition, our
study has reported laboratory values that were independently associated with SCD status (low
levels Hb and ALP and high WBC, HbF and Bilirubin). This is of particular importance in
African countries, as there are limited resources to set up confirmatory tests for SCD (Hb
electrophoresis or HPLC) in all laboratories. Therefore, these values could be used to screen
and identify children that should be referred for confirmatory SCD testing.
In the selection of SS individuals to include in the cohort there are two limitations of
note. First, SS individuals who received blood transfusion within 3 months of enrolment
visit were excluded from the seD cohort, on the basis of having HbAo from transfused
blood. Second, confirmation of diagnosis of S-J3°thalassemia and S-HPFH requires
genotyping. Although hypochromic microcytic red cell indices may be used to identify
individuals with co-inheritance of thalassemia, the high prevalence of iron deficiency anaemia
in our population limits the use of these parameters in this setting. In order to identify
individuals with S-J3°thalassemia who will have severe disease, genotyping should be
done. Although this description is limited in that it may have included individuals with S-
J30thalassemia, published reports suggest that the predominant sickle genotype in most
East African countries is SS, with a low prevalence of S-pOthalassemia. For those with S-
HPFH, the assumption is that they will have mild disease and will most likely not present
to hospital or require hospital follow-up. The plan is to establish genotyping facilities in
Tanzania that would allow us to determine the prevalence of S-J3°thalassemia and S-
HPFH as well as to understand the genetic determinants of clinical disease.
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This study has been able to demonstrate that with relatively limited resources it is feasible to
set up a cohort study, integrated into health care provision in LIe in Africa. However, we
acknowledge limitations of hospital based cohorts; selection bias, since the SeD population
have described may be those with mild disease who have survived or those with severe
disease who come to the hospital. In addition, MNH is the national hospital, linked to the
main medical school. Although the resources are limited, the situation is likely to be worse in
small, rural health facilities. It is therefore important to interpret the results in this context as
the SeD population in these areas is likely to be worse. As part of future studies, I hope to
collaborate with other sites to describe the spectrum of SeD in other areas of Tanzania.
The second limitation is that the proportion of the seD population under 2 years (166/1,725;
9.6%) and above 20 years (195/1,725; 11.3%) was low. Therefore, the information from my
study should be interpreted with caution for these age groups. This limitation highlights the
need to identify SeD children at birth with prospective follow up of this birth cohort, which
is of importance for research as well as development of clinical programmesi/? 277.. It also
highlights the importance of population-based approach to epidemiological studies. With
regards to the small number of patients above 20 years of age, this may be due to mortality or
it may be due to patients having mild disease when older and therefore not requiring regular
visits to health facilities. Further studies are required to determine the burden of disease in the
older age group. The third limitation is related to the controls. The control population should
ideally be matched for age, geographical residence and time of recruitment. They should also
be followed up in order to determine key events such as death and health facility visits which
could be part of a demographic surveillance system. The controls in this study were
recruited from siblings and individuals referred to the hospital which could result in bias.
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There was no information on mortality. This was not done due to limitations of resources
and it is proposed that future studies should be planned bearing in mind these limitations.
Notwithstanding these limitations, I have provided a description of SeD in Africa and have
developed the framework for further studies into understanding disease mechanisms and role
of different disease modifying factors SeD. In addition, this framework will allow the
development of an evidence-base, through clinical trials, to determine the interventions that
would be locally-appropriate.
Hospitalisation
The burden of SeD is frequently quantified by estimating the birth prevalence of SeD
individuals and the mortality rates. However, SeD is a lifelong illness and causes significant
burden on individuals, communities and health systems with episodes of acute clinical events
which sometimes require care at hospitals. During the course of the study, 29% of the 1,725
SeD patients recruited into the cohort were hospitalised. This rate is higher than the estimate
quoted that 10% of SeD require inpatient care2. 3. 6. The reason for the higher rate of
hospitalisation in this study may be due to more severe disease but is more likely due to lack
of comprehensive dedicated services for SeD. In settings with specialised care for SeD,
hospital care is organised in such a way that patients may receive treatment such as blood
transfusion, antibiotic treatment, or undergo investigations on an outpatient basis in the form
of day wards. In many African countries, services are not organised in that way. Therefore,
seD patients are either seen in the emergency department (ED) or are hospitalised. A
dedicated SeD service, particular with day ward facility has been found to be an efficient
way of providing care which results in reduced need, as well as reduced length of stay during
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hospitalisatiorr'f", In the UK, the frequency of hospitalisation in a SCD cohort in South
London, UK in 1981, reported that 63/211 (29.8%) SCD patients were hospitalised'f? which
is similar to the frequency in this study. However, day wards were reported to reduce hospital
admissions by 43% and resulted in a 49% reduction in length of stay in hospitals''?'. In
Africa, ambulatory care (which includes care in the community) has also been found to be
feasible and effective402.
The main causes of hospitalisation in this study were pain (76.1 %), fever (59.6%) and
anaemia (21.9%). Painful episodes, are the commonest cause of hospitalisation in SCD23403.
They account for the following proportion of hospitalisation; 26.7% in Congo Brazzaville404,
36% in Yemen405, 63.2% in Kuwait406, 65% in Senegal149and 50010 in USA407• However, some
studies have reported infections as being more common than pain as a cause of
hospitalisation; a study in Congo Brazzaville reported cause of admission as infections
(36.6%), pain (26.7%) and anaemia (20.3%)404 and in another study in Nigeria, infections
accounted for 69% of admissions408• Therefore, pain and febrile episodes appear to be the
two most common causes of hospitalisation in SCD.
At baseline visit, the 3 factors that were independently associated with increased risk of
hospitalisation were a history of hospitalisation or febrile episode within 12 month of
baseline visit and high RDW. The former two factors are useful indicators, as they are
relatively reliable from reports of parents or guardians. Therefore they can be established
easily from taking a good clinical history. This information would then be used to alert health
care providers of SCD patients who are at increased risk of hospitalisation. Therefore, the
high-risk individuals would be monitored more closely. The relationship between RDW and
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hospitalisation is less clear. A high ROW suggests that there is mixed population of red blood
cells, both small and large cells. Small cells or microcytic RBCs may be due to iron
deficiency whereas large cells, macrocytes, may be due to deficiency of vitamin B12 or
folate. Macrocytes may also be due to increased erythropoiesis resulting in large RBCs
circulating in peripheral blood. The increased erythropoiesis may be in response to low Rh
levels. On univariable analysis, low Hb was significantly associated with risk of
hospitalisation but not on multivariable analysis. This relationship, between anaemia and risk
of hospitalisation requires further exploration inmore detailed studies.
During hospitalisation, 20 of 882 hospitalisation events resulted in death; giving a case
fatality ratio (CFR) of 2.3%. This rate is lower than that reported in Zambia, where a study
that tried to determine cause of death in 62 seD deaths for 3 years, between January 1987
and December 1989, found a CFR of 6.6%. The lower CFR in this study may be due to a
'healthy-survivor effect'; where the SCD patients that are seen at MNH are those with less
severe disease and therefore will have lower mortality.
The information from this study is an initial step in identifying the causes and risk factors for
hospitalisation. I acknowledge that some SCD patients do not come to MNH for healthcare.
Factors such as physical distance, referral system, and socioeconomic factors may influence
who is hospitalised at MNH. It is therefore important to develop a system that will capture
events that occur at home and that are managed inhealth facilities outside MNH.
Mortality
This is the first study that presents the rates and risk factors for mortality in SCD in Africa,
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where over 75% of SeD patients in the world live. The median survival amongst patients
with SeD was 33 years, which is 19 years less than life expectancy at birth (52 years) in
Tanzania?". This life expectancy is markedly lower than the 40 to 60 years of SeD patients in
the United States of America" and Jamaica409. The mortality rate in this cohort is 2.0 per 100
PYO (95%eI 1.6-2.5) is not dissimilar to the 3 per 100 PYO reported from the USA in the
1970sbefore use of penicillinprophylaxis410,411, but is markedly higher than the current incidence
of 0.13 to 1.39per 100 PYO reported from Europe and the USAI8, 19,61. The second important
finding is that most deaths occur in children rather than adolescents or adults. This is similar
to reports from Jamaica and USA where, before prophylacticpenicillin, the highest incidenceof
deathwas reported between 1-3yearsl9• 20,22,23, 106.This highlightsthe importanceof identifying
children at birth by newborn screening as seD children are probably dying before the
diagnosis is made. Pilot studies have shown that newborn screening is feasible in Africa276
and its establishment with comprehensive care will most likely significantly improve
survival.
In this study, low haemoglobin was independently associated with mortality. It has been
previously reported that there is an association between low haemoglobin and mortality'" 20
22,23, 61, 71, 106, 177,408. However, more evidence is needed to identify underlying cause of
anaemia so that interventions that ameliorate the effects can be considered and targeted. So
far, interventions to reduce mortality have been aimed to address the recognised causes of
death, namely infections, acute splenic sequestration and acute chest syndrome. Blood
transfusion therapy is necessary in SeD, particularly during acute episodes and
perioperatively'P: 125,but chronic blood transfusion is not a viable treatment option in Africa
due to problems of inadequate blood supply, risk of transmission of infections and
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cheap, easy to administer and has been shown to reduce blood transfusion requirements and
to modestly increase haemoglobin and improve survival128• 358. However, despite these
advantages, it is not widely used in SCD patients in Africa and there have been no trials to
determine its role in this setting.
There is increasing evidence of the role of hemolysis in pathogenesis of clinical events in
SCD, such as pulmonary hypertension and stroke73-75, via a mechanism involving
interference with endothelial nitric oxide by free haemoglobin. However, hemolysis and the
hyperhaemolysis phenotype are thought not to be common in Africa". In this study the
relationship between haemolysis and mortality was carefully explored. Analysing, the risk
factors at baseline associated with overall mortality, markers of hemolysis, such as lactate
dehydrogenase 73 and total and indirect bilirubin did not show significant association.
However, during hospitalisation, total bilirubin and indirect bilirubin, were significantly
associated with increased risk of mortality on univariable analysis. This may suggest that
during OPD visits, SCD patients are stable with low levels of haemolysis, hence the absence
of an association with mortality. However, during the acute phase, there is an increase in
haemolysis which is associated with mortality. It is therefore essential to conduct further
studies to accurately elucidate the role of haemolysis in SCD as interventions that reduce
haemolysis, such as hydroxyurea, may be effective in improving survival.
In this study, direct bilirubin was an independent predictor of death when analysing the
relationship between levels at baseline with overall mortality as well as during levels at
admission during hospitalisation. The association between direct hyperbilirubinemia and
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mortality may be related to liver disease, as there was also a strong trend in univariable
analysis for an effect of alkaline phosphatase, although aspartate transaminase was not a
predictor. It is possible that the direct hyperbilirubinemia is related to the upregulation of
haem-oxygenase in response to the hypoxia associated with SeD. This may have protective
effects via the antioxidant effects of bilirubin and the vasodilatory effects of carbon
monoxide'l':'. Adaptations may have downstream costs, however, and there is a suggestion
that upregulation of haeme-oxygenase may have detrimental effects in patients who are
acutely m414. Haeme-oxygenase also up-regulates Vascular Endothelial Growth Factor,
potentially leading to further angiogenesis'T" 416.. Dysfunctional angiogenesis, haeme--
oxygenase and Nitric oxide are factors that are implicated in the pathogenesis of clinical
events and disease in SeD.
One of the aims of the study was to determine the cause of mortality in seD. However, in
this study it was difficult to make valid conclusions from the data that I was able to collect as
only 20 (23%) out of 86 deaths occurred in hospital. On reviewing the notes of these 20
cases, I was able to confidently ascertain the likely cause of death in 8 cases (9.3%); inwhich
anaemia and infection may have been the cause in 5 (20%) and 3 (15%) cases respectively. In
order to ascertain cause of death, it is important to conduct verbal autopsy on deaths that
occur outside health facilities. For those that occur within health facilities, such as Muhimbili,
efforts should be made to conduct post-mortem studies. This information is critical to
ascertain cause of death which would improve interventions to prevent future mortality.
This cohort study highlights four key areas to improve survival in SeD and identifying
knowledge gaps to guide further research. First, over 85% of patients enrolled into the study
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survived, providing evidence to challenge the dogma that seD patients do not survive
beyond childhood in Africa. Modell et al estimated that 6 million Africans will be living with
SeD if average survival of affected children reaches half the African norm". The burden of
disease to individuals, communities and health systems has not been quantified yet, but these
patients will suffer from anaemia, painful crises, infections, stroke and other complications'',
Undoubtedly, SSA countries need to develop programmes to provide appropriate care for
these individuals as the burden will be considerably high. Second, only 25% of deaths
occurred in the MNH. This is probably an underestimate as we did do not have data on deaths
in undiagnosed seD children < 5 years. Although it is possible that these deaths occurred in
other health care facilities, the burden of disease survey reported that 50% of deaths in
Tanzania occur outside a health facility417. The finding has important implications for
planning services as it highlights the need to develop a strong network of community-based
health care and not focus resources in specialist hospitals. The responses on questioning
relatives about events surrounding death suggested that most deaths occurred at home but
further studies following recognised verbal autopsy procedures are required. Third, although
1,903 patients were identified at clinic and in wards, 10% did not return to the clinic and for
those who did return to clinic and were recruited into the cohort, 12% were lost to follow-up.
Therefore, SeD patients may be seen at a health care facility only once. This is in contrast to
US, Jamaica and Europe where steady state values (average annual routine measurements) 22,
61,418are used, as the health system in these countries ensures that patients can be seen
regularly, or at least easily traced if they are found to be high risk. Therefore, in this study,
factors at baseline clinic visit were explored to identify high-risk patients. Attendance may be
improved by health education to seD patients and their caregivers on the importance of
regular follow-up as well as improving access to health care.
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This study provides the first description of mortality rate of SCD in Africa. As expected,
there is a high mortality in SCD, with children significantly affected. Level of haemoglobin
and direct bilirubin at baseline visit were independently associated with mortality. Although I
have provided data that will guide initial policies and guidelines of management, the study
has highlighted the areas where there are gaps in knowledge. I propose that priority should be
given to the establishment of a seD birth cohort to provide accurate survival data and
identify causes of mortality particularly in early childhood. Furthermore, since anaemia was
associated with mortality, detailed studies to identify causes of anaemia and randomised
clinical trials to determine appropriate interventions to ameliorate the effects of anaemia are
recommended.
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Chapter Five
Sickle Cell Disease and Malaria
INTRODUCTION
Malaria is widely considered to be one of the major causes of illness and death in patients
living with SCD in SSAI4, 100.However, the evidence to support this has been conflicting. An
association between malaria and both admission to hospital and anaemic crises 76,177-179,202,419
and increased mortality'?' 100have been reported in a number of studies. However, these
studies included a relatively small number of seD patients and were generally conducted in
areas with a high prevalence of malaria in the general population.
On the other hand, the evidence of increased protection from malaria in seD individuals is
11· 1 1 f' malari :_.c- . 180 181 183 d 1 .more compe mg; a ower preva ence 0 rna ana infection ' , an a ower parasite
densityl82 have been reported. The evidence that the HbSS genotype may confer resistance
against malarial infection per se would make more sense, given that subjects heterozygous
for the J3s-gene (Hb AS) show unequivocal protection from malaria158-161.This raises the
question of whether, if HbS protects the heterozygotes against malaria, those with SeD, who
have even higher levels ofHbS, might be even better protected.
Recently there have been three important developments in the field of malaria. First, effective
interventions against malaria are available, in the form of insecticide-treated nets 173, and
artemisinin-based combination therapies'f", Second, there are reported changes in the
epidemiology of malaria in some parts of East and West Africa, with reductions in both
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transmission rates and the incidence of diseasel74• 175.421. . It is possible that this reduction is due
to effective interventions and control measures as well as climate change. Third, due to
increasing resistance by Plasmodium Jalciparum parasites most countries have had to stop
using chloroquine. In Tanzania, during the period of the study, first line therapy for malaria
changed from monotherapy with chloroquine to sulphadoxine pyrimethamine (SF), with the
current recommendation being artemisinin-based combination therapy (ACT) - artemether
lumefantrine (ALU)191 . However, it has been difficult to determine which drug to use for
prophylaxis. SF has anti-folate properties and is not recommended for prophylaxis in patients
with SCD who are considered to be folate deficient. The folate deficiency is thought to be a
result of chronic haemolysis and compensatory increase in erythropoiesis. Most malaria-
endemic countries have therefore been unable to decide which drug to use and have
continued to recommend chloroquine for prophylaxis in SCD.
The changes in malaria epidemiology and management as well as the increasing evidence of
protection against malaria by HbS, emphasized the need to determine the role of malaria as a
cause of morbidity and mortality in SCD. However, the general perception that malaria is a
major risk in patients with SCD means that the prescription of anti-malaria chemoprophylaxis
is now standard recommended practise in endemic areas 127. As a consequence, ethical
considerations make it difficult to study this question directly. The cohort of SCD in
Tanzania provided a unique opportunity to study the importance of malaria as a cause of
morbidity in SCD. Tanzania stopped using chloroquine for treatment of malaria in 2001, due
to high resistance. Although the national malaria control programme continues to recommend
that children with SCD should receive prophylaxis with chloroquine, the importation of
chloroquine is banned and in practise most patients are not on effective prophylaxis. Dar-es-
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Salaam has ''Urban malaria ,a pattern that is characterised by low transmission intensity and
variable parasite prevalence, ranging from 0.8% to 10% 422-424. The primary aim of this study
was to determine the role of Plasmodium falciparum infection as a cause of ill health in
individuals with SeD in Tanzania.
METHODS
Patients
All SCD patients were seen at the outpatient department (OPD) clinic. Routine appointments
were scheduled at 3-6 month intervals and the majority of patients attending these
appointments were well. During these routine visits, the results of a standardised clinical
history and examination were recorded and blood samples were collected for full blood
count, biochemical analysis and malaria investigation. Patients admitted for inpatient care
were identified by active daily ward surveillance. Routine clinical and laboratory data,
including a full blood count, biochemical analysis and malaria diagnostic tests, were collected
at admission onto standard proforrnas. Additional investigations were performed as clinically
indicated. Data were collected from two populations of non-SflD individuals: (1) subjects
invited for SeD screening at the OPD clinic, including relatives and friends of SCD patients,
and (2) non-Sf'D patients who were admitted to the paediatric wards of MNH between July
2006 and July 2008.
Laboratory methods
Regardless of their clinical status, all individuals who were enrolled into the study were
investigated for malaria at all visits. Malaria was confirmed using rapid diagnostic tests
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(RDTs) (Parahit, Span Diagnostics, India or Paracheck, Orchid Biomedical Systems, India)
and or Giemsa-stained thick blood films following standard methods. Plasmodium
Falciparum densities were assessed by counting the number of asexual-stage parasites per
200 WBCs. The parasite density was calculated and expressed in parasites/ul, by reference
to the mean WBC count in this study population of 14.8 x 1012 I~. These results have not been
presented in this thesis.
Statistical methods
A general outline of descriptive statistics, disease estimates, univariable and multivariable
analyses is provided in the methods chapter. Malaria events were analyzed according to three
definitions: (1) malaria parasitaemia (MPS) - positive blood film and/or a positive RDT
irrespective of clinical status; (2) clinical malaria (cM) - positive test in the presence of fever
(an axillary temperature of>37.50C) and; (3) severe malarial anaemia (SMA) - Hb <5g/dl in
the presence of malaria parasitaemia. For the purposes of this analysis, the diagnosis of SMA
did not require a threshold parasite density of > I0,000 parasites/ul., the defmition used by
WH0425• This asswnption was made for two reasons; first, an Hb <5g/dL is a life-threatening
condition as it associated with high risk of mortality. Second, since patients with SCD often
receive treatment for malaria when febrile. Therefore, malaria parasitaemia may be low, but it
may have already triggered events leading to severe anaemia.
The factors that were examined to determine an association with malaria included
demographic (age, sex, place of birth, residence), clinical variables (fever, pain, anaemia,
chest or neurological event) and laboratory parameters (haematology, clinical chemistry and
microbiology). Time dependent variables were age, date of visit, clinical and laboratory
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parameters at each visit. For purposes of the analyses, the parameters of each individual at
recruitment into the study (baseline visit) for SCD patients and first visit for control
individuals were used
Continuous variables were compared using two-sided Student's r-tests while categorical
variables were compared using the i test and results presented as odds ratios (ORs) with
95% confidence intervals. Multivariable logistic regression was used to identify independent
associations with malaria, using all variables that were significantly associated (p<O.05) on
univariate analysis. Here the focus will be on the analytical groups and outcomes of interest.
The analytical approach that was used was to answer the 4 specific questions.
What is the prevalence of malaria in SeD during OPD visits? The data of all visits to
OPD clinic by SeD and control population were examined. The groups being compared
were SCD and non-Sf'D patients at OPD clinic.
What is the prevalence of malaria during admission? For this, the analysis was limited to
data of patients who were admitted, with the two groups being SeD and non-SCD
populations. The prevalence of malaria in the two inpatient population groups was compared
with the SCD population. Comparison was then done looking at hospitalised SeD patients
with malaria and without malaria. A description of specific clinical syndromes of malaria that
SeD present with and then looked at factors associated with malaria was made.
What is the difference in malaria prevalence and associated factors during OPD and
JPD visits of SeD patients? Data from OPD and IPD were combined. The groups that were
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being compared were SeD at OPD and SeD who were hospitalised.
What is the incidence of malaria in SeD? The incidence rates for malaria events were
calculated for the whole study period, combining events at OPD clinic and during
hospitalisation. The data was set for survival analysis using the following command: stset
datetod, id (demographic_id) failure(malariaanaemia) exit(time end_date) scale(365.25).
The incidence was calculated by the ratio of malaria events (MPS, cM and SMA as defined
above) divided by the number of person-years of exposure. This was done for the 3 malaria
events using the following STATA commands strate, per(JOO). In order to calculate the
incidence of the malaria event stratified into 2 age groups, above and below 5 years, the
following command was used: strate agegp, per(100). The result was expressed as the
number of events per 100 person years of follow up, with 95% confidence intervals and a p -
value of 0.05 was considered to be of statistical significance. Note that in the example given,
the event is severe malaria anaemia, coded as malariaanaemia. This analysis was repeated for
clinical malaria and malaria parasitaemia as defmed above.
RESULTS
The analysis period was from March 2004 to March 2009. The OPD clinic data derived from
10,491 visits amongst 1,808 SeD patients (median age II years; range 4 months to 47 years)
and 773 visits from amongst 679 non-SCl) individuals (12.8 years; 3 months-64 years) while
the inpatient data derived from 691 admission events in 497 SeD patients (10.8 years; 5
months-O years). Please note that this chapter included all patients at OPD clinic visits and
hospitalisation. There are some SeA patients who were seen at clinic or in wards who did not
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return for enrolmentlbaseline visit. Therefore the numbers differ from the baseline
description. Control data were collected from 2,017 non-SCD patients aged 6 months to 10
years who were admitted between 2006 and 2008. The prevalence of malaria in the various
subject groups is summarized in figure below (Figure 25). Note that the prevalence of
malaria in the control population during hospitalisation is limited to children.
Figure 25 Summary of individuals and visits in the study with prevalence of malaria
°tparasi aenua
number of visits
n = 5,001
number of visits = 13,972
malaria 221 (1.58)
I
I I
cunic Admissions
n= 2,487 n= 2,514
number of visits = 11,264 number of visits = 2,708
malaria 88 (0.78%) malaria 133 (4.~
I I
I I I I
SCA Non-SCA SCA Non-SeA
n = 1,808 n = 679 n = 497 n= 2,017
number of visits = 10,491 number of visits = 773 number of visits = 691 number of visits = 2,017
malaria 76 (0.72) malaria 12 (1.55) malaria 21j3.0~ malaria 112 (5.6)
I
I I
AS AA
n =402 n = 277
number of visits = 469 number of visits = 304
malaria 3 (0.64) malaria 9 (2.96)
. .Clinic refers to events at outpatient clinic VISItS;admissions refer to events dunng hospitalization .
Number of visits refers to all visits; n is number of individuals. The number after malaria is the number
of episodes of malaria parasitaemia, figures in parentheses is the prevalence per visit (not per individual).
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Malaria in the outpatient clinic
The overall prevalence of malaria parasitaemia at the OPD clinic was 88/11,264 (0.78%)
(Figure 25), with the proportion in SCD patients being 76/10,491 (0.72%) and non-SCD
patients being 121773 (1.55%) [OR (95%CI) 0.46 (0.25 - 0.85); p=O.OI]. Further
subdividing the groups into the three sickle phenotypes (SS 1,808; AS = 402; AA = 304), the
prevalence was significantly lower both in subjects with AS 0.64% and SS 0.72% than
those with HbAA (2.96%). This is illustrated by showing likelihood (odds ratio) of malaria
parasitaemia (Figure 26) in the three phenotypes.
Figure 26 Odds ratio of malaria parasitaemia in AA, AS and SS individuals at OPD
clinic
• •
o
AA AS
Sickle status
SS
HbAS 0.64 %; (OR 0.21 (95% Cl 0.06 .0.79); p= 0.02) and HbSS 0.72 % (0.24 (0.12 .
0.48); p<O.OOI) than those with HbAA (2.96%).
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Due to the variation in malaria prevalence with age, comparison was made between SeD.
and non-Sf.D at different age groups. The proportion with malaria in seD compared to non-
sen was as follows: < 5 years; sen 20 (1.17) vs. non-SeD 3 (1.33) [OR (95%eI) 0.88
(0.26 - 2.99); p=O.84]. 5 - 9 years; SeD 20 (0.77) vs. non-Sf'D 4 (2.44) [0.32 (0.11 - 0.93);
p=0.04]. 10 - 19 years; SeD 27 (0.60) vs. non-SflD 3 (1.61) [0.37 (0.11 - 1.23); p=0.1O].
Over 20 years; SeD 9 (0.53) vs. non-SCl) 2 (1.07) [0.49 (0.11- 0.29) p=0.37].
Limiting analysis of malaria in SeD, the prevalence of malaria parasitaemia, out of 10,488
OPD visits where data of age was available, was as follows: <2 years 2 (0.53%); 2 - 5 yrs 18
(1.36%); 5 - 9 yrs 20 (0.77%); 10-19 yrs 27 (0.60%); over 20 years 9 (0.53%). This is
illustrated in figure below (Figure 27), with the 2 - 5 year age group having the highest
prevalence of malaria.
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Figure 27 Odds ratio of malaria parasitaemia in SeD at OPD clinic stratified by age
•
•
o •~----------~-----------.----------~r-----------~•
<2 2-5 5-9
age grouped in years
10·19 20+
Factors associated with malaria at OPD clinic
The factors associated with malaria parasitaemia in SeD patients at OPD clinic are
summarised in table below (Table 31). During OPD clinic visits, factors that were
significantly associated with parasitaemia on univariable analysis included fever, higher
oxygen saturation, spleen and liver enlargement, high WBe and MeV and low Hb.
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On multi variable analysis, high WBe was the only feature that remained significantly
associated (OR 3.3; 95% er 1.5-7.18; p<O.Ol), while fever (3.3; 0.97-11.29; 0.057) showed
an association but did not reach the conventional cut-off for statistical significance.
Table 32 Multivariable analysis of factors associated with malaria parasitaemia at OPD
clinic in SCD
OPD clinic visits
Variable OR(CI) P
Age 1.00 (0.951 - 1.06) 0.916
Febrile (>37.5ue) 3.30 (0.97 11.29) 0.057
Saturation (SP()2), (%) 1.07 (0.94. 1.21) 0.300
Hepatomegaly 12.95(.85- 10.18_} 0.087
Splenomegaly 1.09 (0.40 - 2.95_} 0.867
High WBe (> 17.7 xlO~/l) 3.29 (1.50.7.18) 0.003
Haemoglobin (gldl) * p.79 (0.59- 1.047) 0.101
Malaria during hospitalisation
During the course of the study there were 691 hospital admissions amongst 487 patients
with SeD. This is limited to seD patients who were hospitalised and had malaria data.
Malaria parasitaemia was detected in 21 (3.4 %) admissions, only 1 patient testing
positive during more than one admission. The overall prevalence of malaria
parasitaemia during hospitalisation was 133/2,708 (4.9%) (Figure 25), with the
proportion in sen being 211691 (3.04%) and non-seD 112/2,017 (5.6%) [OR
(95%el) 0.53 (0.320.86); p=0.08]. Due to the variation inmalaria prevalence with age,
comparison was made between SeD and non-SflD below 10 years of age. The
proportion with malaria in SeD was 10/380 (2.63) compared to 112/2,017 (5.6) in the
non-Sf'D group [OR (95%el) 0.46 (0.21 - 0.89); p=0.02].
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Limiting analysis to SeD only, the figure below shows the odds ratio of having
malaria parasitaemia stratified by age group (Figure 28).
Figure 28 Odds ratio of malaria parasitaemia in SCD patients during hospitalization,
stratified by age
•
• •
•
o ~----------.----------.-----------.----------~
<2 2-5 5-9
198 gauped In years
10-19 20+
Clinical features associated with malaria during hospitalisation
The factors associated with malaria parasitaemia during hospitalisation on univariate analysis
are summarised in table below (Table 33). At admission, SeD patients with parasitaemia
were older and had lower Hb concentrations and higher MeVs, reticulocyte counts and AST
than those without parasitaemia. The risk of death during hospitalization was higher in those
with parasitaemia (OR 4.9; 95%CI 1.04 - 23.20); 0.04).
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The factors that were independently associated with parasitaemia were severe anaemia (OR
3.46; 1.279.45; 0.02) and high AST (3.41; 1.23-9.45; 0.02) (Table 34).
Table 34 Multivariable analysis o( (actors associated with malaria parasitaemia during
hospitalisation in SeD
IPD
Variable OR (CI) P
Age (years) 1.0410.99 1.09} 0.088
Severe anaemia (Hb<5g/dl) 3.46 (1.27 - 9.45) 0.016
Macrocytosis (MCV> 93fL) 2.22 (0.73 . 6.72) 0.158
Reticulocyte count (%) 1.04 (0.97 - 1.10) 0.264
High AST (AST > 97.2 lUlL) 3.41 (1.23 - 9.45) 0.018
Death 0.49 (0.04 5.74) 0.573
Malaria in SCD at OPD clinic versus hospitalisation
The prevalence of parasitaemia was lower in seD compared to non-St.D individuals during
hospitalization (3.0 vs. 5.6; OR 0.46; 0.25-0.94; p=O.OI). Table 35 shows the events in seD
patients both at the outpatient clinic and during hospitalization. The prevalence of
parasitaemia, malaria and SMA were all higher during hospitalization than at the outpatient
clinic. Amongst SeD patients visiting the OPD clinic, subjects were clinically ill (with either
fever or severe anaemia associated with parasitaemia) on 14/10,466 (0.13%) of visits. 6
(0.06% of the total visits) had fever alone, 8 (0.08%) had severe anaemia alone and 4 (0.04%)
had both fever and severe anaemia. During hospitalization, 11 out of 691 (1.59%) had either
clinical malaria or SMA, 7/682 (1.03%) had clinical malaria alone, 111644 (1.71%) had SMA
and 4/691 (0.58%) had both clinical malaria and SMA. The difference between malaria
events during OPD clinic and hospitalisation is summarised in table below (Table 35).
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Incidence of malaria in SeD
During the 5 years of study, 3,827 person years of observation (PYO) were recorded. The
incidence rate (95% Cl) ofparasitaemia was 2.53 (2.06-3.09), malaria 0.37 (0.20-0.61) and
SMA 0.50 (0.30---{).78)episodes per 100 PYO. Please note that the number of SCD patients
included in this analysis is different from that presented in the general results chapter. This is
because the numbers are determined by SCD patients who had malaria data and included
patients who did not have an enrolment visit.
Table 36 Age - specific incidence of malaria, clinical malaria and severe malarial anaemia
in 1,862 SeD patients
Total <5 years >5 years OR(eI) p
MPS 1,862_(l 00.00) 380 (20.4) 1,482 (79.6) 0.57 (0.291.08) 0.08
CM! 85 (4.6) 11 (2.9) 74 (5.0) 2.96 (1.02-8.57) 0.05
SMA.l 14 (0.8) 6 (1.6) 8 (0.5) 2.29 (0.895.88) 0.08
19 (1.0) 7 (1.84) 12 (0.81)
MPS - Malaria; 'Malaria and tempemture above 37.5°C; 2Malaria and haemoglobin <5g1dl;
number, parentheses percentage
Table 36 shows malaria events stratified into two age bands (above and below 5 years),
excluding events clustered in individuals. Compared to individuals over 5 years, children
under 5 years had a lower prevalence of malaria (OR 0.57; 95%CI 0.29-1.08; p=0.08) but a
higher prevalence of clinical malaria (2.96; 1.02-8.57; 0.05) and SMA (2.29; 0.89-5.88;
p=0.08), with clinical malaria reaching statistical significance.
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DISCUSSION
This is the first detailed report to have focused on the importance of malaria as a cause of
morbidity and mortality in patients living with SCD. This cohort of patients living with SCD
in Dar-es-Salaam provided an opportunity to study this question in more detail; although
chloroquine is recommended for prophylaxis, resistance rates are high and may not provide
adequate protection. Ethical concerns about conducting an observational study of SCD
subjects, generally considered to be at risk of malaria, in a group who were essentially not on
effective chemoprophylaxis, was countered by the fact that the malaria prevalence in Dar-es-
Salaam is generally low (0.80/0-14%) 423,424,426 and interventions such as insecticide treated nets
and prompt, effective treatment with ACTs is available. The overall prevalence of malaria
parasitaemia at the OPD clinic was 0.78%, which is considerably lower than 3.9% reported in a
recent health facility survey conducted in Dar-es-Salaarn423•
The most striking finding in this study was the lower prevalence of malaria parasitaemia in
SCD than in non-SCD patients, both at the outpatient clinic and during hospitalization. A
degree of malaria resistance in patients with SCD seems plausible, given that protection is
unequivocal in heterozygotes (HbAS)158, 161.The prevalence of malaria parasitaemia and
parasite densities were significantly higher in AA than in AS subjects (OR 0.21; p=0.02)
while the prevalence and density of infections was similar in SS and AS subjects. These
findings suggest protection from malaria parasitaemia and raise the question of the view that
malaria is a major cause of morbidity and mortality in SCD. This observation raises the
question of whether, if HbS protects the heterozygote individuals against malaria, those with
SCD, who have even higher levels of HbS, might be even better protected. A dose-dependent
effect is certainly seen in HbC, another haemoglobinopathy, commonly found in West Africa,
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where both heterozygous (HbAC) and homozygous (HbCC) individuals are protected against
malaria'?" ,with protection considerably greater in HbCCl7l.
The incidence of malaria parasitaemia in this study was 2.S3 events per 100PYO. The
prevalence of parasitaemia in children under S years was lower than in those over 5 yrs, a
finding that may be due to protection of younger children by insecticide treated nets (ITN),
provided free in Tanzania to children of this age-group'".
The spectrum of malarial disease includes asymptomatic infection, febrile episodes and
severe illness (anaemia and cerebral complications). The likelihood of a child progressing
from one stage to the next in a malaria endemic area is as follows - parasitaemia (SO% of
each year); clinical febrile (twice per year) and severe disease (anaemia or cerebral malaria-
3% per yeart27 . This is illustrated in Figure 29. There was a similar trend in this study, with
high prevalence of malaria parasitaemia (4.6%) and fewer episodes of malaria fever (0.8 %).
However, in this study more patients had SMA (1.0%) most likely due to pre-existing
haemoglobinopathy. As expected, younger children had a significantly higher prevalence of
malaria (p=O.OS) since they have not yet developed immunity.
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Figure 29 Progression of malarial disease in a malaria-endemic region
Bitten by infectious mosquito
Infected 10 times per year
Parasitaemia
50% of each year
Malaria Fever
Twice a year
Severe Malaria
Probability of3% per year
Death
Probability of 1% per year
Source427
Malaria events occurred more frequently in SeD patients during hospitalization than at the
outpatient clinic. This suggests that, although seD patients are at lower risk of malaria than
non-SCl) individuals, protection is not complete and malaria is an important factor that needs
to be considered during hospitalization. It is acknowledged that this finding may simply
reflect the fact that patients with malaria are more likely to have severe illness and to be
hospitalized. Parasitaemia was significantly associated with mortality during hospitalization
(9.5 vs. 2.2%; OR 4.9; p=O.04) and was independently associated with severe anaemia and
high AST. Therefore, the consequences of malaria in SeD appear to be severe during acute
illness, as previously suggested by Molineaux and colleagues" . These fmdings highlight the
importance of prompt and effective management of malaria in patients with SeD during
hospitalization, even though such patients appear to benefit from a degree of protection from
the disease.
214
There are a number of limitations. First, the overall prevalence of malaria parasitaemia at the
OPD clinic was only 0.78%, which is lower than the 3.9% reported in a recent survey of
health facilities conducted in Dar-es-Salaam424• Therefore, it is necessary to validate these
results in areas with higher and more intense malaria transmission. The second limitation is
that the control (non-Sf'D) population for hospitalized individuals was collected for only 2
years during the 5 year period of study and it did not include adults. The other limitation
is that since this study was conducted in a referral hospital there is a possibility that some
events may have been missed as a result of treatment at casualty, other health-care facilities
or at home. Furthermore, although there was no change of protocols of referral and management
in the hospital, the seD patients were both part of a cohort study and were encouraged to
present early in the event of an intercurrent illness, a fact that may have introduced a bias
towards higher rates of presentation in those with seD.
In summary, through this study, conducted in an area of low but perennial malarial
transmission, it was found that malaria was less common in SeD than in non-SflD subjects
both at the outpatient clinic and during hospitalization. This raises the question of whether,
and under what circwnstances, malaria prophylaxis is required in patients with seD. Further
studies are required to establish the role of malaria as a cause of ill-health in such patients
under conditions of higher malarial transmission. Nevertheless, it was also found that malaria
was significantly associated with severe anaemia and death in hospitalized patients with SeD
and therefore it is recommended that malaria should be promptly and effectively diagnosed
and treated in such patients. Evidence is needed, ideally in the form of randomized clinical
trials, regarding the most appropriate approach to the prevention and treatment of malaria in
patients living with SeD in malaria-endemic environments.
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Chapter Six
Sickle Cell Disease and Bacterial Infections
INTRODUCTION
In the absence of intervention, bacterial infection is the leading cause of mortality in
individuals with seD in developed countries, and the age group that is most affected is between I
to 3 y~' 22, 2m, 428 • Interventions with daily oral penicillin and vaccination against pneumococcal
infections have successfully reduced mortality in developed countries'f 117,429.
InAfrica, these interventions have not been implemented as the evidence to demonstrate a similar
role of bacterial infections has been lacking. This has made it difficult for hospitals and
governments in developing countries to implement these interventions. Furthermore, published
reports have actually questioned the role of prophylaxis against Streptococcus pneumoniae (SPN),
in Africa229 • However, there has been increasing evidence of the role of bacterial infections, particularly
due to SPN in causing high childhood mortaliti70,272 . Since seD patients are highly susceptible to
SPN infections due to impaired immunity, this makes it even more likely that SPN infections will
have a more significant role in SeD mortality. Therefore, there has been an increase in the appeal to
implement these interventions+?' 278.
With this background, this study set out to determine the rates and pattern of bacterial infections
in SeD who were hospitalised at MNH. During the course of this study, Williams et ai, started
another study in Kilifi, Kenya that set out to address the same objective=" .
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METHODS
Patients
The study population was all SCD patients who were hospitalised at :MNH. Every day, active
surveillance was done in the medical and paediatric ward to identify any SCD patients who had
been hospitalised. For SCD patients who had not yet been recruited into the study at outpatient
clinic, confirmation of SCD phenotype was done by HPLC.
Clinical and laboratory data were collected onto standard proformas. The clinical data collected
included age, gender, symptoms that caused them to come to the hospitals. Physical examination
included pulse and respiratory rate, peripheral oxygen saturation and temperature. Systemic
examination was done noting physical signs including pallor, jaundice and the presence of a
palpable liver and spleen. The laboratory data included a full blood count, biochemical analysis
and malaria diagnostic tests, were collected at admission. Additional investigations were
performed as clinically indicated.
Clinical and laboratory methods
All SCD individuals who were hospitalised had a sample taken for blood culture, regardless of their
clinical status. The skin at the site for venous sampling was cleaned with 70% ethanol and
allowed to dry. Blood was drawn and the needle was changed. The top of the blood culture bottle
was also cleaned and allowed to dry.
Blood cultures were initially done in the microbiology laboratory within the hospital. The results
were received and documented and the isolates were frozen at -70°C. These isolates were then
taken to the microbiology laboratory at the KEMRI Wellcome programme in Kilifi, Kenya, to
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confirm the status. The results revealed a significant difference from Muhimbili. It was therefore
felt that the data collected during this period were not reliable. Furthermore, there were procedures
within the routine hospital laboratory that were suboptimal and were likely to reduce the
possibility of growing organisms and particularly fastidious organisms such as SPN, Neisseria
Meningitis and Haemophilus Influenza B. First the use of human blood to make blood agar was
unlikely to successfully grow bacteria as human blood had microcidal properties. Horse blood was
initially sourced from Dar-salaam, but this was not reliable and there were difficulties in collecting
blood. Two sheep were bought and were kept at a farm that belonged to the hospital. But this
system also did not work because of the difficulties in bleeding the sheep. Therefore, commercially
prepared blood was ordered from overseas and used. The limitation in setting this up in the first
place was the high cost in doing this as horse blood had a short shelf life and needed to be brought
every 3-4 weeks. Considering that the number of SCD patients who were being hospitalised was
small, it was very expensive to set this system up. The second limitation was that the blood culture
media were prepared locally and there were no external quality control systems in place. This was
considered not to fulfil good laboratory practise (GLP). Itwas therefore decided that an automated
blood culture system would be used. Second, media were commercially bought and prepared by
the study laboratory team. Third an external QC system was set up. This was initially with the
NetSPEAR programme in Nairobi, Kenya. This is the network for pneumococcal surveillance
programme that was established to support the development of capacity in the surveillance of
pneumococcal infection in laboratories in hospitals in east African countries.
For these reasons, in 2006, the BACTEC system (BACTEC, Becton Dickinson, Franklin Lakes,
NJ, USA) was established in the SCD research laboratory. When the BACTEC system was
established, blood culture bottles were weighed before and after inoculation to make sure that
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adequate amount of blood were collected. The blood culture bottle was then inserted into the
BACTEC system. Positive blood cultures were sub-cultured on standard mediums with the use of
routine microbiological techniques. Positive QC systems were done on the blood culture bottles as
well as the media for sub-culture.
Statistical methods
A general outline of descriptive statistics, disease estimates, univariable and multivariable analyses
is provided inmethods chapter. The organisms that were identified were reported with frequency
and proportions. The clinical and laboratory features that were associated with bacteraemia were
explored using logistic regression with results presented as odds ration and 95% confidence intervals.
Clustering of admissions within individuals was accounted for during analysis by random effects
modelling. Multivariable logistic regression was used to identify independent associations with
bacteraemia for variables that were significantly associated at p-O.05 on univariable analysis.
RESULTS
The results were limited to a description of the rates and pattern of infections for three calendar
years, 2006, 2007 and 2008. During this period, a total of 890 blood cultures were done. Of these,
143 (16.1 %) were positive. 118 (13.3%) were gram positive.
There were a total of 143 organisms isolated. The following organisms were considered
contaminant and were excluded from analysis: Coagulase negative Staphylococcus Aureus (88),
Bacillus species (11) and Micrococcus species (I). Therefore, 43 pathogenic organisms were isolated
from 890 blood cultures, giving a bacteraemia prevalence of 4.8%.
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The pattern of bacteraemia from SCD individuals hospitalised at MNH is shown in table below
(Table 37). Of 43 organisms cultured, the commonest organisms was Staphylococcus Aureus 12(27.7
%), Salmonella species 11 (25.6%) and Streptococcus species 6 (14%). The commonest organisms
were Staphylococcus Aureus (1.3%) and Non-Typhii Salmonella (1.0%). Streptococcus
pneumonia had a rate of 0.3% which was similar to E. Coli, Klebsiella Species, Pseudomonas
Species, Salmonella Typhii and Proteus Species.
Table 37 Bacterial isolates from 890 blood cultures of hospitalised SCD patients
Organism identified Isolates Percent Bacteraemia
Staphylococcus Aureus 12 27.9 1.3
Non-Typhii Salmonella 9 20.9 1.0
Streptococcus pneumoniae 3 7.0 0.3
Streptococcus species 3 7.0 0.3
Escherichia coli 3 7.0 0.3
Klebsiella species 3 7.0 0.3
Pseudomonas Species 3 7.0 0.3
Salmonella Typhii 2 4.7 0.2
Proteus Species 2 4.7 0.2
Acinetobacter species 1 2.33 0.1
Aeromonas salmonicida 1 2.3 0.1
Morganella morganii 1 2.3 0.1
Total number of isolates 43 (4.8%)
Negative bacteraemia 847 (95.2%)
Total number of cultures done 890
Factors associated with bacteraemia
Univariable analysis
The clinical and laboratory features of those with bacteraemia were compared to those who did
not have bacteraemia. The differences in means or proportions were compared taking each
hospitalisation as a separate event.
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However, on tmivariableanalysis, the clusteringwithin individualswas taken into account by applying
a random effects model. Although patients with bacteraemia were more likely to have symptoms
of anaemia and worsening of jaundice, this did not reach statistical significance. A palpable
liver was the only factor on physical examination that was significantly associated with
bacteraemia. Of the laboratory findings, patients with bacteraemia were more likely to have
lower haemoglobin, higher level of direct bilirubin and creatinine. Bacteraemia was not associated
with an increased risk of death [OR 1.19 (1.51 .9.38); p=O.87].
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Table 38 Clinical and laboratory features in SeD patients' associated with bacteraemia during
hospitalisation
No Bacteraemia Bacteraemia OR (950/0Cl) p
847 (952) 43 (4.8)
Clinical features at hospitalization
Fever 137/600 (22.8 9/25 (36.0' 1.90 (0.78-4.63) 0.16
Pain 187/478 (39.1 11123(47.8 1.43 (0.61-3.36) 0.42
Anaemia 50/600 (8.3 5/25 (20.0 2.75 (0.98-7.73) 0.06
Jaundice 39/595 (6.6 4/25 (16.0' 2.72 (0.90-8.17) 0.08
Examination
Jaundice 430/630 (68.3 20178 (71.4' 1.1670.49-2.73) 0.73
Pallor 284/589 (48.2 12/25 (48.0 0.99 (0.46-2.13) 0.98
Temperature 36.7 (0.7) 36.9 (1.0) 1.57 (0.94-2.62) 0.08
Febrile 64 (10.2 4 (16.0) 1.68(0.58-4.85) 0.33
Sp02(%) 97.7 (2.8) 98.4 (2.2) 1.12 (0.93-1.35) 0.22
Hypoxia (S~95%) 11(1.9 0(-) - -
Palpable spleen 129/588 (21.9 4/26 (15.4) 0.65 (0.22-1.94) 0.44
Palpable liver 43/551 (7.8 3/25 (12.0 1.61 (0.45-5.72) 0.05
Laboratory features
White blood cell count (xI09/l) 18.5 (11.6) 23.0 (15.9) 1.0i(0.99-1.05) 0.06
Haemoglobin (g/dl) 7.1 (1.6) 6.2 (1.8) 0.72 (0.56-0.91) <0.01
Mean corpuscular volume (fL) 80.6 (9.9) 82.1 (10.8) 1.01 (0.97-1.06) 0.49
Red cell distribution Width (%) 22.7 (4.3) 22.6 (4.1) 0.99 (0.90-1.09) 0.89
Platelet count (xlO~/l) 399.2 (206.1) 371.1 (167.7) 0.99 (0.99-1.00) 0.47
Reticulocyte count (%) 13.9 (6.6) 13.9 (7.9) 1.00 (O.93-1.01) 0.98
Bilirubin - total (umol/L) 67.6 (71.5) 49.6 (34.1) 0.99 (0.98-1.00) 0.23
Bilirubin - direct (umol/L) 20.8 (26.6) 70.3 (164.3Y 1.01(1.00-1.01) <0.01
Bilirubin - indirect (J.I.IIlol/L) 53.2 (41.3) 30.4 (42.8) 0.9970.98-1.00) 0.18
Aspartate transaminase (lUlL) 56.1 (41.3) 56.2 (29.5) 1.00 (0.99-1.01) 0.98
Alkaline phosphatase (lUlL) 265.7 (144.3) 225.9 (119.6) 0.99 (0.99-1.00) 0.28
Creatinine (J.I.IIlol/L) 42.4 (26.9) 58.4 (51.8) 1.01 (1.00-1.02) 0.05
Lactate dehydrogenase (lUlL) 1068.2 (610.9) 1141.4 (471.1) 1.00 (0.99-1.00) 0.55
Haemoglobin F (%) 6.8 (5.2) 7.9 (6.4) 1.0470.96-1.12) 0.33
Death 19/606 (3.1 1126(3.7 1.19 (1.51-9.38) 0.87
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Moltivariable analysis
During multivariable analysis, two models were built. In the first model, direct bilirubin was
not included as data were not available for many patients. In this model, none of the factors
that were signiftcantly associated during univariable analysis were independently associated
with increased likelihood ofbacteraemia during hospitalisation.
Table 39 Multivariable analysis of factors associated with bacteraemia in hospitalised SeD
patients n = 308; admissions = 530 (excluding bilirubin)
OR P
History of anaemia 1.99(0.55-7.13) 0.29
History of jaundice 2.25(0.55-9.25) 0.26
Temperature COC) 0.92(0.49-1.70) 0.78
Haemoglobin (/dL) 0.77(0.57-1.04) 0.09
White blood cell count (x109/l) 1.00(0.97-1.04) 0.94
In the second model, bilirubin was included in the model resulting in the analysis of 245
events in 208 individuals. Direct bilirubin was independently associated with increased
likelihood ofbacteraemia during hospitalisation.
Table 40 Multivariable analysis of factors associated with bacteraemia in hospitalised SeD
patients n=208; admissions = 245 (including bilirubin)
OR P
History of anaemia 3.l5(0.75-13.27) 0.12
History of jaundice 1.60(0.29-8.73) 0.59
Temperature (OC) 0.95(0.45-2.00) 0.89
Haemoglobin (gldL) 0.82(0.57-1.17) 0.27
White blood cell count (xl09/l) 0.99(0.95-1.04) 0.81
Bilirubin direct - (J.1IIlollL) 1.01(1.00-1.02) 0.05
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DISCUSSION
This is the largest study of episodes of bacteraemia in SeD patients in Africa. The prevalence
and pattern of bacterial infections in SeD hospitalised at MNH during a three year period is
reported. During this period, data were analysed from 890 hospitalisation events from 667
SeD patients. 143 (16.1%) of the 890 blood cultures grew organisms. 100 of these organisms
(69.9%) grew coagulase negative staphylococci (88), bacillus (11) and micrococcus (1).
These were considered contaminants and were classified as being negative for infection. 43
out of 890 hospitalisation events in SeD patients had a positive infection, giving a prevalence
ofbacteraemia of 4.8%.
A study conducted in Kenya reported a prevalence of bacteraemia of 1,094 from 16,750
(6.6%) patients admitted to Kilifi district hospital between 1998 and 2002 270. The age range
was from 1 day to 13 years. In patients who were above 1 year of age, the prevalence was
5.4%. A retrospective study at the same site analysed 38,441 blood cultures from admissions
between 1998 and 2008 of children less than 14 years. 2,157 (6%) cultures grew important
bacterial pathogensi" . Despite the small number of patients with SS SeD (108 (6%) of
1,749), the robust framework in Kilifi was able to clearly demonstrate the increased risk of
bacteraemia in seD between 0 to 13 years. This was reported as 26.3 (95%eI 14.5 - 47.6).
Within SeD patients, the highest incidence reported at 5.34 (95%eI 4.38 - 6.44) was in the
12-23 month age group. Furthermore, the study was also able to unequivocally illustrate the
role of S. pneumoniae infection in patients with SeD. The strongest association was with S.
pneumoniae, non- Typhii Salmonella and H Influenza type b, with reported incidence of 2.18,
1.58 and 0.64 per 100 person years of observation respectively.
224
The prevalence of bacteraemia in seD patients in this study was 4.8% compared to 6.6% in
Kenya230, 6.1 % in Jamaica'i" and 5.2 in the USA235 . Although these rates could be
considered comparable, three possible factors can account for the marginally lower rate in
Dar-es-Salaam. First, the age structure of the seD population in Dar-es-Salaam was older,
with a median age of 10.5 (8.5) years. Although studies in Kenya, Jamaica and USA did not
report a median age, the study population from other studies was limited to children.
Furthermore, although only 30% of the study population were less than 5 years, 43% of the
positive isolates were in children in this age group. Therefore, these results were probably an
underestimate of the true bacteraemia rates as there was no information on the younger
population where the incidence of bacteraemia is likely to be highest. The second factor may
be that this patient group may represent the individuals with mild phenotype who have less
severe disease (as the ones with severe disease have already died), and therefore less
susceptible to bacterial infections. The third possible factor that may have contributed to the
low prevalence of bacteraemia in Dar is that this study was conducted in a referral hospital.
Therefore, there are differences in access to care with patient's most likely receiving care
before being hospitalised at MNH. Prior treatment with antibiotics would therefore reduce the
prevalence ofbacteraemia.
The pattern of bacteraemia from hospitalised SeD individuals found that the commonest
organisms isolated were .S Aureus, non- Typhii Salmonella species and S. Pneumoniae.
Staphylococcus Aureus, non- Typhii Salmonella and Mycobacterium tuberculosis were the top
three causes of bacteraemia in patients who were older than 15 years hospitalised at MNI-t30.
Salmonella species has been reported as one of the top three causes of bacteraemia in both
hospitalised=" 270 as well patients attending outpatient clinic in Kenya 431.
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The age of the SCD patients greatly influences the type of bacteraemia. In a study in the
USA 235,S. Pneumoniae accounted for 66% infections under 6 years whereas Gram negative
rods accounted for over 50% infections above 6 years. The commonest Gram negative rod was
salmonella species. This has been reported in other seD populations where S. pneumoniae is
more common in the younger age group209. Norris et al reported that the mean age was 3.5
years in a group of SeD patients where S. pneumoniae accounted for 42% of total pathogens
isolated whereas the mean age was 8.1 years in the group where the Gram negative rods,
mostly Salmonella species, were the commonest organisms accounting for 28% of total
isolates433. These findings are in keeping with the evidence of the epidemiology of
pneumococcal infection. It has a higher burden before 5 years. It is therefore not surprising
that in Africa, where the SeD population that is seen in hospitals is usually older, the
prevalence ofbacteraemia due to S pneumoniae is low. This may be because children with
SCD and S. Pneumoniae infections die before presenting to hospital.
The other factor that could explain the low prevalence of S Pneumoniae bacteraemia in
this population was prior treatment with antibiotics. During the course of the study a
methodological issues was identified as a limitation to the data that were being collected.
Since MNH was a tertiary health facility and in an urban setting, SeD patients were likely to
seek health care at a health facility near their home or take medication that they had bought
over the counter. This would either be an anti-malarial or antibiotic. The antimalarial that
were available were chloroquine, Sulphadoxine - pyremethamine (SP) or Artemether
Lumefantrine (ALu). SP and ALu both have anti-bacterial activity. Furthermore, when
patients were hospitalised, they received anti-malarial medication within 24 hours. In order to
address this limitation, blood cultures were taken before patients received antibiotics in the
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hospital. However, it was difficult to influence the use of antibiotics before seD patients
were hospitalised. It was felt that since patients had easier access to peripheral clinics,
discouraging them from receiving treatment that was prescribed would be unethical.
The association been salmonella osteomyelitis with SCD was reported almost 50 years
ag0207 and mechanisms involve deficiency of opsonising factors222 . Although over 70% of
haematogenous osteomyelitis is due to salmonella+" and over 77% of salmonella
bacteraemia is associated with osteomyelitis'", salmonella bacteraemia is not frequently
considered as a cause of infection in seD patients435 • However, there is evidence that
salmonella infection is common in hospitalised SCD patients suspected to be infected,
with210, 267, 268 or without involvement of bone 198,433,436,437.
In summary, this study has reported high prevalence of bacterial infection in SeD patients
who are hospitalised at MNH. The commonest organisms were S. Aureus, non-Typhii
Salmonella and S. pneumoniae. Guidelines for prompt management of infection in patients
who are hospitalised are recommended. This study has limited information on bacteraemia in
SeD children who are less than 2 years old and highlights the need of a birth cohort to
identify natural history of infection. There were only 3 episodes of bacterial infection due to
S. pneumoniae and the number of children under 5 years was small, making it difficult to
make conclusive recommendations from this study. However, during the course of this thesis,
published reports have provided this evidence. It is now recommended that all seD children
below 5 years should receive prophylaxis against infection, particularly due to S.
pneumoniae. The questions that need to be addressed are the appropriate agent that should be
used and the mechanism of delivering this agent to ensure compliance and access.
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Chapter Seven
Sickle Cell Disease and Stroke
INTRODUCTION
Stroke and transient ischaemic attacks (TIA) are the most common neurological
complications of SCD, occurring in 11% of patients with SCD by the age of 20 years 245438.
Approximately 25% patients with SCD will have had a stroke by the age of 45 years'", Most
vascular events occur between the ages of 5 and 10 years and are thought to be cerebral
infarction resulting from cerebral blood vessel occlusion. High-risk patients can be predicted
by raised cerebral blood flow velocity (CBFv) in the middle cerebral artery (MCA) as
measured by Transcranial Doppler Ultrasonography (TCD)319. Interventional strategies for
primary and secondary prevention of stroke include blood transfusion and hydroxyurea 120
129361.All this is information from studies conducted in the USA and Europe with limited
information from Africa.
Prior to the work reported in this thesis, I conducted a pilot study in Kilifi where I looked at
the rates and risk factors of high CBFv in SCA population in Kenya. In a cross-sectional
study of 105 Kenyan children, the mean CBFv was 120±34.9 cm/sec. However, we found
that only 3 had conditional CBFv (170-199 cm/sec), but none had abnormal CBFv>200
cm/sec. After adjustment for age and haematocrit, CBFv~150 cm/sec was predicted by
peripheral oxygen saturation (Sp02) ~95% and history of fever. Four years later, 10 children
were lost to follow-up, none had had neurological events and 11195 (12%) had died, predicted
by history of fever but not low Sp 02392
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InTanzania, there has been no description of the magnitude of neurological events in patients
with SeD, but there have been a few case reports439 and anecdotal evidence that suggest that
with an increase in the prevalence of SeD surviving past 5 years of age, ev A may be a
common cause of morbidity and mortality, as found elsewhere in the world. Therefore, the
third aim of my PhD was to investigate the relationship between cerebral blood flow
velocities (CBFv) and cerebrovascular accidents (eVA) in SeD patients in East Africa.
Initially, I measured the eBFv in a proportion of SeD patients in order to assess the range of
eBFv in this population in Tanzania and to determine the factors at enrolment that were
associated with abnormal CBFv. I then determined the prevalence of neurological events in
the cohort of SCD patients. During the period of follow-up, I evaluated the incidence of
stroke and tried to establish an associationwith CBFv in order to determine a cut-off point for
CBFv that would be used to identify high-risk patients who would benefit from intervention.
METHODS
Procedures
Description of CBFv by TCD measurement
Between November 2004 and June 2005, TeD examination was undertaken in a cross-
section of patients between the age of 2 to 16 years of age who were attending the outpatient
clinic and had consented to participate in the study. Patients were recruited consecutively at
the OPD clinic and were given an appointment to return for a TeD examination. All patients
had TeD examination done which was recorded. For those patients who had an inadequate
examination, a repeat TCD was performed.
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Prevalence of neurological events
All patients recruited into the study had screening questions to determine whether there were
any neurological deficits that were present or had occurred in the past. For those patients who
had a CNS event during the course of the study, a thorough neurological assessment with
detailed clinical history and neurological examination. Neurological events included stroke,
seizures, transient ischaemic attacks, lower limb weakness, cranial nerve deficit and cognitive
impairment.
Incidence of neurological events
The incidence of neurological events was determined at follow up clinic in the outpatient
department (OPD) as well as during admission. At the clinic, all patents coming for follow-up
visit would be specifically asked for a history of any neurological deficits that occurred at
home, required care at any health facility. During admission, any evidence of neurological
deficit was assessed and documented.
Imaging
High resolution computerised tomography (Cl) was performed on patients who were either
admitted or had attended outpatient clinic and suspected to have a stroke. The CT scan was
performed in the radiology department at Muhimbili National Hospital. The images were
scanned and saved in JPEG format. The results of this will not be included in this thesis.
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Statistical methods
Description of range of CBFv in SCD population
CBFv was measured following the STOP protocol440 using the Companion II (Nicolet,
Warwick, UK) machine. The highest CBFv [time-averaged maximal mean velocity in the
distal internal carotid artery (ICA) and MCA on either side] was determined. We classified
the higher (right or left) CBFv as low «50 cm/sec), normal (50-169 cm/sec), conditional
(170 - 199) or high (>200 cm/sec) based on Adams' (1990) criteria. The lower limit of
normal was based on CBFv data from TCD measurements in Kenya'?' .
I documented the factors at enrolment visit that have been previously reported to be
associated with increased risk of abnormal or high CBFv including clinical features such as
history of specific clinical events e.g. painful episodes, admissions as well as laboratory
features previously suggested to be predictors of high CBFv, such as haemoglobirr'Y 442,
haemoglobin oxygen saturation, MCV, WBC, HbF levels and markers of haemolysis such as
lactatedehydrogenaseleve1s398,443, 444. Effect modifier variables includedage, sex, past history of
CNS event e.g. seizures, stroke.
Continuous variables were analysed using two-sided t-tests. Categorical variables were
analysed by X-squaredtest. Logistic regression was used to explore associations between high
CBFv (>200 cm/sec) and clinical and laboratory variables, presenting the results as odds ratio
(OR) with 95% confidence interval. A p-value <0.05 was considered statistically significant.
Multivariable analysis included all variables with univariable significance of <0.05. Using
backward elimination, the final model included all variables significant at the 0.05 level.
Binary logistic regression was also used to assess factors associated with abnormal CBFv.
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Determining the prevalence of eNS events
The prevalence of neurological event was determined at enrolment where gross neurological
impairments such as hemiplegia, dense cognitive impairment or neurological deficit was
recorded. During the course of the study, any neurological event was identified and
documented The results presented include the prevalence of neurological events identified
throughout the study period.
The prevalence of neurological events was described. This included stroke, transient
ischaemic attack, loss of consciousness, seizures and any other focal or general neurological
deficit. Explanatory variables included clinical and laboratory features with specific focus on
the following variables as confounders/effect modifiers: age, sex, Hb, MeV, WBe, oxygen
saturation, LDH, AST, unconjugated bilirubin, reticulocyte percentage.
Determining the incidence of CNS events
This analysis was done to determine the incidence of neurological events during the study
period. Therefore the outcome was any neurological event captured during the study period
and if possible confirmed by C'I' scan. The explanatory variables were clinical and laboratory
features including TeD reading, which were explored to look for any association.
Confounders/effect modifiers: age, sex, Hb, MCV, WBC count, oxygen saturation. Some
individuals will have more than one event and for some patients, the exact time of event may
not be known.
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Inclusion criteria;
1) Enrolled into the main SeD study population. This is defined previously but requires
an entry visit at outpatient clinic.
2) Laboratory confirmation of SeD
Exclusion criteria;
1) seD patients who were identified at hospitalisation,but had not returned to outpatient
clinic for enrolment into the cohort.
2) No laboratory confirmation of SeD
Data were analyzed using STATAvl0 (StataCorp, College Station, TX). The overall
incidence of stroke was estimated for the cohort. This was calculated from the ratio of
number of strokes that occurred during the course of the study divided by the number of
person years of observation (PYO), expressed as stroke rate per 100 PYO.
In order to determine the factors at enrolment associated with stroke, I grouped the
individuals in the cohort into two groups; those who had a stroke documented at MNH and
those who had never had a stroke during the study period. Data were summarized as medians
or proportions. Logistic regression analysis was used to analyze factors at enrolment
associated with stroke, with results presented as odds ratios (ORs) with 95% confidence
intervals (95%eIs). Multivariable logistic regression was used to identify independent
associations with stroke, using variables that had significant association (p<0.05) on
univariable analysis.
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In order to determine the association between CBFv and TCD, the analysis was limited to the
sub-group who had a TCD examination done. Note that the TCD sub study was conducted
from November 2004 to June 2005. During this period, I conducted detailed neurological
examination on all patients who came for a TCD examination. Individuals who had a
previous stroke were not included in the analysis.
The overall and age-specific incidence of stroke was estimated for this sub-group. This was
calculated from the ratio of number of strokes divided by the number of person years of
observation (PYO), expressed as stroke rate per 100 PYO stratified by age. In order to
explore the association between CBFv and stroke, I explored this relationship using different
categories of CBFv. Data were summarised as means and proportions. Logistic regression
was done to explore this relationship with results presented as OR (9S%CI).
The categories for CBFv were as follows:
1) Definition used in the trials in the USA (STOP trial). STOP definition'j'' uses the
following cut-off points: >200cms/sec abnormal, 170-199cms/sec conditional, SO -
170cms1sec normal.
2) I used the interquartile range of the CBFv in this study to group CBFv (in ems/sec)
into low (0 - 103), medium (104 - 156) and high (1S7 and above)
3) I used the 150cms1sec cut off point used from Kilifi data392 to group CBFv into low
(below 15Ocmslsec) and high (above 15Ocmslsec).
4) I used the 150cmslsec cut off point used from Kilifi data392 to group CBFv into low
and high. In this instance, I excluded all individuals with CBFv less than 70 ems/sec.
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The rationale for this is that these individuals either have low velocity due to stenosis
and Moya Moya syndrome or the examination was not valid
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RESULTS
Description of cerebrovascular flow velocity (CBFv)
A total of 6,416 cerebral blood flow velocities (CBFv) were measured in 401 SCA patients.
6,096 of these measurements were successful and we selected 1,934 CBFv representing the
maximum velocity measured in each vessel, irrespective of side. The velocities for the five
vessels are shown (Figure 30) shows the maximum CBFv of the five blood vessels which
were measured, stratified into 3 age groups as well as summary of the velocities for each
vessel.
Figure 30 Age stratified maximum CBFv of specified blood vessels or sites
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Following this, the highest velocity at the MCA or bifurcation of MCA and ACA was
selected for each person. The spectrum of maximum CBFv is shown in Figure 31 with a
mean velocity of 132.2 (49.4) and a range between 0 and 309.
Figure 31 Histogram of maximum CBFv in 397 SeD patients
100 ~{cmsJsec) 200o 300
Classifying the CBFv into 4 groups, the frequencies were as follows: low «50 cm/sec) 13
(3.3%), normal (50 - 169 cm/sec) 331 (83.4%), conditional (170 - 199 cm/sec) 13 (3.3%)
and abnormal (>200 cm/sec) 40 (10.1%), which is illustrated graphically inFigure 32.
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Figure 32 Distribution of CBFv in SCD patients
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For purposes of analyses, we classified CBFv into normal or abnormal using 200cms/sec as a
cut off. For 36 patients with available information about age, 16 out of 117children (13.7%)
were between 6-9 years with abnormal CBFv compared to 9 out of79 (11.4%) under 5 years
and 11 of 133 (8.3%) above 10 years. The difference in odds ratio is shown in Figure 33. This
is not statistically significant (p=0.38)
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Figure 33 Odds ratio of baving abnormal CBV in 3 age groups
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Associations with abnormal CBFv
Univariable analysis
To explore the association of clinical and laboratory features with abnormal CBFv,
univariable analysis was done and the results are shown in Table 42. Individuals with
abnormal CBFv complained more often of symptoms of anaemia and were reported to have
received more frequent blood transfusions within 12 months of the baseline visit. On
examination, these patients also had higher levels of peripheral oxygen saturation and for
laboratory factors, direct bilirubin showed a significant association with abnormal CBFv.
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Multivariable analysis
Two separate models were built for multivariable analysis of factors associated with
abnormal CBFv. In the first model, we did not include peripheral oxygen saturation and the
analysis included 291 individuals. The results are shown in Table 44. In this model, all the
three factors, symptoms of anaemia, history of blood transfusion and direct bilirubin were
independently associated with abnormal CBFv.
Table 44 Multivariable analysis of factors associated with abnormal CBFv (n=291); excluding
saturation
OR (95% Cl) p
Symptoms of anaemia 8.55 (1.58- 46.4) 0.01
History of blood transfusion 0.36 (0.15- 0.88) 0.03
Direct bilirubin (J.1IlloVL) 1.02 (1.00- 1.03) 0.03
For the second model, this was restricted to those individuals who had peripheral oxygen
saturation at time of TCD and included 64 individuals. During analysis, the variable reporting
symptoms of anaemia was dropped from the model because of collinearity. The results are
shown in Table 45 and show the association of history of blood transfusion, direct Bilirubin
and peripheral oxygen saturation. Higher peripheral oxygen saturation was independently
associated with abnormal CBFv (p=O.04).
Table 45 Multivariable analysis of factors associated with abnormal CBFv including
saturation (n=64)
OR (95% Cl) p
History of blood transfusion 0.51 (0.09 - 2.72) 0.43
Direct bilirubin (J.UDollL) 1.03 (0.98 - 1.07) 0.26
Peripheral oxygen saturation (%) 2.04 (1.04 - 4.00) 0.04
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Prevalence of neurological deficits
Data were available from 435 CNS forms from 1,573 patients. Please note that neurological
events forms were only completed during TCD examination or when there was clinical
suspicion of neurological event. There were 77 recorded neurological deficits with 47
patients reporting history of seizures (10.3%) and 16 episodes of stroke (3.8%). This is shown
in Table46.
Table 46 Neurological deficits in 435 SeD patients
Neurological event Total Number Percent
Stroke 426 16 3.8
Seizures 434 47 10.8
TIA 423 9 2.1
Weakness 365 14 3.8
Cranial nerve deficit 428 9 2.1
Cognitive impainnent 425 10 2.4
Total 435 77 17.7
The numbers vary depending on data available.
The table below (Table 47) shows the prevalence of neurological deficits in 1,573 SCD
patients, with stroke occurring in 16 (1.02) patients.
Table 47 Prevalence of neurological deficits in 1,573SeD patients
Total N Percent
Stroke 1,573 16 1.02
Transient ischemic attack 1,573 9 0.57
Seizures 1,573 47 2.99
Weakness 1,573 14 0.89
Cranial nerve deficits 1,573 9 0.57
Cognitive impairment 1,573 10 0.64
1573 77 4.9
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Incidence of stroke
During the course of the study there were 16 episodes of stroke from 1,573 SeD patients
(1.02%) with available neurological data. 2 of the patients had repeated episodes. The
incidence of stroke was 0.3 (0.18 . 0.52) per 100 PYO for patients who were not lost to
follow-up (n=I,516).
Factors at baseline associated with stroke
Univariable analysis
The risk factors for stroke during the course of the study were explored by looking at the
association of clinical and demographic features at baseline with stroke. A reported history of
painful (p=0.03) or febrile episode (p=0.04) was more common amongst the patients who
had a stroke.
With regards to laboratory values, patients with stroke had higher Mev (83.6 vs. 77.2;
p=O.OI)and reticulocyte count (12.7 vs. 6.9; p=O.OI)but a lower level ofHbS (83.5 vs. 87.5;
p=O.02)compared to the patients who did not have a stroke.
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Table 48 Factors at enrolment visit associated with stroke during the study
No Stroke Stroke OR p
412 (96.3) 16 (3.7)
Male 222 (55.8) 6 (46.2) 0.68 (0.22 - 2.06) 0.49
Age in years Mean (SD) 8.5 (3.8) 7.8 (4.6) 0.95 (0.72 - 1.24) 0.69
<5 76 (22.7) 1(25) 1.1 (0.31 - 4.01) 0.88
5-10 120 (35.8) 1 (25)
>10 139 (41.5) 2 (50)
History of hospitalisation 125 (44.8) 7 (70) 2.87 (0.78 - 11.3) 0.13
History of blood transfusion 3 (23.1) 0.47 (0.13 - 1.73) 0.26
Pain 220 (55.4) 3 (23.1) 0.24 (0.07 - 0.89) 0.03
Fever 191 (48.1) 2 (15.4) 0.19 (0.43 - 0.89) 0.04
Laboratory features
White blood cell count (xl<1ll) 15.9 (5.1) 15.8 (4.4) 0.99 (0.89 - 1.11) 0.92
Haemoglobin (gldl) 7.5 (1.2) 7.9 (1.1) 1.29 (0.79 - 2.11) 0.30
Red blood cell count (x lOLl) 2.9 (0.8) 2.8 (0.5) 0.70 (0.28 - 1.75) 0.45
Mean corpuscular volwne (fL) 77.2 (8.3) 83.6 (6.1) 1.11 (1.03 - 1.19) 0.01
Red cell distribution width (%) 244.1 (4.9) 22.5 (2.9) 0.93 (0.81 - 1.06) 0.27
Platelet count (xlOY/l) 431.5 (178.0) 527.7 (269.2) 1.00 (0.99 - 1.01) 0.06
Reticulocyte count (% of RBC) 6.9 (5.2) 12.7 (5.9) 1.17 (1.05 - 1.30) 0.01
Creatinine (umol/L) 40.9 (18.6) 42.8 (35.0) 1.00 (0.98 - 1.03) 0.73
Aspartate transaminase (lUlL) 56.2 (28.4) 52.5 (13.3) 0.99 (0.97 - 1.02) 0.65
Alkaline phosphatase (lUlL) 264.8 (102.9) 285.3 (153.0) 1.00 (0.99 - 1.01) 0.50
Bilirubin (umol/l.) - total 80.0 (55.2) 58.3 (37.4) 0.99 (0.89 - 1.05) 0.18
Haemoglobin F (%) 5.3 (3.8) 6.6 (55.6) 1.07 (0.95 - 1.22) 0.26
Haemoglobin S (%) 87.5 (5.1) 83.5 (10.7) 0.92 (0.86 - 0.99) 0.02
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Multivariable analysis
Two separate models for multivariable analysis of factors associated with stroke were built.
In the first model, we did not include reticulocyte count because there were not enough data
points for reticulocyte at the baseline visit. The analysis included 363 and the results are
shown in table below Table 49. Sickle haemoglobin levels were independently associated
with risk of stroke.
Table 49 Multivariable analysis of factors associated with stroke (0= 363)
OR (95% Cl) p
Pain 0.42 (0.S9 - 1.96) 0.27
Fever 0.35 (0.06 - 1.99) 0.24
Mean corpuscular volume (fL) 1.09 (1.01 - LIS) 0.04
Haemoglobin S (%) 0.S9 (O.S2 - 0.97) 0.01
For the second model, reticulocyte count was included and the model included 101
individuals. The results are shown in Table 50. Reticulocyte and sickle haemoglobin were
independently associated with risk of stroke.
Table 50 Multivariable analysis of factors associated with stroke including reticulocyte
count (n= 101)
OR (95% Cl) p
Pain 0.71 (0.05 - 9.23) 0.79
Fever 0.32 -(0.03 - 4.0S) 0.38
Mean corpuscular volume (fL) 1.02 (0.92 - 1.13) 0.73
Reticulocyte count (%) 1.19 (1.02 - 1.39) 0.03
Haemoglobin S (%) 0.87 (0.77 - 0.99) 0.04
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Incidence of stroke and relationship with CBF
Incidence of stroke
The association between CBFv and stroke was explored by focusing on the individuals
who had CBFv that was considered valid. The figure below (Figure 34) shows the flow
of patients in the study who had CBFv measurement and known stroke during the course
of the study.
Figure 34 Summary of patients to explore relationship of CBFv and stroke
SCA patients
n = 798
I
seA eligible for
TeO
n =654
I
SCAwith Teo
done
n =401
I
seA with valid
csrv
n =372
•
Not abnormal
n = 332 (89.3)
Abnormal
n = 40 (10.8)
Stroke
n = 0 (-)
Stroke
n = 3 (0.9) -
No stroke
"'"n = 304 (88.6)
No stroke- n=39(11.4)
There were 372 SCD patients who had valid CBFv of which 348 had documented presence or
absence of stroke. Amongst the 348 SCD patients, 3 individuals (0.86%) had a stroke and the
CBFv was 135, 155 and 188 erns/sec. The patients had 240.1 patient- years of observation
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(PYO). The incidence of stroke was 1.25 per 100 PYa, with the rate decreasing from 2.0 (0.29
- 14.5) inunder 5 year age group, 1.13 (0.16 - 8.01) between 5 -9 years and 0.98 (0.14 - 6.93)
above 10 years (Table 51). This was not statistically significant (p=0.85).
Table 51 Incidence of stroke in patients with CBFv, stratified by age at TeD
Age (group) # patients I Observation (yrs)' # stroke Incidence"
<5years 81 48.9 1 2.0 (0.29 - 14.5)
5-9 years 121 88.6 1 1.13 (0.16 - 8.01)
>10 years 146 102.5 1 0.98 (0.14 - 6.93)
Total 348 240.1 3 1.25 (0040 - 3.87)
The mean CBFv was higher amongst the individuals who had a stroke compared to those who
did not have a stroke (133.5 vs. 159.0). The odds ratio was 1.01 (95% Cl 0.99 - 1.03) but this
did not reach statistical significance (p=0.37). The relationship between CBFv was explored
using different cut-offs for CBFv (Table 52) and there was a trend of association between
CBFv and stroke with a lower CBFv cut-off of 150cms/sec. However, there was a very wide
confidence interval since there were very few episodes of stroke.
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Table 52 Association between CBFv and stroke during course of the study: The
relationship using different cut-off points to predict risk.
No stroke Stroke OR p
CBFv (cmslsec) 133.5 (49.7) 159 (26.8) 1.09 (0.99 1.03) 0.37
STOP definition I
50-169 292 (85.1' 2 (0.7) 1.16 (0.24 5.69) 0.85
170 199 12 (3.5\ 1 (7.7)
>200 39 (11.4 0(-)
Inter quartile ran2e~
Low (0 103) 88 (24.0\ 0(-) 1.95 (0.35 10.79) 0.45
Medium (104 156) 184 (50.3 2 (1.1)
High (157+) 94 (25.7) 1 (1.1)
Using ISO"' (include CBFv<70)
0-150 247 (67.5 1 (004) 4.15(0.37 46.2) 0.25
>150 119 (32.5 2 (1.7)
Usin2 ISO (exclude CBFv < 70)
50 149 236 (66.5 1 (004) 3.97 (0.36 44.2) 0.26
150+ 119 (33.5 2 (1.65)
STOP definition'j": uses the following cut-off points: >200cms/sec abnormal, 170-
199cmslsec conditional, <17Ocms/sec normal. Interquartile range of the CBFv in the
Dar cohort, 150cms1sec is cut off point used from Kilifi data391•
DISCUSSION
This is the first description of neurological events and CBFv in SCD in Tanzania. Most of
the information that is available on the neurological events and CBFv in SCD is from
studies that were conducted in the USA and Europe. Although there have been studies
in Nigeria and Kenya, these studies involved small number of patients. There are key
differences between the spectrum of CBFv in Tanzania, Kenya and USA. The mean
CBFv in the Tanzanian population was (132 erns/sec) higher than what was found in
Kilifi (l2Ocm/sec) and that reported in the US (129cmlsec). One possible explanation
for the higher CBFv in the Tanzanian population may be that SCD children in this
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population have lower levels of haemoglobin. However, anaemia can only explain the
difference in CBFv up to 15Ocms/sec, as studies done in the US and UK suggests that
velocities beyond 15Ocm/sec are most likely due to stenosis.
The second important finding in this study was that the prevalence of abnormal CBFv was
10%. This is similar to the finding from studies in the USA where prevalence rates were
between 3_17%319.444.-446. It was expected that that the spectrum of CBFv would be similar in
the two areas inAfrica because the populations are similar with regards to sickle haplotype and
well as genetic and environmental exposures. On the contrary, SCD patients inKilifi had lower
mean CBFv and there were no abnormal CBFv detected. This unexpected result may be
because the SeD patients inKilifi are different from that in Dar as it is rural with the highest
rates of people living below the poverty line, low educational and nutritional status and poor
access to health care447 • Furthermore, the site where the study was done is a district hospital. In
comparison, Dar-es-Salaam is a large city with a more heterogeneous population and MNH is
the national referral hospital. It is therefore possible that the patients seen at Muhimbili have
more severe disease.
Another factor that may explain the difference is that children in Kilifi die before there is a
chance for them to develop stenosis which would be detected by TCD. Reports from Kilifi
suggest that the mortality in SCD in Kilifi is particularly high with only 5% of SS births
reported to be alive by five years of age (personal communication). However, in Kilifi, CBFv
was not associated with mortality 392as was the case in this study.
The other explanation for this finding is that the natural history of neurological complications
251
in SCD may be different in Kilifi. According to proposed pathophysiological mechanisms,
progressively worsening stenosis may result in complete occlusion of the vessel leading to
infarcts/stroke. In this case, patients will have gradually increasing eBFv which can be
identified by TeD measurements. However, it is possible that, rather than leading to
occlusion, the progressive stenosis, may precipitate the development of collaterals. In this
situation, there is a decrease in eBFv as less blood flows in the affected vessel. This
phenomenon, Moyamoya syndrome, has been described in seD children309 311 448 . InKilifi, low
CBFv, compatible with449 but not diagnostic ofMoyamoya, was documented in 7 SeD patients,
one of whom had had seizures; none of these patients was known to have died or have
neurological complications 4 years later. It is not clear whether the development of
cerebrovascular disease in Dar-es-Salaam would involve stenosis leading to occlusion or
stenosis leading to Moya Moya syndrome.
To determine the factors that could be used to identify SCD patients who may have abnormal
eBFV, we looked at the association between clinical and laboratory features at time of TeD
measurement. For some of the laboratory investigations, e.g. chemistry the investigations
were not available at time of TeD. In this instance we used the measurement done at the
closest time point to TCD measurement. On univariable analysis, patients with high CBFv
had symptoms of anaemia, history of blood transfusion within the past 12 months and had
higher peripheral oxygen saturation. High levels of direct bilirubin were associated with
abnormal CBFv. On multivariable analysis, peripheral oxygen saturation was independently
associated with high eBFv; however the model included only 64 SeD patients because at this
visit, patients did not have peripheral oxygen saturation measured. However, evidence from
Kilifi and USA suggests that low oxygen saturation predicts neurological events 304, 392, 442,
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whereas in this case patients with abnormal eBFv had higher oxygen saturation. However it
is known that hypoxia promotes polymerisation of HbS and adhesion of RBe to endothelium
314 and platelet and WBe adhesion": The hypoxia may be caused by upper airway
obstruction, since enlarged adenoids are associated with CVA304. It is difficult to make any
conclusions from the study as there were incomplete data for peripheral saturation. However,
this requires further investigation as the evidence suggests that peripheral oxygen saturation
has a significant role in cerebrovascular dynamics.
The second objective of our study was to describe the prevalence of neurological events in
SeD patients. Neurological events that have been described in seD patients include seizures,
coma, and stroke, visual and hearing disturbances. In a study reported from Nigeria,
neurological events were more common in individuals with seD (76%) compared to controls
(32.1%). Stroke, febrile convulsions and headaches were common in children whereas
paraplegia, epileptic seizures and localizes sensory neuropathy were more common in
adolescents and adults450 . During the study period we identified 77 neurological events out
of 1,573 SeD patients (4.9%). Of the 77 events, the commonest events were convulsions
(2.99%) and stroke (1.02%). Seizures were more common than stroke as they accounted for
47 out of 434 individuals (10.8%) examined for neurological events, when compared to
reports in Kenya where they accounted for 6 out of 18 events (33.3%) and were less frequent
than stroke298 • Seizures have been previously reported in seD in Nigeria where ten out of 96
patients (1.1%) satisfied the criteria for clinical diagnosis of epilepsy, with a prevalence of
epileptic seizures of 10.4%451. The question of whether seizures are more common in seD
children than in the normal population cannot be addressed by the study but the results
highlight the need for further investigations.
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During the course of the study, the incidence of stroke was 0.3 (0.2-0.5) per 100 PYO while
or the subset with eBFv the incidence was l.25 (0.4 - 3.9) per 100 PYO. The reason for this
difference is not clear, but may be due to the different ages since eBFv was measured only in
children below 16 years. It is possible that there is an increase in incidence of stroke when the
patients get older. This would be in keeping with previous descriptions of stroke risk, which
suggests that there are two peaks, during childhood between 2-5 years, where stroke is due to
cerebral infarction. The second peak occurs during adulthood, above 30 years, and is
commonly due to cerebral haemorrhager'. Both of these rates are higher than the rate of
0.611100 PYO reported from the USA83.Previous studies reported ranges of prevalence of
stroke between I% in Saudi Arabia and 18% in Brazil illustrating marked variation of rates
between populations. In this study stroke occurred in 1.02% of patients. In Kenya, strokes
were reported to be more common than seizures, accounting for 67% of neurological
events298and in 4 out of 6 patients with seD admitted within a 18 month period with a
neurological event had a stroke284. Furthermore, stroke causes significant morbidity to
individuals and causes a high burden of disease to the individual, family and the community.
Therefore, there have been concerted efforts to understand the natural history of stroke in
seD and improve the outcome either by preventing the occurrence or prevention of recurrence.
Good diagnostic methods in the form of TeD and neuroimaging to identify high-risk
individuals319452.Interventions, such as chronic blood transfusion and Hydroxyurea, have
also been shown to be effective 120,328,330,61,453.
The risk factors for stroke were determined by assessing clinical and laboratory features at
the baseline or TeD visit. This visit was chosen as the health care system in Tanzania,
particularly for SeD patients, is not comprehensive. Therefore, since seD patients may be
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seen at a specialist clinic only once, it is vital that the patients are assessed at this stage for
risk of stroke. In this study, the factors that were associated with stroke were history of pain
and fever as well as high MCV, reticulocyte count and HbS level. HbS level and reticulocyte
count were independently associated with stroke. The finding that HbS concentration is
associated with risk of stroke is of interest. This is a recognised disease mechanism as
therapeutic intervention aimed at a reduction of HbS by exchange transfusion to below 30%
has been found to improve outcome during acute events such as stroke, acute
chestsyndrome'<' 122. 125.454
The association between reticulocyte count and stroke may be due to an increase in
erythropoiesis. It is interesting that reticulocyte numbers were associated with stroke but
haemoglobin levels were not as one would expect both to be related as an increase in
reticulocyte normally occurs with a decrease in haemoglobin. The exception to this is when
the bone marrow fails to respond. However, this analysis was done on a small subset of
patients. Therefore, further studies are required to determine the natural history of the
relationship between stroke and red blood cell indices. This is of particular interest as
previous studies have reported an association with low haemoglobin level, low HbF level,
low red blood cell count and high nucleated cell counts83• 455: In this study, there was no
association with any of these factors. This may reflect a true difference in the
pathophysiology of stroke in the two populations. Alternatively, it may be that we have not
been able to see the association because this was a clinic-based cohort rather than a birth
cohort and therefore the seD patients that have been studied may be survivors with mild
forms of the disease.
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The final objective was to explore the relationship between CBFv and incidence of stroke.
Patients who had a stroke during the study had higher levels of CBFv (159cms/sec) compared
to those who did not have a stroke (133.5cms/sec). However, this was not statistically
significant (p 0.37). The level of 200cmlsec used in the STOP trial to define high-risk
individuals 120, was not associated with risk of stroke, as none of the 3 patients with stroke
had a CBFv above 200cmslsec and only I had conditional velocity (188cms/sec). The OR of
having a stroke when CBFv was above 200cms/sec was 1.16 (95% Cl 0.24 - 5.69); p=0.85.
When a CBFv of lSOcm/secwas used. the OR was higher at 4.15, suggesting a trend towards
a positive association. However, the confidence interval was very wide, 0.37 - 46.2 and this
association did not reach statistical significance (p = 0.3). These results suggest that the cut-
off value that was used in the STOP trial may be too high for the SCD population in Africa.
This has certainly been the case in other populations outside of the USA. A study done in
Brazil found that a CBFv of 123.4cmlsec in the MeA was able to accurately identify stenosis
in these vessels with a sensitivity of 100% and specificity of 73%456.It is therefore vital that
the threshold for CBFv that is used in identifying patients with high risk of stroke should be
guided by the STOP trial but local-evidence should be determined for each population.
In summary, this study has reported the spectrum of CBFv in a cohort of children with SCD
in Tanzania. High peripheral oxygen saturation was independently associated with risk of
having an abnormal CBFv. During the course of the study, stroke occurred in 1.02% of
patients, and these were independently associated with HbS levels and reticulocyte count. It
is difficult to accurately determine the cause-effect relationship of the various factors,
including CBFv, and their change over time with stroke. In order to determine this
relationship accurately, detailed examination during steady-state and during acute clinical
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events are required to ascertain whether there are any changes at different time points. In this
way, accurate descriptions of the natural history of cerebrovascular disease in SeD in
children will be possible. It is possible that the course and mechanisms of cerebral
vasculopathyand neurological events inAfrica are different from North America and Europe.
More detailed neuroimaging studies with magnetic resonance angiography are required to
elucidate this further.
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Chapter Eight
Sickle Cell Disease and Foetal Haemoglobin
INTRODUCTION
Foetal haemoglobin (HbF) is a major ameliorating factor of clinical illness in individuals with
SeD. High HbF levels are associated with milder forms of the disease with patients having
less painS7, 4S7, lower morbidity and improved survival" . Clinical epidemiological studies in the
Eastern region of Saudi Arabia. where the Asian J3S - globin haplotype predominate, SCD
patients have haemoglobin F levels of 10-40%, and rarely have severe disease458, 346.. a -
thalassaemia is also common in these regions and therefore the relative importance and
correlation between HbF, a -thalassaemia, and other factors, is not clear 459
The association of HbF and seD severity has led to several interventional studies undertaken
using agents to increase HbF levels in seD individualsi". Hydroxyurea (HU) is one of these
agents and has been effective in reducing painful episodes, rate of blood transfusion
requirement and rate and duration of hospitalisatiorr'". HU is also effective in reducing
mortalizy363459. However, not all individuals with SeD have a similar response to HU. About
60-80010 of SeD patients, received HU to a maximum tolerated dose, and were not able to
increase the HbF levels. The factors that determine the response of individuals to HU are not
well understood/" .
In Tanzania, although there is a high prevalence of SCD, HbF levels are not measured for
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clinical purposes to assist with therapy or for research purposes. This is because the
laboratory measurement of HbF levels has been difficult, requiring meticulous laboratory
skills which have not previously been available. However, with the increasing use and
availability of high performance liquid chromatography (HPLC), HbF levels can be measured
easily, with reliable results that can be validated and compared with other centres around the
world. In 2005, Hb fraction quantification by HPLC was established in our laboratories.
We hypothesized that the spectrum of HbF levels in Tanzania was likely to be different from
that elsewhere because of the different ethnic origins of people in Dar-es-Salaam. There is an
admixture of people with African, Arab and Indian ethnicity and these 3 groups have
different JiS -gene haplotypes. People of Bantu descent will most likely have the Central
African Republic (CAR) haplotype which is associated with low levels of HbF and severe
disease. On the other hand people of Arab or Indian descent are most likely to have the Asian
haplotype which is associated with high HbF levels and milder forms of SCD. Because HbF
has such a key role in determining clinical severity in SCD, I included a study to determine
role of HbF in SeD as part of this thesis. The aim was to describe the spectrum of HbF in
SCD patients and look at the association of HbF with disease morbidity and mortality. With
regards to morbidity, the clinical factors that I examined included malaria, CBFv, stroke and
hospitalization.
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METHODS
Procedures
From June 2005, HPLC for quantification of Hb fractions was included as one of the
investigations to be done on all SCD patients who came to the clinic. Since all patients had a
sample of whole blood for FBC, an aliquot was taken for HPLC. Measurement of HbF, HbS,
HbAOand HbA2 was done. For patients who were being recruited into the study, HPLC also
served as a test to confirm the sickle phenotype. Patients who were already in the cohort also
had HPLC measurements. All patients had a single HbF measurement at OPD clinic which
was then taken as representative of his or her HbF level at that age. HbF measurements were
not available for some patients within the cohort who were either lost to follow up or
deceased before HbF levels were determined.
HPLC testing was repeated 3 months later in patients who had received a previous blood
transfusion. HPLC was also repeated in some patients in whom the HPLC results did not
match previously undertaken haemoglobin electrophoresis. For both these groups of patients,
a thorough assessment with detailed clinical history and examination was undertaken to
determine whether they had received blood transfusion or had symptoms and signs suggestive
of SCD. Only patients who had confrrmed SCD were included in this analysis.
Statistical methods
HbF measurements were undertaken consecutively on all SCD patients from June 2005.
However, there were some patients who were already lost to follow up or had died when HbF
measurements were established. Therefore, for purposes of the thesis, the analysis was
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limited to SCD patients who had HbF with data on the primary outcome measure, death, at
time of analysis.
The explanatory variables included were laboratory factors such as Hb, MCV, WBC, and
markers of haemolysis and liver function such as bilirubin, AST and LDH levels. Effect
modifier variables included age and sex. For purposes of this thesis, clinical factors at
baseline were not included. Continuous variables were analysed using two-sided t-tests.
Categorical variables were analysed by x-squared test. Logistic regression was used to
explore associations between HbF and clinical and laboratory variables, presenting the results
as odds ratio (OR) with 95% confidence interval. A p-value <0.05 was considered
statistically significant. Multivariable analysis included all variables with univariable
significance of <0.05. Using backward elimination, the final model included all variables
significant at the 0.05 level.
RESULTS
The analysis included 1,668 SCD (HbSS) patients with HbF measurements and known
survival status. The median HbF level was 5.3 with an interquartile range of 2.9 - 8.6%. The
mean HbF level was 6.3% (SO 4.7) with men having a lower mean of5.8% (4.4) compared
to females, who had a mean of6.9% (4.8) (OR (95%CI): 0.68 (0.55 - 0.85); p<O.OI).
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The spectrum ofHbF levels is shown below, with a minimum ofO and maximum of25.7%. It
does not show a normal distribution.
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Due to the distribution, the data were log transformed and the histogram shown below.
Figure 37 Histogram of log transformed HbF levels
The levels of HbF are known to vary within the first 5 years of life, following which they
remain relatively stable although there is a slow fall in levels with age. This pattern was
similar in this study, which showed higher HbF variation levels in patients in this age group;
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Figure 38 Distribution of HbF stratified by age and sex in SeD patients
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For the purpose of analysis, we used HbF level of 8.5% which was the 75th percentile of the
study population, as the cut-off to differentiate patients as having high or normal HhF. There
were 428 SeD patients out of 1,688 (25.7%) with high HbF. With regards to variation of
femafemale
5-9Y.ears
female male femala mala
110-19Years above 20 Years
HbF levels with age, there were 86/136 individuals under 2 years (63.3%) and 123/330
(37.3%) of those between 2- 5 years having high HbF. After this, the HbF levels were lower,
with less variation.
To illustrate the age-stratification of HbF levels, the odds ratio of high HbF in the 5 age
groups was plotted, showing that in the younger age group, the likelihood of having high HbF
is high but there is wide variation as evidenced by the wide confidence interval.
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Figure 39 Odds ratio of high HbF in 5 age groups
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Factors associated with high HbF
Univariable analysis
To explore the association of laboratory features with HbF, univariable analysis was done and
the results are shown in Table (Table 53). Since the HbF level is variable until the age of 5
years, the analysis excluded children below the age of 5 years. Individuals with high HbF had
significantly higher haemoglobin (7.6 vs. 7.4), and Mean Cell Volume (80.5 vs. 78.5)
compared to those with normal HbF and there was a trend for an association with RBC (3.1
vs. 2.9). The platelet count (383.9 vs. 439.2 xl09/1) and RDW (22.2 vs. 23.5 %) were
significantly lower in the group with high HbF compared to in group with normal HbF. Total
bilirubin was significantly lower and there was a strong trend for lower creatinine. Alkaline
phosphatase level was higher in those with high haemoglobin F (Table 53).
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Multivariable analysis
On multivariable analysis, the results are shown in table below (Table 54). In this model, sex,
haemoglobin, MCV, ROWand platelets were independently associated with high HbF.
Table 54 Multivariable analysis of factors associated with high HbF (0= 1,434);
OR P
Sex 0.57 (0.41 .0.82) <0.01
Haemoglobin (gldl) 0.97 (0.951.01) 0.20
Mean cell volume(fL) 1.35 (1.161.56) <0.01
Red Cell distribution width (%) 1.06 (1.041.08) <0.01
Platelet count (x 10'1/1) 0.93 (0.88 .0.98) <0.01
Reticulocyte count (%) 0.99 (0.9960.998) <0.01
DISCUSSION
This is the first study to report the spectrum of HbF in SCD patients in East Africa. The mean
HbF was 6.3 (SO 4.7) with a range ofO to 25.7%, which is lower than that reported in Congo
Brazzaville (8.8 (5.8i97• Various reports from Nigeria have reported mean HbF levels
ranging between 5.9 and 9.5150•460,461 • This may suggest either a wide variation in mean HbF in
seD patients within the same geographical location or differences in methodological
approaches in measuring HbF levels. In the studies in Nigeria, the alkaline denaturation
method was used
In this study the mean HbF levels were significantly higher in females compared to males,
similar to reports in Jamaica where adult males had a mean HbF level of 4 compared to the
mean level in females of mean 5._s462. The HbF levels from seD patients in the USA were
higher, with mean values of 7% in those aged <24 years and 6% in older patients in the
267
Co-operative study of sickle cell disease 463 • As expected, the levels in Tanzania were much
lower than the mean levels in countries in the Arab peninsular, where the mean HbF is 27.8
346,464. Although it is likely that both the CAR and Arab-Indian haplotype exist in the
population in Dar-es-Salaam, the predominant haplotype is expected to be the CAR
haplotype, as reports from Kenya suggest that this is the common haplotype in this region 465,
466. Reports suggest that within the CAR haplotype, there are two chromosomal types that
determine different levels of HbF and G-gamma expression'"; which in tum influence HbF
levels. Therefore, there may be differences in the sub-haplotypes that could be affecting the
HbF levels. In this study, the J3s-haplotypes were not characterised but this will be an area of
further research.
The laboratory factors that were independently associated with high HbF levels were sex, Hb,
MCV, RDW and platelets. High levels ofHb have been associated with Hbp468.The reason for
this association is due to the fact that high levels intraeyrthocytic HbF improves RBC
survival469• Individuals with higher HbF levels have higher MCV values which could be
explained by a pleiotropic effect of the genetic factors underlying the increase in HbF470
One of the suggested mechanisms for the increase in HbF relates to an accelerated
differentiation of erythropoiesis leading to the release of relatively 'younger' erythroid
precursor cells, hence the lower RBC and larger MCV values. These 'younger' erythroid
precursor cells are still synthesising relatively more HbF. The association of higher F cells
(erythrocytes that contain HbF) with lower RBC and higher MCV values, has also been
shown in healthy non-anaemic white Europeans?". Independent genetic association has also
been demonstrated with the HBS1L-MYB locus, one of the three major HbF-associated
quantitative loci (QTLs), with these haematological variables, including platelet counts.
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In summary, this study has the first report of the spectrum on HbF in a cohort of SCD
patients in Tanzania. There is a significant gender difference, with females having higher
levels than male. Factors that were independently associated with high HbF levels were
female gender, haemoglobin, MCV, RDW and platelet count. The association with clinical
events such as death, hospitalisation and high CBFv was difficult to elucidate as the
differences did not reach statistical significance. HbF levels are highly genetically controlled
and recently three major loci (QTLs) have been shown to account for 20-50% of its variation
in diverse populations including healthy individuals of European descent as well as
Sardinians, African-Americans, Brazilians, African-British, Chinese and Thai, healthy and
with thalassaemia or SeD. Genotyping of the sequence variants in the three HbF QTLs is
underway to investigate if these three loci are also associated with modulation of HbF
production in Tanzanian sickle populations. If so, we will explore the incorporation of these
variants into a prediction algorithm as part of the care pathway for sickle cell disease.
Information on the HbF -associated QTLs should also be of value in better understanding of
therapeutic reaction of HbF using agents such as hydroxyurea.
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Chapter Nine
Discussion
INTRODUCTION
Although seD results from a single gene mutation, it is a complex disease with marked
variation in clinical presentation of disease. There are environmental and genetic factors that
influence disease patterns within individuals at different stages, as well as within populations
in different geographical locations. Therefore, the approach with regards to interventions and
management differs within individuals at different time points and the interventions that are
applicable in one setting may not be appropriate in another setting. Much of the knowledge
that is available regarding seD is based on evidence from SCD populations in Europe,
United States of America and Jamaica. There is limited information on the causes of illness
and death in SeD in Africa, where 75% of global population of SCD individuals live.
The work presented in this thesis increases the knowledge of the clinical spectrum of SCD in
Africa. A prospective study was conducted between 2004 and 2009 in Muhimbili National
Hospital in Dar-es-Salaam, Tanzania. This is the largest cohort established in Africa for
research from a single centre. Clinical events, at outpatient clinic and during hospitalisation
were described in order to understand the course of disease in this setting. The rates and risk
factors for hospitalisation and death were described. The decision to focus on malaria,
bacterial infections and stroke was due to the previously described role of these conditions in
SCD within Africa or in the case of stroke, within SCD populations outside Africa. There
was evidence, in some cases conflicting, that these conditions cause significant morbidity and
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mortality. However, this study has provided a description of factors that can be used to
identify SeD patients who have high risk or are protected from these outcomes. The details
of the study findings have been reported in chapter 4,5,6, 7 and 8.
This chapter will swnmarize the key findings and discuss the validity of the study findings
with regards to the seD population at Muhimbili (internal validity) as well as the
generalisability or validity of the fmdings in relation to other SeD populations (external
validity). This will be followed by a brief outline of the implications of the findings to current
policy for management of seD as well as future research.
FINDINGS AND EVIDENCE TO SUPPORT FINDINGS
General results - baseline, hospitalisation and mortality
This study has illustrated that it is possible to conduct a prospective, cohort study on a genetic
disease in a country with limited resources. During the study period, 1,725 patients were
enrolled, with a survival rate of 80% and loss to follow-up rate of 12%. The mean age at
recruitment was 9.7 (7.9) years. Since SeD is an inherited disease that is present at birth, the
high median age at recruitment in this cohort suggests that children remain undiagnosed for a
long period of time. The natural history of the disease is such that there are many clinical
events in the first 3 years of life and that the highest incidence of death is between 1-3 years.
This finding highlights the need for newborn screening to identify children at birth. Once
identified, these children can be managed optimally with prophylaxis against infections as
well as prompt treatment of acute clinical events such as anaemia, pain and infections.
Identification of a birth cohort, would also allow accurate description of clinical events in
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early childhood in this setting.
504 (29.2%) of the cohort were hospitalised during the course of the study. Pain was the
most common cause of admission, followed by fever and anaemia. A history of
hospitalisation within the preceeding 12 months period was a risk factor for hospitalisation
during the course of the study.
The median survival amongst patients with SCD in the study was 33 years, which is 19 years
less than the life expectancy in Tanzania, which in 2008 was52 years472 . The mortality rate in
the study was high, with an incidence of 2 per 100 PYO. The age group that was most
affected was under 5 years, although, the confidence interval was wide because of the small
number of children within this age group. The risk factors for mortality were low level of
haemoglobin and high total bilirubin. 23% of the deaths occurred in Muhimbili.
There were several issues that highlighted the importance of having a good health system that
includes good service delivery at different levels of health care starting from within their
homes. The first is that there were some SCD patients who were identified, during
hospitalisation, or were screened and found to have SS phenotype, but never returned for a
baseline visit. Second, from the 1,725 SCD individuals recruited during the study period, 209
(12.1 %) individuals were lost to follow up. Although this rate is acceptable to make
conclusions about the information collected from the cohort, it is important to address the
factors that contribute to patients not attending the clinic. Third, only 23% of deaths occurred
at MNH. There may be different factors that contribute to these fmdings. However, these
issues suggest that SCD patients may only be seen once at a specialist clinic in a tertiary
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centre. Furthermore, acute clinical events and death occur at home or outside these
specialised centres. Therefore it is recommended that if any SeD patient is identified, risk-
stratification is done immediately at this stage. Health education and counselling of patients
and their guardians about the importance of regular attendance to clinics may improve
attendance. It is also important to explore whether there are any issues within the health
system that can be addressed to improve access to care. First, health services provided for
SeD patients in peripheral clinics and in the community can be improved. National centres
should work with the public health system to ensure that there are good systems in place for
delivering care to seD patients at different levels of care. Second, outreach services can be
improved by the use of telephone and community based health workers so that doctors in
MNH or other specialist centres can provide advice to patients or health care workers. Third,
day care facilities would also reduce the time that patients spend at hospitals for clinic or
inpatient care. This would also improve adherence as spending long periods of time at
hospital may contribute to patients not coming to MNH.
Malaria
Falciparum malaria is usually considered a significant cause of morbidity and mortality in
seD. In this study, the prevalence of parasitaemia was lower in seD than in non-Sf.D
patients both at clinic (0.7% versus 1.6%; OR 0.53, 95% confidence interval 0.32-0.86;
p=0.OO8) and during hospitalization (3.0% versus 5.6%; 0.46; 0.25 - 0.94; 0.01). However,
SeD patients had higher rates of malaria during hospitalization than at clinic, the DRs being
4.29 (2.63 - 7.01; p<O.OOI)for malarial parasitaemia, 17.66 (5.92 - 52.71; p<O.OOI)for clinical
malaria, and 21.11 (8.46 - 52.67; p<O.OOl) for severe anaemia associated with malarial
parasitaemia respectively. The implications of these findings have significant consequences
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to the management of malaria in SeD. First; since malaria was rare amongst SeD patients at
outpatient clinic, this suggests that prophylaxis may not be necessary. The caveat to this is
that this result may only be pertinent to areas with low malaria transmission like Dar-es-
Salaam. Further studies in areas with high prevalence would need to be done to validate this
finding. The second implication, is that malaria parasitaemia during hospitalization was
associated with both severe anaemia and death. It is therefore vital to ensure that during acute
illness prompt diagnosis of malaria is made and effective treatment is given for malaria as
well as anaemia.
Infections
From this study, the pattern of bacterial infection in seD patients admitted with acute clinical
events was ascertained. There was a low yield of pathogens from blood cultures during
hospitalisation of seD patients. There were concerns that this was due to methodological
limitations in laboratory techniques within microbiology. After these issues were addressed,
the prevalence of bacteraemia was 4.8%, and the commonest organisms isolated were
Staphylococcus Aureus, non-Typhii Salmonella and Streptococcus pneumoniae. It is therefore
recommended that SeD patients who are hospitalised should receive prompt diagnosis and
treatment of bacterial infection.
Reports from Kenya, Uganda and other areas in the worlds suggest that bacterial infection
(most likely due to streptococcus pneumonia) is the most likely cause of death in SCD
individuals who are less than 5 years. Evidence is required to advise on the most appropriate
vaccination and chemoprophylaxis for SCD individuals in Africa.
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Stroke
The spectrum of CBFv in SCD patients in Tanzania was described in 372 SCD patients, with
the mean CBFv [132 (SD 49.4) ems/sec] higher in Tanzania than that previously reported in
Kenya and the US. However, the prevalence of abnormal velocities (above 200cms/sec) was
10% which was comparable to that reported by the US studies. Peripheral oxygen saturation
was independently associated with likelihood of having an abnormal CBFv. Further studies
are required to elucidate the role of hypoxia in cerebrovascular events.
During the course of the study, stroke occurred in 1% of patients. The incidence of stroke was
3.0 per 100 PYO and the factors that were independently associated with increased risk of
stroke were level ofHbS and reticulocyte count. For the subset with CBFv measurements; the
rate was lower at 1.3 per 100 PYO. This is most likely due to the age difference as the latter
group were younger. Although patients with stroke had higher CBFv compared to those who
did not have a stroke, this was not statistically significant. Furthermore, the level of CBFv of
200cmlsec was not useful in predicting stroke. It is recommended that further evidence is
required to determine the relationship and establish whether a lower threshold of CBFv
would be more appropriate for predicting stroke. The fact that this was a self-selecting,
hospital based cohort may bias these fmdings as this patients group may have less severe
disease, including cerebrovascular disease. It is therefore essential that this study is conducted
in a cohort of SCD patients identified at birth while also expanding the SCD population by
either recruiting from several sites or including all SCD patients that can be recruited from
the community so that the selection and study is not limited to a hospital cohort.
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Foetal haemoglobin
The spectrum of HbF levels was described in 1,668 SeD patients. The mean HbF level was
6.3% (4.7) with females having significantly higher levels (6.9%) compared to males (5.8%).
There was variation of HbF with a gradual reduction in the first 5 years of life. The factors
that were independently associated with high levels of HbF were gender, haemoglobin,
MeV, RDW and platelets.
Analysis of relationship between HbF with significant clinical events, in their respective
chapters, did not show a significant association between HbF levels with mortality,
hospitalization, high eBFv and stroke. This is a surprising result as HbF has been shown to
be associated with mild forms of seD and agents such as hydroxyurea which increase HbF
have been found to improve survival and quality of life in seD. However, such results have
been reported from other studies and the recommendation is that more detailed description of
the phenotype of HbF is required to understand the role of HbF in the clinical heterogeneity
of SeD.
VALIDITY
The validity of a study refers to how accurately the study measured its fmdings. Internal
validity refers to the adequacy with which the fmdings of the study can be used to draw
inferences about the study population. On the other hand, external validity refers to the
findings and how they relate to other populations. The lack of validity of a study results in
systematic error.
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Internal validity
The effect of selection bias
Selection bias can arise from errors in the study design that causes a difference in the way
individuals are recruited into the study.
This was a hospital based study, with limited recruitment in the community. The SeD
patients seen at Muhimbili were those who had been referred for investigation or had already
been diagnosed as having SeD. Therefore, most of these patients had symptoms suggestive
of seD. This means that the patients that are at MNH may consist of those patients who have
not died in early childhood and therefore have relatively mild disease, i.e. the "healthy
survivors . However, this population may also present patients with disease severe enough to
warrant seeking health care.
This study has described the rates and patterns of bacterial infections during hospitalisation in
SeD patients. Although the SeD population is older, the evidence from this study reports that
SPN is one of the most common cause of infection. Further research is required to
determine the rates and patterns of bacterial infections in the younger age group and before
antibiotic use.
The effect of information bias
Information bias refers to errors that are caused by collection of inaccurate information. This
may be due to recall; reporting or observer bias. Recall bias may have arisen when
interviewing children and adults about past events. It is likely that the caretakers of young
children will have a more accurate recollection of events. Older children, adolescents and
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adults may not have an accurate recollection of events that occurred in childhood. In order to
address or reduce this error, it is necessary to include age in the multivariable analysis of
association between outcome and exposure. Furthermore, designing a study where
individuals are recruited at birth would allow the careful and accurate documentation of
rates and risk factors of events.
Reporting bias may have resulted from individuals with SeD seeking health care or health
care workers referring individuals to Muhimbili because of the knowledge that there was an
ongoing study. During this study, attempts were made to reduce this error by not influencing
the criteria for referral or hospitalisation. However, when exploring the role of malaria in
SeD, it is acknowledged that SeD patients may be more likely to report and be investigated
for malaria compared to non-sickle individuals.
The other issue that may have influenced the information that was collected was related to
access to care. As a referral hospital there are some events which would be managed at home
or in peripheral clinics. This is because there is a referral system which encourages patients to
initially seek care at a health facility near their homes. Furthermore, patients may come to
the hospital and receive care at casualty without being admitted. In these instances, clinical
events would not be captured during the study. The other factor that may have caused
information bias is physical and economic barriers to access to care. Individuals who live far
away from the hospital and those who cannot afford to travel to come to hospital are less
likely to come to the hospital.
Because of the potential for information bias, it is vital to reduce the factors that may
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contribute to this bias. Health education should be provided to SCD individuals and their
caretakers about the importance of attending clinic or contacting the health care providers
about clinical events that occurred and were managed at home. The second intervention that
can be put in place is to improve the care in the community by forming a network of care
with health facilities in the periphery. In this way, clinical events will be identified and the
appropriate intervention recommended. There is an urban demographic health surveillance
system that is being established in Dar-es-Salaam and in addition, there are community based
health workers that are providing care at home or in primary health care facilities for
individuals with chronic illnesses such as RN/AIDS, Tuberculosis and Diabetes Mellitus. As
such, rather than set up a separate network of community-based and primary health care for
SeD, it is recommended that care for SCD uses these existing networks.
The effect of losses to follow up
In a cohort study, individuals are followed up over a period of time to determine the rate and
risk factors for clinical events. Patients may be lost to follow up because they drop out or stop
coming to the hospital because they have died in the community and this information has not
been collected. Alternatively, patients may move away from the study area or have physical
or economic reasons that prevent them from coming to the hospital. In this study there were
209 patients who were lost to follow up. It is difficult to conclude whether the patients who
were lost to follow-up are those with mild disease who stopped coming to the clinic because
they did not feel there was any advantage or benefit from coming to the hospital. It may also
reflect patients with severe disease who have not returned to clinic because they have died or
have a severe event like stroke that makes it difficult for them to come to hospital. However,
from the patients who were successfully traced, the suggestion was that there was no excess
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of deaths or severe events in those who were lost to follow-up.
Confounding
Confounding occurs when an estimate between outcome and exposure is mixed up with a
third factor. The third factor is associated with exposure and independently associated with
the outcome.
Within this study, attempts were made to minimise confounding. In the design of the study
and analysis of risk factors for key events of interest, confounding was controlled by
restriction of the analysis only to individuals with SCD. Therefore, comparison was made
between individuals who all had SeD. The other way that confounding was minimised was
by multiple regressions analysis. Variables that were significant during univariable analysis
were included in a multivariable regression model.
External validity - Generalisability of study findings
The external validity of the study refers to how the results from this study can be applied to
other populations. The fmdings from this study reflect the spectrum of SCD in a hospital
based-cohort in an area with low but variable malaria transmission. As it is in an urban
setting, the socio-economic status, level of education and access to health care is relatively
better than in a rural community. However, the rate of urbanisation in many African countries
is high and there is considerable success in public health interventions such that there is an
increasing number of seD individuals who will be living in a setting similar to that where the
study was conducted.
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However, is acknowledged that these results may not be applicable to rural communities.
It is therefore important for evidence to be gathered in these settings. In this case, the results
from this study would be used as a reference point.
APPLICATION OF FINDINGS AND RECOMMENDATIONS FOR FURTHER
WORK
Implications for policy
The results from this study have demonstrated the burden of disease and highlighted the rates
and risk factors of hospitalization and mortality. Furthermore, it has provided initial evidence
with regards to the role of malaria, bacterial, infections stroke and HbF in seD. The aim is
to start developing guidelines for the diagnosis and management of seD patients at MNH.
Within MNH, guidelines for prophylaxis and treatment of malaria in SeD in Dar-es-Salam
have been proposed. Effective treatment for malaria during acute illness is of utmost
importance to minimise morbidity and mortality due to malaria and its complications such as
severe anaemia.
With regards to infection, it is recommended that SeD individuals who are below 5 years of
age receive prophylaxis against infection with oral penicillin and pneumococcal vaccination.
It is recommended that the introduction of prophylaxis should be accompanied by collecting
further evidence to determine the most appropriate intervention.
During the course of the study, a programme for control and management of SeD was
developed and submitted to the Ministry of Health. The aim is to establish a comprehensive
programme for detection, management and prevention of seD in Tanzania. In addition it will
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aim to promote education and awareness in health professionals and the community regarding
the magnitude of sickle cell anaemia in Tanzania and develop active research programmes
that will provide an evidence-base for the detection, management and prevention of sickle
cell anaemia in Tanzania.
It has been proposed that Muhimbili is established as the national centre for the
comprehensive care and management of SeD. It will also act as the national referral
diagnostic centre that will provide laboratory and other diagnostic facilities for the detection
of seD and its complications. Muhimbili will also support the establishment of regional
centres that will provide comprehensive care for the prevention and management of SeD in
other areas of Tanzania. The programme will explore appropriate strategies to introduce a
minimum package of simple, evidence-based essential interventions amongst seD patients at
different levels of health care. This will include anti-malarials, antibiotics and guidelines for
prompt diagnosis and treatment of acute clinical events. All this will be supported by active
research programmes that will provide evidence for locally relevant policies and
interventions.
Implications for research
It is recommended that molecular studies should be established in Tanzania to identify
individuals with genotypes such as S/~oThalassemia and S/HPFH. This would improve
the characterisation of the clinical spectrum of SS cohort. It is also recommended that
further work should be done to define the clinical events in SeD in early childhood. This
should be done by identifying SeD at birth by newborn screening. With the seD birth cohort,
we would understand the natural history of seD in Tanzania in the first 5 years of life. This
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would allow us to determine the most appropriate interventions. Second, the logistical issues
of NBS would be identified and used to guide and advise the ministry of health on how to
introduce NBS within Tanzania. In addition, the birth cohort would allow the study of
mechanisms of disease as well as understanding the genetic and environmental factors that
determine disease severity.
With regards to stroke, it is recommended that all SeD individuals between 2-16 years
should have measurement of CBFv by TeD. This should be done at least once a year, and
those with high risk of stroke, determined by locally appropriate eBFv as well as other
associated factors, should also have careful neurocognitive assessment and neuroimaging to
further defme neurologic events. Furthermore, the natural history of neurological events can
be explored within the seD birth cohort.
The role of foetal haemoglobin needs to be examined further by improving the phenotypic
description of HbF, by more descriptive epidemiologic studies. This needs to be accompanied
by careful genotyping to understand the genetic factors that determine Hb F levels.
This thesis forms part of a programme of work that is aimed at integrating research, clinical
care and education in SeD. There are various research questions that cut across different
disciplines, ranging from laboratory science aimed at understanding disease mechanisms to
social sciences which seeks to understand the social and behavioural factors that influence
disease and interventions. This is in partnership with clinical sciences focusing on morbidity
and mortality at individual level and public health sciences which approaches the same issues
at population level.
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CONCLUSION
This thesis has defined the spectrum of SeD in individuals at MNH. The study described the
characteristics of SeD patients at recruitment and determined the rates and risk factors for
hospitalisation and mortality. The role of malaria as a cause of morbidity and mortality was
determined and the usefulness of eBFv and other factors in identifying risk factors for stroke
was evaluated. Although the data were limited, information about the rates and patterns of
bacterial infections was described. Pilot data was gathered on the spectrum of HbF which
has important implications for interventions with agents such as Hydroxyurea.
This study has provided important evidence for developing policy for management of seD at
MNH which will also help to guide principles of care at other levels of health care; it has also
highlighted important areas where there are gaps in knowledge which require further
research.
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Appendices
APPENDIX 1 INFORMED CONSENT FORMS
MUHIMBILIUNIVERSl1Y COLLEGE OF HEALTH SCIENCES
P.OBedJlIl Du .. s.taa.. TuzuIa
INFORMED CONSENT FORM
Site But' ..
MUCHS
SI'1JDY 11TLE
The Sickle cell di.sease (SeD) Study
11IE RESEARCHERS
OUl' re search team consi sts of reseuchers from Muh:im1:ili Ur:iver lity Call ese of health
.cionce. lAd Mubim bill Ncanal H olPpital. Tbi. ia;l1Jd.es doctor., D.If'U, 1,bor,ttry
tecmologsts etc. We also wcxk with other people fr em other \riversities end hospitals
frOHl all (Net! the wor1 d 1tlc1udmg Kenya. and UK.
PURPOSE OF STUDY
Siclde cell maaa (SCD) is an inherited comiticn that ~fects m any pe op1e in T anuria.
As you know some people become velYill with frequert cemplications end risk r% death
while others remain relatively healthy despite the feet thllt both have seD. We need to
find 01.& why this i.,o. If We CIA msco"Verhow .emeo people do not h~e lOYIX" ~Ic'fe
we may be able to use information to mue a medicine that we can gve to everyone or to
develop ways to prevent them from deve10piflg severe com. ph cations ofS CD.
The aim et' the study is to describe the spectnm r:f din cal disease in p atieris with SCD
attending and'or altnitted to Mulimbili National HO'llital (MNH). Tbis will be the first
step in trying to understan! the causes of illness in SCD in Muhim 1:ili end will focus on
some aleU whch are relevant in determinng treatment guidelines: malarie, infections,
wlliliw IAti Rake.
WHO WILL BE INTHE STUDY
All patierts with proven or suspec1ed SCD who attend the outpatient clini c or who are
admitted to the paedi.atric ex medical wards at MNH will be told about the study and
~ven the option to participate in the study. We will also be askillg re1atiws Of people
witho,", SCD to participate in the study.
WHAT PARTICIPATION INVOLVES
We will ask you to _tend the Haem.otology cline eve2Y3 months where a doctor will ask
you questions regarding the symptoms of SCD ihat you have had. that mayor may not
have broulflt you to hospital to seek medical attention. You win al.so be asked q_uesticns
abo,", m edic. problem s in the past. demolJe.phi.c, family astory etc. This is because it is
thougtt that SCD is thou&hi to p-esent with various p-oblems in <iffererIt people and
levels at severity is determined by venous factors. You will then be examined to
determiDl and doclDent anyphyaical sip and irlV'estigati.onswin be taken A blood
SGmpo win also be cd1octod - wo ch is a normal prac1ico fex SCD patients attending thII
haematology' clinics.
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Fe. p .... who do IlCi haw SCD, the _. proc.cbellri11 be taken and you will be
iDformed of the re ails of Ile te_ If yru do mt han SCD you will mt be recpt' ed to
a&tend tbII cliDic.
WllATWILL IlAPPENTO 1BE IWIIPLJ:
W. will tab a _pit cl blood &oa JOU CIl' yow child to do the t...u that Ibrul d be done
(Il 111 pdiau etten6ng tbe hosptll. .. betber or art ym are participatingin the 5b.dy.
The .. 18.. w1l1 be claDe in Ile labonScly at MulUabili. In additi01\ there will be .cme
IJllcitl teltt tbIl ri1 be done wDch \V •• Id prmcmly dc:me bee .... r:llack rL
"lOWe".
n.e 1IriI1 be lOIle tIIJII tha will. allO be ae as part of the f •• ch to improve 0\.2'
tmdIuleoding ciSCO. Soa. cl1bI ..... will be daDe imm.edia"telyin MuDmbili while
alblrnrill be doaa in a lIbontoryoWide TammL
We will 8110 ItUlSythe pDt1:ic .. alaitl thati. inthe blood _pte, end we woudlike to
_PleiA to 7W whit ~ amdc _.al it. The pmtic materiali.wbatm ••• enryme
ciA'•• ha bdl· in ow bIi~ in our look., IDd in mmy~ .. vray.. including why
peop. ban cIift'erent cClllplicUiODl ofSCD. W. Ut ~ the pattic m&teia! from
JCIIl e dilctm .. be .e TfSJ ill... ithSCD, IDeS other children who areml illwilll SeD, to
try to cilccnw what.t oftbt p»tic malerilllbali.re.pcaible fe. tal diiferenc •.
n..wiIlb. 1CIIl..... tbIi tab mmy yll" to drmap. Therefore w. an uking yo\&'
peaau.ioD to lII«elle _pi", iac1udiDg (llmric maletial, 10 th. we can pedoDn cdlute. it iD tbI n.un.W. In 1110 IIkirlgfor permillim to perfoml. leIt8 (Il_pl. woch
bid be. 1II«.s itClll your prnicg "filit. to hollittt linee YOUI'emolmed to Ibe SCD
1Iudy .
• NEnTS or THE SI1JDY
There will be no .. eel bmefit. 1imDci1l or othmri .. that you will get & CD Ui. ltudy.
yO\&' pricipdioD in be IIudy will ... m that. cpe.aon. about SeD, which i. known to
cauee death, will b. ~CS. ni.infomaUian wiIlllerefon be m uee in understanci!@
tis cOlditian and Uw dew1q:1 mecic:ines and p'mnl canplicatiom by developng
better...,.. oflo*iDI aftet'p.ldlwritbSCD in Tcmzaria 1nlother place. in the wodd
POTENTIAL RISKS OF DE STUDY
n.. will b•• _ pain ad dUcomfort at tu lite ri liood cdlectioo. For Ibe tiooc1
eo11ectioo we will we e.ppum that i. fiee rIgetIIl. and tbat it lIlade to felllee pain
~ pic:kiDg. There will be DO ftIW'" e. special ctug or treatm _ that. yc:u will :receive.
If yow ebilcS bu fit! niclea;, SW 1U@Bt. iD:reut Ii* tI dtnlop.ng .. ctmJiicmiWl.
WI \riD di~ U. Iitu.OIl with J01.IIDd WI will ctfer increaltcl frequm:y of follow up
to by to prt"'8d tb. caUliDg cy problem in U. iUIur.. A. OIW ways are dewlap ecl to
pr..- the. poblem. tbey will b. cSUcu.ed withyou and offere d to JOl.a' c1ild
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FREEDOM TO PARTICIPATE IN THE STUDY
We w ~ d hk e to $Um that yWf pw ~ P ~ on In thI s rudy Is stri.;;U y yol1JtlWrY- it i $yO\Jf
de cisro n Should you de c d e not to p8rticlpate; it ""';11 not affect the trea1ment or
m enagem ent thft you will receive tYcm the hospital In addition, at any time point dmng
the study. deCIde that you do not wish to particIpate any further; you are free to end you
paruclpatlon, effe cuve imm e diately Any such decision will be respected and w:ill not
mfluenc e the quality et ne al th car le we Wlll grve you or your child
If you nu ss som e VlSl ts for any re ason, but wish to corn e back int 0 the study or attend the
di rac, we WIll be ready to IICcept you back
CONFIDE Nll ALITY
All the mform an on that you ~ve will be corfiderai al. You will be ~ven a code number
and we wil l be very careful WIth the worm all on that we have collected. We will make
eb solutely sure that when we tell people about 01.1' findings on the genetic material, no-
one MIl be able to discover that ths genetic material came from you or your child."
Only the prinup el researcher or somebody auhorized by him or her wi11 be a.ble to link
the sample back to each partlC1p8l'1t
Plrase feel free • ask aJlY IIurstioJlS all out tJv bdDnnatio JI yo u have just been g.. en.
or aJly 1ll inC else • do witk SCD aM tke care ofyourdwl.
There is lItO re inill'1fta tin in tJv tilI"JIl 0 f leaflets, P 11116sJted P lip elS tha t B availab Ie
IDr you to leaMl moore M01lt SeD. Please irel free io take this heme with you and
yo u ca. co.tac1 usoor ask us .urln; your nextvisit for more in.tilnnation.
Far the mady, we will :ask }'Iu to ~Jl this P :lper 10 confinn that you )QVI') received.
tkis ooonnau.. aft. that YDUCDJlsent til partidp ate in thii study.
1ft cue there is aft,. fUrther w.l1IlatilJl that yn require with rcpr4 tv the stucly
please ask • speak _ Dr J Makani, Department of Haema."gy aftd Blood
Transfusion, Muk .. llili University College 0 fHealth Sciexces. Tel: 07'877680688 or
any of the otMr investica_rs. If you _er have q uestiaons about your rights as a
pa.rtkipaJlt, yo u may caD ike dtairmaJl of tke college rese:arck. and PuhliratioJls
Connaittre, P. O. BOI 6!ll0l. Trl: 2150~2.
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MUHIMBILIUNlVIRSllY COLLEGE OF HEALTH SCIENCES
P.OS.x.'l Du I!I ..... T.....
INFORMED CONSENT FORM
MUCBS
hd'.z.. .. e._lit. r,artidpaats:
I haYe fead (l' I han been fead the atialilcd iritmutlm fegardi~ tbl SCD study in
Englilb I Swahdi (}:iease circle one), IS 1anpge I speek fluedly. I have also had an
opportuaty to dlscu. the study with the investigetors and I am satisfied that I understa:nd
what the ltudyinvo1vu
I agree to or atw my child I chllt'cn (listed below) to take pGrtin tbs study:
(1)' _
(2), _
(3) _
(~------------(~,----------(~,-----------
Pa.tIeJltllPanu IG.utia.'s
SlpahlreertJruJU ,riIlt Daa _
PueldIGartiu'. Nute:_~=-----_:_----------
(Plea 3CP' i~ 1G72e)
WbaII
Slpahlre (lfc:annkereua.t reai), _:Date, _
~ Na.e: -::;::;--_--:--:--_~------
(Please p'i~ name)
I eerdf) tIIat tit. do ... as apia ... YeDally .. tile ,.e.toIunUD, _II that sIl&e.. ,at.... tlII _taw ... .., ,WIt ne .r t. ...)'.. C.IIID:II'II 1. tlao
,artE9a •• bt tile __ ,. dtlle " ••e 'ada ....
I have ~van them the Dpp <X1unity to ask cpestions wh ch have been answered
satiafactaily.
Researcla OtIkIer
~ahIre Da. _
ResearclaOtlklerN .. e: ~~----~----------
(1'IUlS4 pint 1'm7Hl)
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MUH IMBIL [UN IVERSITY COLLE GE OF HEAL TH
SCIENCESJMUHIMBILI NATIONAL HOSPITAL
MAELEZ OKUHUSU UI'.Ufn WA KUCHUNGUZA MADHARA YANAYOT (I(EA
KWJ\ WATU WJ'\NOJ\IHIR1WJ\ NJ\UGONJWA WA"SICKLE CELL"
HOSPIT AU YA TAlJi' A YA MUHIMDll.I
Kama '4i1lilV", _.. i mmto ~ huJudhuria kiIiniki ya \RfPJVwa WUl,}W muadhi ya
-.,wcufu wa damu mwiIini ya ,'-it Ide cell" kat3a laolp i&JI. ya Taifa ya muldmbm.
Jam. hili linam_ hR watuwuP ....a Jll:h:ini. HaIi lUi inamaimilha hvaniI awalati
~ .... ~. ioJ.a _taU- kama harma, ........mru rnwiIini,. m., uncuk:iYa damu.
IIaadhi ya matatim kama ha;ya ~ kuzuilava, na lUi nil;"" mama JmV_
~a man hva mG'a lva 111:~ lImM J.rphli nil wMl:ti ~ h~i
_tIoabu.
CJwo cha MulUmiliIi {MUCH!ij Du- kinalhiriJdIuIa 1Iihu:i na hD..,Dali ya
iaifa y.lI\uhimhili Vu_iviM MolJI\laJm ya ~ 'Ul1wll&uri \Va ~a II\lIUi
1Mali .... a Taruan». L~ la uchwlcuri waft ta:ifani, bolp iaJinl ,. latiha jamB, ni
Iwraida ~ _am.., ya IOJya ya W1Itu. iaiJuQ, na In.aidia. km.,red.a Jwa uma.
ziIim .. , huJ.inca ,... kutiou maradhi. K_ Nbabv. tam. hili la "ark» ceIr'
~ iii_tu wenci. MU CHS Duiir hlcJaaIirha. ,. ta1im :hili iii lniua zaili kuhuru
hi;Yo hali Ra Indafuia " .. Infra za JnI, .. rMha afra za wato., wa watu. waziJna ~
hali Ni.
MAELEZO KUHU!ru UCHUNGUZJ
Upll\jwolwol "Sirk» teIr' M ~ ~utihuIo'l kw_MUM Matao rnhaJi.!Mali
.. hata.ri ya kifo. Madhunwni ya 111: h~ h-uu ni lniuibu InangiIia ni maiatizo pili
yan.a.yuw..Jul.;K W'aQI~ wa ''-rJ* cd' wa-..lnd1kuna ldIrUJQ au wanaoI.uwa.
nwhimbiIL
TuiaaJlplia _tm. ~a Jnaiatu: ~ .... rna ,. Nbabv. mbali mbali
zinouD2ia Juana na kiarUI i Vitu hWiVDUu turaaona. nim.uhim.u n.ato maJi»u i6. NweD!!
kqj~jni PHi ~ ~"au Jwni.amli&ti&9 ~
UT J\MTmU mJ\ICA(JlU,\TW,\
Tunawaomba wU woto ~ 1JClO11iwa wa ''sic'' ceIF' w_hwUwria Idiniki na.
wanaelazw.a Iwpa ~ iiiwaaJ.iriIG J.v~ ut.6D.1wu.
K.,imo chaclunu
K.,imo CAa damu lliiuhukutiwa ~ mJenD b ad ala ya JaveJ\l"e Isidole. VipimD
vitalav",~ a ni v.,im.o amIIavyo IIJIIl.hitaji ~ a uhiwa na rna.tim ya "sitJde,
c:elI" haa J.una haUlhurihi hv~ utafuD. K\Va k.vaida v\» imo hivi vimdnava.
hlvi&n;rik:i Mp a muhimhili &va Mhabu Ju.pDali iIikuwa Mina QVUO wa kw~
hwa ~abu tiwrlllU ya}e ni Inmn. Mi@bu )a damu yatapatiJaull baada ya m1lla
mn., i JIIil bUlla ya ~ 0 umonvv. Ra. daktari Jan. ilWyo lmwaid ...
K utoa maelezu
UiauIbwa ma.wali kuJwn& maWizo ~ata ~ayo ~ ~ Jwauma.
IIoIp ialini. Pia utaulizwa ma.wali kuhut"U ma_mo ya Uya ~Ja., Ca Nip 0 zurumi.
Aid ha uiaGm, 11l utoe maelezu Jmhuru ma.haIi un8poirhi, &miIR"...., nk. Hii ni Java
_ab u upmJwa wa ••• rickIe cd'·' undo .. na manmo m,u m,ali lava _tu to:fa.uti.
&ada ya ""0, uapu..n ,. daJdari.
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FAIDA YA UCHUNGUZI
Len,p k'*wa la ur~ ni hutaka JaG- matam.. ~ata. _tu W"""_
'tIWIC'Ufu, -. 11111\.11 wet.. "t~Jde tell'. HUaaM _hoavirhl child..,. kft1a.thll.1ew6, !lA
tunamatumaini h.vamh. _tu watahDnili. lenp lIB Ia&ruIa..u _mm wao kw....,..
urh.~ Lenp 1nMv. nI Iadeta maend.eJeo _ Jaa_J. Q,. J.va ~ "drlde
c:eJr"w. Dar- _aJaarn na ndu nzina ~ T ~ HWyo bui utafiti utalria mamaila
Iva jam..ii nrlma.
ATHARI VA UTMITI
M.. aJnui Ra wuJwnea:i __ ddriJR Imtika w:hunpzi h.UIl w&IIUI'.ta mUunm
-mm..
Utard u1m" haw. madhara _ hawahab.hi _umivu waJa ..... K.,:imo eha d_u
hiia£JwkuliwIl" wailaliuma \\la Iw.a. clanm i6kttI~ maumarll Javawato •.
Ddwa ........... .tapadlana k1M'a UI8 m.adhara ~ kuIeta aihlri k1inva,
tqadiliana _e _ tu'ialouma Jdinihi mara ..... mara ili~ hili tam.o .iIw z:a
Ulom. I"ijia .... " _ kuzuia ma..am ~ zinapor;unduliwa ~ JW\ft _
Jaantltu. __
SIR!
llib an DtI! :rltllllUDpa1ibna kubalam na udrungwi h.azi:Ia1DlAvaJan mm ~
an,aye haNuihi .. tlta -........ M-,iina ~ wam._ yataando __ Ra hakuna
mtu~a~Jao.wp.", -~J.wa.J.ughuli~
ICU.mnJSISHA NI mvARI
Si Iazima JMta,.."..ne .~a _..,iillini MuhimJliIi:kuhudJa ~ 1I£lwngurl.
KuJ-.ta. kqjih __ ha JadIa ur10utcurl ~ m.adhara ~m. Mawaidha
~, maeImt kuhIuu v"imo na __ dt ab u yata.lI!wa lava wapnJwa _. aidha
wanaJa.iIa __ havaJauiki kaDha urhuncun. V")O hivyo, un.-vem ku,jiDndoa
~ 1K~w.bDWOW1I1Iebill"WuwUa~
Tafadhali Jruwa Jwru huu.Ii:m ~ kuInuu madmI t1JIboJrupa, au hitu chldlD.
huh.UIU -mi ~ :mw_. T uta.kuamh. __ ..:hihi ~ c:heu c:ha maJMa.liano
J.v..Jm. u..-Iuw. J.ya m-Juo _ ~.Ji kudUrihi ~ uia6D hull.
K --.H J.dD •• u ~i m.t- zaidi JruJauu uta6d Jwu, ta£adhaH omLa
kuD~ _ Dr JMaJam, idara ya damu, ho.pitali~ mllhimbili. Sirnu: 0744331551.u
wam.iIa~.
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MUHIMBILI UNIVERSITY COLLEGE OF HEALTH SCIENCES
CHEll CHA MAKUBALIANO KUOIUNGUZA MADHAKA YANAYOTOKEA KWA
WA1lJWANOATIDRIWA NA UGONJWA WA"SlCKLE CELL"
The Sickle Cell Disease Study.
W.Jo.iJa: Dr Jclle Miliru (PI). Dr F Ka1okola, P Magesa, E Nkya
CJ.ti cl. :maJa.I» __ ltwa w.hirihi:
NutasorN1~~om!W ~ maele70 Ialm ru u ~ti utakaos ~ ha.w.atu wen}'!! ugortjw ~wa sickle cell kw~
~ha nna'jOelew~ (IGswaluh.llain;ere:za) Pu, r1IftI!pata rafasl ya lcuonge~ m.lcuuliza. nwwali madalctari
wana.ofany-~ Uclu~Zl mu. Nm&ndhh kw anb ~ nmae lew a lltafiti mu wWusu nini.
NuWolbah mmilm~ w~ (w~Jw~ mpo dun) kushUilci kwenye utafiti1mu:
(1), _
0) __
(3)(4)----------
(5)(6)----------
SlhWyal'tlMu!ilaiMnriI'MIai: TiftM _
.!ina laMzui auMmi: -=--:-:::-::-_-:-:--:-----::_-:-:--:---:- _
(1'qfadhah l7I,uka Jc...ahmJi .wbwq)
Nimslu:JUJJi~ kwunb~ ~mlezi/m(Orjw~ unep~ta m.a.eleoo yoIIe jw y~ utaliti luu no kwanha
U1ae lew~ nu na m.adhwnJm y .. kazl hii. Hivyo, arne lcub.ali Ial ,hirik iJw~iolo w aliot ~w~ ha..pojuu Ialshiriki.
Amepew ~ nuda w .. kulosha lruflkln ria. nafUl ya kuuliza mlSW ali uri. ~yt:) yarrejib iw~kw~lruridhisha.
Sahihi ya 5hahiIIi: Tarehe __
JiM. Shahi4i: ----(T.=;if<--:~;-d},~~-::!c-.<7l----;-dl-;-·~-:kw,--~-:-""-~-=-Akuh;-;-"'-~-:--------------
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APPENDIXIIPROFO~S
SCD Study Nol_U_U
PROFORMA FOR SICKLE CELL DISEASE STUDY - CONTROL
_,=REE= NIllN~ _
• Informed consent (NIY) 1 1
• Today's Date (DD-MM- YY) · 1 1 -U H_U DATETOD
DEMOGRAPHIC HISTORY
• Name 1 NAME
• Sex (MIF) I_j SEX
• Date ofbirth I_U-U_I-I_U DOB
• Place of birth (District) 1 POB
• Tribe of mother 1 1 TRIBEMUM
• Tribe of father 1 TRIBEDAD
______ ~~RES~IDEN 0 ON
District I _
Ward ··..·..·.. ·..··..·.. I ___!
Contact tele hone number /Y) 1 1 -Ui~ -+-...l-oI.-!-.l--J.-!.!~
..... ......,~L Y and SOCIAL HISTORY
• Number of siblings (ALIVE) · ·I_I_j-I_U-I, 1SIBLIVE
• Number of siblings (DEAD) · ·I_U-I_U-I 1SIBDEAD
• Siblings known to be affected by SCD (LIVE) ·..·II_I_j-1 SIBSSCDLIVE
• Siblings known to be affected b SCD (DEAD) .:.:..;,:;~ ~..;::..:, ;;,:.:,. ..:.:;,;;.:J..I:_II-~-li.--_-_-.....J,.~~
GE. NATION
• Temperature ·..·..·.. I_I_j· 1_j_loC TEMP
• Pulse rate I_I_I_I bpm PULSE
• Respiratory rate (per minute) ·I_j_1 breaths per min RESP
• Systolic blood pressure 1_1_j_lmmHg SBP
• Diastolic blood pressure I_I_j_lmmHg DBP
• Oxygen saturation I_I_j_I%SAT
• Length !Height ·..·..·..·..··..·..·..·I_U_I·I_jcm HEIGHT
• Weight (kgs) I_U_I·Ukg WEIGHT
• Head circurnference ·I_I_j.I_lem HC
• Mid-u em MUA
SAMPLES TAKEN
• EDTA(NIY) I_I EDTA
• Serum separator ( Y) · · ·..· · I_I SS
• Other 1 other
• Initials of investigator · ····..·..·..·.. 1_1_j_1
SCD Study control
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SCDStudyNol_LLU
PROFOR.\L\ FOR ICKLE ELL DISEASESTIJDY- ENTRY
SCREENL"'.1G
• Informed consent (_ •yl ·.· · · · · · ·..·· ·..·..· · I_I
• Toda "s Date(DD-~e-f-'tY) 1 I - -I I IDATEfOD
'-- DEMOGRAPHIC H=IST::.=...::O=R=._;'\;_· ~
• Hospital ID number(HID) U_j_U_I_1 HID
• 'ame 1 NAME
• Se. (l\lFJ ·..· · I_j SEX
• Datcofbirth I_I_j-I_j_H_I_1 DOB
• Place of birth (D' lrict) · 1 POB
________ ~IMUMNAME
__________________ ~TRIBE~
• IDADNAME
• ITRIBEDAD
-I RESPON
........................................................................................." IDlSTR
Div Ion ,1 DlVISION
Ward " __j
Ten Cell leade- L- _
• 'carest School I, __j
• . ar IHealthpost __j
• 'carest B Stage., I _
Contact tele on number .')) I
______ -'GE.~I. EXAMJNATIO
• Temperature I_I_j· 1_j_loC TEMP
• PuJ'Ie rate I_ _j_1 bpm PULSE
• ResplralOl') rate (per minute) ,_j_1 breathsper minRESP
• Sy tolic bloodpreslure I_I_j_lmmHg SBP
• DI tolie bloodpres ure · ·..· I_I_j_lmmHg DBP
• Oxygen aturallon ·· ·I_I_j_I% SAT
• Length ·'Hetghl · ·..·..· ·.. I_I_I_I·I_jcm HEIGHT
• WeIght (l..g$) _1_j_,.I_jk:g WEIGHT
• Head circumference I_I_j.I_lem HC
• Iid-u eer arm circumference ·.. ··1 emMUA
LABORATORY INVESTIGATlO, S
SA.\lPLE~1AKE~ (Pleasetick)
Other
1
• lmtiab of investigator ·..·· ·..·..·..·..I_I_j_1
2m1s EDTA 2mb scrum separator
Bloodslide Urine
CD tudyentry
321
•• If yes, please ~ive historv of num r 0 a missions in lifetime and etails of last admission
Lifetime(#/<5/ 5-10/ 10+) Number in last 12 mths Date (mm-yy) and Place Cause of last admission
NUM ADMIT LIFE NUMADMlT 12 DATE PLACE PROBLEM
Previous Hospital Admissions
• Have you/your child ever been admitted to hospital (N/Y) 1_1 ADM
be fd' d
• Have you/your child had any of the Sickle cell crises below that required OPD attendance or
d .. ? If h h lb' I 12 th d h h d f I ?a missron. I yes, w at was t e tota num er In ast mon s an w at was t e ate 0 ast crisis .
NIY Date of last episode Number in past 12 months
Blood transfusion I BLOOD I I 1-1 I I BLOOD DATE I I I BLOOD NUM
Dactylitis I DAC 111=1 I IDAC DATE I I IDACNUM
Painful crises I PAIN II I-III PAIN DATE I I IPAINNUM
fever for >3 days I FEVER 1 I H 1 1FEVER DATE I I I FEVER NUM
Acute Chest illness 1 CHEST I 1 H 1 I CHEST DATE I I I CHEST NUM
Convulsion I FITS I I I-I I I FITS DATE I I I FITSNUM
Neurological deficit 1 NEURDEF 1 I H I I NEURDEFDATE I I I NEURODEF NUM
Leg ulcers I LIULCER 1 1 H I I LlULCER DATE I I I LlULCER NUM
Priapism I PRIAP I T 1-1 I I PRIAPDATE I I I PRIAP NUM
Other OTHER 1 I H I IOTHER DATE ITT OTHER NUM
• Medical history of other illness (NIY) · I_j MHOTHER
• Details (Age at onset, Duration, Outcome) ..
............................................................................................................................................. MH OTHER DETAILS
• Other related information of interest to attending phrsician OTHER
_________ CURRENT SYMPTOM HISTORY
• Are you well today? (YIN - IfNo, answer below) I_j CURRENT STATUS
• Febrile illness> 3 days (N/Y -details) I_1 -I ICURR FEV
• Painful episode >3days (N/Y =details) 1_1-1 CURR PAIN
• Anaemia (YIN -details) ·I_j -I CURR ANAEMIA
• Jaundice is worsening (NIY-details) 1_1-1 CURR JAUNDICE
• Acute Chest illness (YIN -details) I_I-1 ICURR CHEST
• CNS event (N/Y -details) ·1_1-1 ICURR CNS
• Other symptom (NIY -details) I_j -I CURR OTHER
SCD Study eotry 2
322
SCD Study N.2,LLU
_________ 1 FA
________ 1 CQ__ ____________~mON
• Jaundice (Nil! TingeIModerateIDeep) I_j JAUN
• Pallor (N!Y) I_j PALL
• Bossing (N!Y) I_I BOSS
• Prognathia (N!Y) UPROGN
• Gingival hypertrophy (N!Y) UGING HYPER
• Tonsillar enlargement (Normal/Large) I_ITONSILS
• Lymph nodes (N!Y - Details) ·1_1-1 NODES
• Skin (Nonnal/Abnonnal-details) ·I_j-I I SKIN
• Other _Q)etails · 1 - IOTHER EXAM
C IOVAS
• Upper limbs (Normal/Abnormal-details) I_I-I. __.J
• Lower limbs (Normal/Abnormal-details) 1_1-1. _
• Joints (Normal! Abnormal-details) 1_1-1.,.- _
• Vertebrae (NormaI/Abnormal-details) 1 -I
__ o&u.loIo:Ji~~(x;~ICA if to an be 011 in CNS event form)
• Comprehension ( Normal/Abnormal-details) I_I-I,.,.- ICOMPREH
• Cranial nerves (Normal/Abnormal-details) I_j-I ICRNL NS
• Peripheral nerves (Normal! Abnormal-details) 1_1-1 PERI NS
• Reflexes (Normal/Abnormal -details) I_I-1 IREFLEX
• Gait(NormallAbnormal-details) I_j-1 IGAIT
•
seD Study entry 3
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r--- RESULTS (till in shaded results_l SCD Stud>::NOLl_~
Date of test Test Result Comment
HAEMATOLOGY
FBC White blood cells 10'1L
Neutrophils 10'1L
Lymphocytes 10'1L
Haemo~obin I!/dL
Red blood cell count
MCV FI
MClI PR
MCHC __g[_dl
RDW
Platelets lO·1L
ESR Mm/hr
Reticulocyte 0/0
HB electrophoresis
Malaria Rapid test (pes/neg)
Thick film MpsllOOwbc
BIOCHEMISTRY Createnine ~ollL
Sodium mmollL
Potassium mmollL
Chloride mmollL
AST UIL
ALP UIL
Bilirubin- T JUIIollL
Bilirubin - D JUIIollL
LDH
URINE Blood / protein
Glucose I nitrite
HB QUANTIFICATION HbF
HbAl
HbS
MICROBIOLOGY HepatitisB
Hepatistis C
Culture (site/result)
OVFRALL ASSESSMENT I
PROB I Actio" ACT
• Follow up appointment (months) I_I_jAPPOINTMENT
• Date of next scheduled visit (DD·MM· YY) I_U·I_I_I-I_U DATE NEXT VISIT
seD Study entry 4
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sen Study Nol_Ll_LI
_~;,;.c..;. ....:._o_u_tm_·e, Follow u ,Acute event, Other ..
DEMOGRAPHIC HISTO""R=Y""- ~~-
• Hospital ID number (HID) LI_I_I_I_I_lHID
• Name 1 NAME
• Sex (rvtIF) · ··..·.. ·.. ··.. ·.. · · ·· U SEX
• Date of birth I_U-U_I-I_U DOB
• Name of mother 1 MUMNAME
• Date of entry (DD-MM- YY) 1-'_1-1_1_1-1_1_1 DATE ENT
• Date of last OPD visit DD-MM- YY 1 DATELV
CE INFORMATIO N__
• Change in personal details,lfY, complete a new form (NN) I_ICHANGE IN DETAILS
• Residency/Caretaker/Other information ·..· 1_1 RESIDFORM
• Contact tele hone nwnber if available · · ·1 - _L..LLU_U 1 1 PHONE
G EXAMINATION
• Temperature I_I_I.I_I_loC TEl'vlP
• Pulse rate ··..·..·..· I_I_I_I bpm PULSE
• Respiratory rate (per minute) I_I_I breaths per min RESP
• Systolic blood pressure I_I_I_lmmHg SBP
• Diastolic blood pressure I_I_I_lmrnHg DBP
• Oxygen saturation I_I_I_I% SAT
• Length !Height U_U.Ucm HEIGHT
• Weight (kgs) U_I_I.Ukg WEIGHT
• Head circumference I_I_I.I_lcm HC
• Mid-upper arm circumference .......................................................................................... 1 1 11 _lcmMUAC
1.AROR -\TOR.Y_.WYEs:tIG~JIQ~ J
SAMPLES TAKEN (Please tick)
2m1s EDTA 2m1s serwn separator
Blood slide Urine
Other
• Initials of investigator I_I_I_I
SCD Study Follow up
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•• Folic acid (NlY - dose per day) I_j-I, _
• Chloroquine (NIY - dose per week) 1_I-I -,--,
• Iron (NIY - dose) I_I-I :-=-=='
• Other ,;.:;:;,;..;J.. ....L.J----~~ __ ~-L..:
MEDICAL ISTORY ----,
Since the last visit, have youlyour child had any of the Sickle cell episodes below that required OPD
d d .. ? If b t th t tal b . It" d h d fl' d ?atten ance or a mission. yes, w a was e 0 num er since as VISitan t e ate 0 ast eprso e .
NIY Date of last episode Number in past 12 months
Blood transfusion llBLOOD I I-I I IBLOOD DATE L llBLOODNUM
Dactylitis I IDAC I I-I I IDAC DATE L 1JDACNUM
Painful crises I IPAIN I I-I I IPAIN DATE I J IPAINNUM
fever for >3 days I J FEVER I I I-I I IFEVER DATE I IFEVERNUM
Acute Chest illness ICHEST I 1-1 I ICHESTDATE J J CHESTNUM
Convulsion I FITS I I-I I IFITS DATE J. JFITSNUM
Neurological deficit INEURDEF I I-I I INEURDEF DATE I I NEURODEF NUM
LeRulcers I ILIULCER I I-I I ILIULCERDATE I J J LIULCER NUM
Priapism I jPRIAP I I-I I IPRIAP DATE I J IPRlAP NUM
Other OTHER JI-I I IOTHER DATE I J IOTHER NUM
• Medical history of other Illness (NIY) I_j MHOTHER
• Details (Age at onset, Duration, OUtcome) .
................... ·..·..··1 1MBOTHER DETAILS
SCD Study Follow up 2
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sen Study Nol_U_j
• Jaundice (Nil/ TingeJModerateIDeep) I_j JAUN
• PaUor (NIY) I_j PALL
• Bossing (NIY) I_I BOSS
• Prognathia (N/Y) I_I PROGN
• Gingival hypertrophy (N/Y) LIGING HYPER
• TonsiUar enlargement (NormallLarge) I_ITONSILS
• Lymph nodes (N/Y - Details) I_I-I NODES
• Skin (Normal/Abnormal-details) I_j-I I SKIN
• Other OTHER EXAM
& RESPIRATORY SYSTEW
• Hearl sounds (Regular / Irregular) I_I-I, __l
• Munnur (N/Y details) 1_1-,1 ___J
• Chest auscultation ormal I Abnormal I -
AB ME
•
,.".....!<l<"'O...... .."... in eNS event form
• Comprehension (Normal/Abnormal-details) I_H ,leOMPREH
• Cranial nerves (Normal/Abnormal-details) ·I_j-I leRNL NS
• Peripheral nerves (Normal/Abnormal-details] ·.. I_I-1 PERI NS
• Reflexes (Normal/Abnormal-details) I_I-1 REFLEX
• Gait(NormaIlAbnormal-details) l_j-I IGAIT
seD Study Follow up 3
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SCD Study Nol_LU_1
PROFORMA FOR SICKLE CELL DISEASE STUDY - IN PATIENT
SCREENING
• Hospital ID number (lllD) · I_U_I_U_I_I HID
• Name 1 NAME
• Sex (M/F) ·I_! SEX
• Date ofbirth · ··U_I-I_U-U_I DOB
• Place of birth (District) 1 POB
• Name of mother 1 I MUMNAME
• Date of entry (DD-MM- YY) I-'_I-I_I_I-I_I_I DATE ENT
• Date oflast visit (DD-MM- YY) ········.·.·I_I_I-U_I-I_I_I DATELV
• Res ndent Se1flParentiGuardianiOther) RESPON
RESIDENCE INFORMATION
District ·..···.. ··..············.·······.····· 1 IDISTR
Contact tele hone number if available (NIY)................................ I-I ! 1 I I I I I I I IPHONE
G EXAMIN 0
• Temperature I_I_I. 1_j_loC TEMP
• Pulse rate I_I_I_I bpm PULSE
• Respiratory rate (per minute) I_j_1 breaths per min RESP
• Systolic blood pressure 1_1_1_lmmHg SBP
• Diastolic blood pressure I_I_j_lmmHg DBP
• Weig!!t gs) ................................................................................................. 1 1 1 1.1 IkgWEIGHT
LABORATORY INvESTIGATIONS ,
SAMPLES TAKEN (Please tick)
2m1s EDTA 2m1s serum separator
Blood slide Urine
Blood Culture Other
r CUKllliN SYMPTOM-HISTORY I
• Febrile Illness> 3 days (NIY -details) · 1_1 -I ICURR FEV
• Pain (NIY -details) ··················1_1-1 ICURR PAIN
• Anaemia (NIY -details) U -I CURR ANAEMIA
• Jaundice (NIY -details) ·······1_1-I CURR JAUNDICE
• CNS event(N/Y -details) ··········I_j -I CURRANAEMIA
• Dactylitis (NIY -details) I_I-I CURRDACTY
• Acute Chest illness (NIY -details) · I_I-I ICURR CHEST
• Fits (N/Y -details) ·.···1_1 -I ICURR FITS
• Additional histo.ry .
........................................................................................................................................................... CURROTHER
1 ATION
• Folic acid (N/Y - dose per day) I_I-II I FA
• Chloroquine (NIY - dose per week) 1_I-I ICQ
• Iron (NIY - dose) 1_1-1 IRON
• Other ·.. 1 OTHR MED
• Other 1 OTHR MED
SCD Study inpatient
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MEDICAL HISTORY
• Since the last admission, have you/your child had any of the Sickle cell crises below that required OPD
attendance or admission ? 1_1 SCD CRISIS
• Ifyes what was the total number since last visit (OPDIIPD) and what was the date oflast crisis?
NfY Date of last crises (MM-YY) Comments
Blood transfusion 1 1 BLOOD 1 U-I 1 1 BLOOD DATE
Dactylitis 1 IDAC 1 U-U 1 DACDATE
Painful crises 1 1 PAIN 1 U-I 1 1 PAIN DATE
fever for >3 days 1 1 FEVER 1 U-I 1 1 FEVER DATE
Acute Chest illness 1 1 CHEST 1 U-U 1 CHEST DATE
Convulsion 1 1 FITS I /_j-/_j I FITS DATE
Neurological deficit 1 1 NEURDEF 1 U-I 1 1 FITS DATE
Leg ulcers 1 ILIULCER 1 U-I 1 1 L/ULCER DATE
Priapism 1 IPRIAP 1 U-U IPRIAPDATE
1 1 OTHER 1 U-U 1 OTHER DATE
• Medical history of other Illness (NIY) I_j MHOTHER
• Details (Age at onset, Duration, Outcome) MH OTHER DETAILS
• Other related information of interest to attendin h sician OTHER
PHYSICAL EXAMJNATION ~
• Jaundice (Nil / Tinge/Moderate/Deep) I_j JAUN
• Pallor (N/Y) I_j PALL
• Bossing (NIY) I_I BOSS
• Prognathia (N/Y) 1_1PROGN
• Gingival hypertrophy (N/Y) ····..·..· UGING HYPER
• Tonsillar enlargement (NormallLarge) I_ITONSILS
• Lymph nodes (N/Y - Details) · 1_1-1 NODES
• Skin (Normal/Abnormal-details) 1_1-1 ISKIN
• Other tails OTHER EXAM
CHEST CARDIOVASCULAR & RESPIRATORY SYSTE
Heart sounds (Regular / Irregular) 1_1 RHYTM
• Murmur (N/Y - details) 1_1-1 MURM
• Auscultation Normall Abnormal) .
ABDOMEN
• Comprehension ( Normal/Abnormal-details) 1_1-1 _
• Cranial nerves (Normal!Abnormal -details) I_j-I I
Peripheral nerves (Normal!Abnormal -details) I_I-I ____j
• Reflexes (Normal/Abnormal-details) I_I-1 REFLEX
• Gait (NormallAbnormal-details) l_j-I IGAIT
SCD Study inpatient 2
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WORKING DIAGNOSIS
SCD Study NoLU_! ......
Issue/problem PROB Action ACT
1.
2.
3.
4.
5.
PR..QQRE_SSlNW_ARD_
......................................................................................................................................................................................
............................................. , " , .
......................................................................................................................................................................................
OVERALL ASSESSMENT
Issue/problem PROB Action ACT
1.
2.
3.
4.
5.
• Date of Discharge/Death ············.·······.·.I_U-I_j_I-I_U DISCHARGE DATE
• Diagnosis on Discharge 1 IDISCHARGE DIAGNOSES
• Follow up appointment (months) ··········································I_I_jAPPOINTMENT
• Date of next scheduled visit (DO-MM-YY) I_I_H_j_I-I_U DATE NEXT VISIT
• Other related information of interest to attending h sician OTHER
EXIT
• Excluded from study (N/Y) · · I_j EXCLUDED
• Refused consentfUnable to obtain sam Ie/other. REASON
• Initials of investigator I_I_j_1
seD Study inpatient 3
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WORKING DIAGNOSIS
SCD Study-Nol_U_I .......
Issue/problem PROB Action ACT
1.
2.
3.
4.
5.
_PR.OGRESS IN.,_WARD
............................................................................................................................................. , .
......................................................................................................................................................................................
., .
............................................. , " ,.." " , , ..
........................................................ " .
OVERALL ASSESSMENT
...,
Issue/problem PROB Action ACT
1.
2.
3.
4.
5.
• Date of Discharge/Death ···.· I_I_I-I_j_I-I_U DISCHARGE DATE
• Diagnosis on Discharge 1 IDISCHARGE DIAGNOSES
• Follow up appointment (months) I_I_jAPPOINTMENT
• Date of next scheduled visit (DD-Ml'v{-YY) I_I_I-I_I_I-I_I_j DATE NEXT VISIT
• Other related information of interest to attendin h sician OTHER
EXIT~ ~~~~~
• Excluded from study (N/Y) I_j EXCLUDED
• Refused consentJUnable to obtain sam Ie/other REASON
• Initials of investigator I_I_j_1
seD Study inpatient 3
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SCD Study Nol_I_I_I_1
PROFORMA FOR SICKLE CELL DISEASE STUDY - CNS EVENT
SCREENING
• Today's Date (DD-MM- YY) ..·· ··..·..········· ··..················......I_I_I-U_1-1_j_1 DATE TOD
• Name 1 INAME
• Sex (M/F) '" I_I SEX
• Date of birth I_j_I-I_I_I-I_I_1 DOB
• Nameofmother.................................................... MUMNAME
TYPEOFEVE~N_T __
• Convulsion (N/Y) I_I CONVUL
• Stroke (NIY) I_I STROKE
• Transient ischaemic attack (NN) I_I TIA
• Cranial nerve lesion (N/Y) I_I CRAN NERVE
• Mental/personality change (N/Y) l_j PERSON CHANGE
• Difficulty in walking (NIY) · I_I S CORD
• Other (not headache) (NN) .
• ········································11- 1OTHER
TATINGE ENT
• KnownlUknown I_I KNOWN
• Fever (NN) I_I PPT FEVER
• Painful crisis (NIY) I_I PPT PAIN
• Infection (N/Y) I_I PPT INF
• General anaesthetic (NN) ····· I_I PPT GA
• Pregnancy (NN) I_I PPT PREG
• Anaemia symptoms (NN) I_IIIPT ANAE
• Trauma (N/Y) I_I PPT TRAUMA
• Other IY CONVUL
____________________ ~Ntt.EUROLOGICHISTOR
Convulsions
• Has child ever had a convulsion? (N/Y-Type-) I_I-I_I_I CONVUL
• G: Generalized P: Partial PG: Partial becoming generalized
• lfPartial, side involved (RlL) I_I SIDE
• Duration (start to restoration) (hours/minutes) 1_1_1_1 : 1_1_1 EVENT DUR
• Loss of consciousness (N/Y) 1_1 EVENT LOSS OF CON
• Body tone (toniclflaccid) I_I EVENT TONE
• Was it associated with fever (NN) I_j FEB CON
• Ever had a fit NOT associated with a fever (N/Y) I_I NON-FEB CON
• Recurrent fits (NN) I_IREC FIT
• Date of first fit... I_I_I-U_I-U_I CON DATE 1
• Date of last fit... I_I_I-U_H_j_I CON DATE 2
• Number of fits in past 12 months I_j_I_1 CON NUM
• Are you/your child on anticonvulsants (N/Y) I_I-I IANTI CON
SCD Study CNS event
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SCD Study NOI_I_I_I_I
NeurologicaJ deficit
• Have you/your child ever noticed weakness of part of body ?(N/Y - Type) I_I-I_1 WEAK
• G: Generalised M: Monoparesis H: Hemiparesis P: Paraparesis F: Facial weakness
• IfPartial, Limb involved I_I LIMB
• Was it associated with loss of consciousness (NN) I_I CONC
• Date of weakness I_I_I-I_j_I-1_I_I DAT WEAK
• How long did weakness last? I-'_I_I Days DUR WEAK
Sleep bypopnoea
• Noisy breathing / snoring at night (NN -Duration) 1_1-1_1_lmonths OSA1
• Wake up at night due to difficulty in breathing (N/Y-Duration) 1 1-1 I [months OSAl
______ __:F:;.:..:AMILYHISTORY
• Handedness (Right/LeftJUndetermined) I-'-I _
• Sense of smell (Normal/Abnormal) 1-'_1 _
• Eye movements (Fullllmpaired - squint/nystagmus) I_I-I _
• Pupils (Normal/Abnormal> reaction to light) I-'-I_I-I _
• Facial Weakness (No/Yes)· ..·........ ·..·........ ·· ·..·· ·..·· ·..·..·..··· ··I_I-1 --=
• Uvula movement (Normal/Abnorrnal- Left/Right deviation) · I_I-1 1DVM
• Tonsillar enJargement (Normal/Large) I_I TONS
• Tongue deviation (No/Yes-Left/Right deviation) I I-I ITONG........................... _
• Other cranial nerve lesion (NIY) ........................................................ I. J-I _IOCN
r PERIPHERAL NERVES 1
Upper Limbs Lower Limbs
Bulk (Normal/Wasted-site) ULB LLB
Tone (Normal/Increased/Decreased) ULT LLT
Power (Normal/Decreased) ULP LLP
Reflexes Left R12ht
Biceps (0/+/++/+++) BL BR
Triceps (01+/++1+++) TL TR
Knee (01+1++/+++) KL KR
Ankle (0/+1++/+++) AL AR
Plantars (Up/Down/Equivocal) PL PR
• Cerebellar function (Normal/Abnormal) I_I-I ICER
• Gait (Abnormal/Normal) I_I-I IGAIT
• Foqs sign (NIY)· I_I-I IFOQ
• Sensory deficit (N/y) ·..· l J-l JSEN
OVERALL ASSESSMENT
Issue/problem PROB Action ACT
1. CNS1
2. CNS2
3. CNSJ
• Initials of investigator I_I_I_I
SCD Study eNS event 2
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Date oftodaYU_I-I_U-I_I_1 ...................... SCD Study NoLU_I_1
RESIDENCE FORM FOR SICKLE CELL STUDY
To beftlled in ifresidence information has changed
• Hospital Identification number I_U_I_l_LIHID
• Nameofpadent _.................................... INAME
• Set (MIF) .....•..•.•••.••••.••.•••••••••••.•••••_ I_ISEX
• Date of blrth. I_I_,-I_I __I-I_I_IDOB
• Name ofmother/Guanilan..................... IMUMNAME
• DbtrictlLocadon DISILOC
• Division 1 IDIVISION
• WardlVWage 1 IWARD/VILL
• Ten cell leader 1 ITENCELL
• Nearest:
• School···· ..· · · I, --'
• Health post '- --'
• Bus stage 1 _
• Neighbour 1 INEIGHBOUR1
• Telephone Number (NIY -Details) U-U_I_U_I_U_I__I_ITEL
• Investicators initials 1_1_1
Date ortoday 1_I_H__j_I-I __I_1 ........................ SCD Study Nol_U_U
RESIDENCE FORM FOR SICKLE CELL STUDY
To befllled in ifresitiolce information has changed
• Hospital Identification number I_I_I_I_l_I_IHID
• Nameofpadent 1 INAME
• Se); (MIF) I_ISEX
• Date of blrth. I_I_I-I __I_I-I_I IIDOB
• Nameofmother/Guanilan 1 IMUMNAME
• DlstrictlLocadon DISILOC
• Division 1 DIVISION
• WardlVWage 1 IWARD/VILL
• Ten cell leader 1 ITENCELL
• Nearest:
• School................................................. SCHOOL
• Health post '- --'
• Bus stage I IBUSSTOP
• Neighbour 1 1 INEIGHBOUR1
• Telephone Number (NIY -Details) I_I-I_I_I_I_I_U __I_U_ITEL
• Investigators lnltials ····..··..•....... I_I_I
residence form
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APPENDIX III LABORATORY PROCEDURES
PROCESSING OF SCD SAMPLES
SAMPLES TO BE RECEIVED FROM SCD PATIENTS
Entry visit Scheduled visit Admission
EDTA (pink) 4 mls EDTA (pink) 2 mls EDTA (pink) 2 mls
EDTA (pink) 2mls Blood Film 2 slides Blood Film 2 slides
Serum separator Iml vials Serum separator Iml
Blood culture 4mls
PROCESSING OF EDT A SAMPLES
EDT A sample - 3mls in HAEMATOLOGY
1. Prepare two blood films
a. Malaria parasitaemia - Giemsa stained. mps/200wbc
b. Reticulocyte counting - stained by new methylene blue. See protocol for
reporting
2. EDT A sample: Perform a FULL BLOOD COUNT using the haematology analyser and
record the result onto the accompanying form and into the laboratory counter book.
3. EDTA sample: perform HB ELECTROPHORESIS by cellulose acetate method (see
protocol). If electrophoresis is not done immediately, prepare the haemolysate.
Preparation of haemolysate
1. Place IOOJ.lIof whole blood into eppendorf tube
2. Wash the whole blood with large volume of normal saline
3. Mix well with vortex
4. Centrifuge at 3000rpm for 3 minutes
5. Pour out the normal saline
6. Repeat step 2-5 three times
Commercially prepared haemolysing reagent
1. Place 60J.llof haemolysate reagent into eppendorf tube
2. Add lOJ.lIof prbc
3. Mix well with vortex
4. Spin for 3000rpm for 3 minutes
Alternate method of haemolysis using distilled water
1. Place 60J.lIof distilled water into pre labelled eppendorftube
2. Add 30J.lIofprbc. (lvolume RBC: 2 volume distilled water)
3. Add chloroform (2 volume lysed RBC: I volume of chloroform)
4. Centrifuge at 3000rpm for 10 minutes to remove stroma
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PROCESSING OF EDT A SAMPLES
1. Centrifuge @ 3000rpm for 10 minutes.
2. Using a PI000 Gilson Pipette, aliquot the plasma into a pre-labelled 2ml alpha apex vial.
a. Store for immunological studies-malaria, parvovirus, pneumococcus and possible iron
studies
3. Transfer the buffy coat, for DNA storage, into a separate 2ml-freezing vial.
a. Store for store for sickle genotyping.
4. Transfer 2 drops of packed red cells onto pre-labelled filter paper.
a. Store for Hb quantification and sickle genotyping.
5. Wash the RBC two times with Normal saline.
a. Store for malaria PCR.
PROCESSING OF FILTER PAPER SAMPLES
1. Cut filter paper into triangles
2. Label with patients number and date
3. Place two drops of blood from packed cells/whole blood onto filter paper
4. Filter paper samples are left to air dry for 48 hours.
5. Each filter paper sample is wrapped in paper and will be stored at-4.
6. HbF and HbA2 quantification by HPLC will be done at KCL, UK until HPLC is set up at
MUCHS.
7. This sample can also be used for sickle genotyping.
PROCESSING OF SERUM SEPARATED SAMPLES IN SPL LAB
1. Perform a BIOCHEMISTRY SCREEN using the clinical chemistry analyser
2. Print out the results and record them in laboratory record book.
3. Store the Serum at
4. This will be processed for HI V, Hepatitis Band C in microbiology laboratory.
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PROCESSING OF BLOOD FROM CONTROL POPULATION
SAMPLES TO BE RECEIVED FROM CONTROLS
Haematolo
le
PROCESSING OF EDTA SAMPLE
1. Prepare two blood films
a. Malaria parasitaemia - Giemsa stained. mpsl200wbc. (See protocol for
reporting)
h. Reticulocyte counting - stained by New methylene blue. (See protocol for
reporting)
2. Transfer 2 drops of packed red cells onto pre-labelled filter paper.
a. Store for Hb quantification and sickle genotyping.
3. Perform a FULL BLOOD COUNT using the haematology analyser and record the result
onto the accompanying form and into the laboratory record sheet.
4. Centrifuge @ 3000rpm for 10 minutes.
5. Using a PlOOOGilson Pipette, aliquot the plasma into a pre-labelled 2ml alpha apex vial.
a. Store for immunological studies-malaria, parvovirus, pneumococcus and iron
studies
6. Transfer the buffy coat, for DNA storage, into a separate 2ml-freezing vial.
a. Store for store for sickle genotyping.
7. Wash the RBC two times with Normal saline.
8. Perform HB ELECTROPHORESIS by cellulose acetate method (sec protocol)
a. If electrophoresis is not done immediately, prepare haemolysate
b. Store prbc for malaria PCR.
PROCESSING OF SERUM SEPARATED SAMPLES
1. Perform a BIOCHEMISTRY SCREEN using the clinical chemistry analyser
2. Print out the results and record them in laboratory record book.
3. Store the Serum at --4°C.
4. This will be processed for HIV, Hepatitis Band C in microbiology laboratory.
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FORM FOR STORAGE OF SAMPLES
RACK NUMBER
A. B. C. D. E. F. G. H. I. J
1.
2.
3.
4.
5.
6.
7.
8
9
10.
A. B. C. D. E. F. G. H. I. J
Place T Temperature I
Freezer I Nature I
Intended
use
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BLOOD SLIDE EXAMINATION FOR MALARIA PARASITES
PRINCIPLE OF GIEMSA STAINING METHOD
Giemsa stain is a Romanowsky stain which has basic and acidic stain components. The basic
component which is eosin stains the nucleus of the malaria parasite giving it a pinkish colour. The
acid component which is methylene blue stains the cytoplasm giving it a bluish colour. The red
blood cells stain greyish pinkish. Neutrophil nucleus stain pinkish while monocytes and
lymphocytes nucleus stain blue. Parasites are examined qualitatively and quantitatively. During
the staining period the red cell in the thick film lyses releasing the parasites. The thin film is
alcohol fixed hence the parasite remain in the red cells
SPECIMEN:
Whole blood. Or Capillary blood All thick blood smears shall be prepared using whole blood
directly from the syringe or from a finger prick.
EQUIPMENT
Microscope, Coplin jars, Slides - grease-free and labels. Slide racks, Measuring cylinders of
50 mls and 100 mIs, Forceps, Para film and Scissors, Filter paper, Timer, lOOml measuring
cylinder, Filter papers, Slides storage boxes
REAGENTS
Absolute methanol (GPR), Giemsa stain - Stock solution, Oil immersion, Buffer pH 7.2, 70%
v/v industrial methylated spirit, 10% Giemsa stain.
PROCEDURE
1. The malaria blood smears are left to completely air dry before staining.
2. Fix the thin smears and stain only one slide per patient using 10% giemsa stain for 10 to
15 minutes by dipping the slides placed back to back in staining jar containing the stain.
3. Remove the slide and gently wash off the staining by dipping the slides in a beaker
containing water.
4. Place the slides in a slide rack to drain and dry.
5. Using 40x objective to check the staining pattern, cell and parasites morphology and their
distribution is satisfactory. Add oil immersion on the film then move the 100x objective
and focus
6. Using power 100 examines the thick film for the presence of parasites and count the
number of parasites per white cells.
7. Examine at least 100 high-powered microscope fields for parasites before the slide is
reported negative.
8. Count the number of parasites against the cells depending on the thick film per 200 WBC.
If the counted parasites are greater than SOObefore 200 wbc are counted, stop the count
after counting all the parasites in that field, then report i.e. S64 parasites per 41 wbc
REPORTING OF RESULTS.
The final report shall be the number of counted parasites per 200 WBC.
SOURCE OF ERRORS
1. Anticoagulated blood may be washed away during staining or when washing the slide.
2. Over- staining can also affect the stain take- up of parasites.
3. The quantity of blood should also be just enough not more or less.
RETICULOCYTE COUNT
INTRODUCTION
Reticulocytes are young blood cells, newly released from the bone marrow, which contains two or
more ribosomal RNA (blue staining small material. When the cells are exposed to certain dyes
like brilliant cresyl blue or new methylene blue, the ribosomes are precipitated and stained by the
dye to appear as a reticular network while the cells are still alive when exposed. This is referred to
as supravital staining. With New Methylene Blue (NMB), red cells stain a pale greenish-blue
while the reticulum stain bluish-purple.
Apparatus
20J..LIpipettes, 75 x 10 mm test tubes, Water bath (adjusted to 37°C), Thermometer, Glass slides,
Microscope, Spreader.
Reagents
• New Methylene Blue, Oil immersion
SAMPLE
Fresh EDTA blood.
PROCEDURE
1. Deliver 20J..LIof patient's blood into a 75xlOmm glass or plastic tube.
2. Add 20 I ofNMB dye to the patient's blood and mix.
3. Incubate the mixture in a water bath at 37°C for 10 minutes.
4. Re-suspend the red cells by gentle mixing.
5. Make a thin film on a glass slide and air dry.
6. Examine the film using xl 00 objective with oil immersion.
COUNTING RETICULOCYTES:
The amount of reticulum in a reticulocyte varies from a large clump in the most immature cells
(group 1 reticulocyte) to a few granules in the most mature forms (group IV reticulocytes). The
minimum requirement varies from a single dot, to two or three dots to a maximum network.
The number of cells counted to achieve an acceptable degree of reproducibility is 1000 cells. The
reticulocyte count is stable with storage of EDTA - anticoagulated blood for up to 24 hours at
room temperature and for several days at 4°C. A common mistake is to make the film too thin.
CALCULATIONS:
Reticulocytes percentage (%) m __ Number of reticulocytes counted x 100
1000 number RBC 1000 cells.
NORMAL RANGE.
• Adult and children -------------------- 0.5 to 2.5 %
• Infant (full term, cord blood----------- 2 to 6 %
SOURCES OF ERROR.
• Wrong sample used.
• Poor staining technique.
• Poor spreading which leads poor distribution of reticulocytes.
• Poor counting technique.
HAEMOGLOBIN ELECTROPHORESIS
PRINCIPLE
The sample is applied to the medium and under the effect of the electric field, groups of particles
with similar charge, size and shape characteristics migrate at similar rates. This results in the
separation of the particles into bands.
REAGENTS
Supreme-Heme Buffer, Haemolysate reagent, Ponceau S, 5 % Acetic Acid, Absolute methanol,
Clearing solution, Hemo control
APPARATUS
Graduated pipette, Timer, Eppendorf tubes, 5 J.!lmicrodispenser , Hellena sample well plate,
Blotter pads, Cellulose acetate paper, Hellena sample applicator, Power pack, Electrophoresis
tank, Wicks, Glass slides, Staining jars, Bufferizer, Microhood
SPECIMEN
Whole blood collected in EDTA tubes. May be stored up to one week at 2-6°c or Haemolysate
PREPARA TION OF SAMPLE
1. Place 100J.!1of whole blood into eppendorf tubes
2. Label the eppendorftubes 1,2,3,5,6,7. Leaving number 4 for the control
3. Wash the whole blood with large volume of normal saline
4. Mix well with vortex
5. Centrifuge at 3000rpm for 3 minutes
6. Pour out the normal saline
7. Repeat step 2-5 three times
8. Place 60J.!1ofhaemolysate reagent to eppendorftubes (150 ul haemolysate reagent)
9. Add 1OJ.!1ofprbc (20 ul of prbc)
10. Mix well with vortex
11. Spin for 3000rpm for 3 minutes
NB: -Haemolysate may be stored at -20°c for one year or more.
Alternate method of haemolysis using distilled water
1. Place 60J.!1of haemolysate reagent to eppendorf tube
2. Add 30J.!1of prbc. (1volume RBC: 2 volume distilled water)
3. Add chloroform (2 volume lysed RBC: I volume of chloroform)
4. Centrifuge at 3000rpm for 10 minutes
5. Using a P20 Gilson pipette take 5-7J.!1of clear red haemolysate which is between a
layer of chloroform and stroma
Haemolysates
1. Dilute 40J.!1of 10g/dl haemolysate with 150J.!1haemolysing reagent
Control
1. Centrifuge sample of control at 3000rpm for 5 minutes.
2. Aliquot the serum using a PIOOGilson pipette
3. Wash the red blood cells 3x with large volumes of normal saline.
4. Add lpart of packed cells to 6 parts haemolysate reagent Or to 20 ul of prbc add 150
J.!lhaemolysate reagent
5. Mix well and allow to stand for 5mins.
PRE PARA TION OF ELECTROPHORESIS CHAMBER
1. Place lOOmIs of TEB/Supreme heme buffer in each of the outer buffer compartments. The
centre 2 compartments should be empty.
2. Wet 2 chamber wicks in the buffer
3. Place one along each divider ensuring that they make good contact with the buffer.
4. The buffer in the tank should be changed every week.
PREPARATION OF CAM PLATES
1. Cut the top left hand comer of CAM to indicate sample position 1.
2. Place in soaking rack
3. Pour buffer from lower reservoir into top reservoir ensuring that you have covered the hole in
the top reservoir.
4. Place the soaking rack into the empty lower reservoir and quickly replace the top reservoir.
5. Leave it to slowly soak with buffer trickling into bottom reservoir.
LOADING THE SAMPLE
I. Place 5JlI - 7JlI of the prepared patient haemolysate in the wells of the sample plates using a
Gilson's pipette.
2. Place 5JlI - 7JlI of commercially prepared control into sample well plate (position 4)
3. Cover the sample well plate with a glass slide or cover slip if the samples are no to be used
within 2 minutes.
4. Prime the applicator by depressing the tips into the sample wells 3 or 4x.
5. Apply this loading to a blotting paper. NB-Priming the applicator makes the second loading
much more uniform.
6. Remove the CAM from the buffer with the fingertips
7. Blot twice between two layers of clean blotting paper. Do not allow the CAM to dry
8. Place the CAM (CAM side up) on the aligning base with the cathodal end on the indicator
line. (This will give a sample application point of2.5cm from the cathodal end of the plate.)
9. Load the applicator by depressing the applicator tips into the sample wells 3-4x.
10. Promptly transfer the applicator to the aligning base. The applicator should be used within
15seconds of being loaded.
11. Press the button down and hold it for 5 seconds.
ELECTROPHORESIS
1. Place the CAM across the bridges with the plastic side up
2. Place two glass slides across the strip to maintain good contact. Make sure the slides do not touch
the wicks
3. Switch on the current at 350V for 25 minutes.
4. Remove the plates from the electrophoresis chamber
STAINING
1. Stain with Ponceau S stain for 10 minutes.
2. Decolourise the CAM by washing in 2 successive washes of 5% acetic acid.
• I st 2minutes
• 2nd 2 minutes
3. Dehydrate the plates in 3 successive washes of absolute methanol for 2mins
4. Place the plates in clearing solution for 10 minutes then drain off excess solution
5. Place the plates with CAM side up on blotter pad under the micro-hood for IOmins.
6. Place the labels on the glossy/plastic side of the now clear CAM
7. Interpret the position of the bands.
EXPECTED VALVES:
At birth, the majority of haemoglobin in the erythrocytes of the normal individual is foetal
haemoglobin, HbF . At the end of the first year of life and through adulthood, the major
haemoglobin present is HbA with up to 3.5 % HbA2 and less than 2 % HbF.
ANODE (+)
A
F
S (D, G, Lepore)
C (E, 0, A2)
+++ Origin
CATHODE (-)
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) FOR DIAGNOSIS OF
HAEMOGLOBINOPATHIES
INTRODUCTION / PRINCIPLES
The Bio-rad variant beta thalassaemia short program (VARIANTTM l3-thalassaemia Short
Program) is intended for the separation and area percent determinations of haemoglobins A2 and F
and as an aid in the identification of abnormal haemoglobins in whole blood using ion-exchange
high performance liquid chromatography (HPLC). The VARIANTTM l3-thalassaemia Short
Program is intended for use only with the Bio-Rad VARIANT Haemoglobin Testing System.
The l3-thalassaemia Short Program utilises the principles of cation-exchange high performance
liquid chromatography (HPLC). Specimens are sequentially injected into the analysis stream at
6.5-minute intervals for a throughput of 9 samples per hour. Two dual-piston pumps and a pre-
programmed gradient control the elution buffer mixture passing through the analytical cartridge.
The ionic strength of the elution buffer mixture is increased by raising the percent contribution of
elution buffer 2. As the ionic strength of the mixture increases, more strongly retained
haemoglobins elute from the analytical cartridge. A dual-wavelength filter photometer (415 and
690 nm) monitors the haemoglobin elution from the cartridge, detecting absorbance changes at
415nm. The 690 nm secondary filters corrects the baseline for effects caused by mixing buffers
with different ionic strengths. Changes in absorbance are monitored and displayed as a
chromatogram of absorbance versus time. Analysis data from the detector is processed by the
built-in integrator and printed on the sample report.
To aid in the interpretation of results, windows (e.g., ranges) have been established for the most
frequently occurring haemoglobins based on their characteristic retention times. The retention
time is the elapsed time from the injection of the sample to the apex of a haemoglobin peak. Each
of these common haemoglobin variants i.e. S, C, D Punj has a characteristic retention time. Minor
differences in the separation efficiency of individual analytical cartridges are corrected by the use
of the Haemoglobin A2/F (HbA2/F) Calibrator. At the end of each sample analysis, a copy of the
chromatogram and report data is automatically printed. The report table includes the corrected
area percent for haemoglobins A2 and F for all subsequent samples in the run.
The Hb A21F Calibrator which has assigned values (in units of area percent of total haemoglobin)
for both haemoglobins A2 and F is analysed at the beginning of each run. Analysis of the
calibrator yields separate calibration factors for both haemoglobins A2 and F. Calibration factors
are the calculated ratio of the assigned value (value imprinted on the labelling) to the observed
value (value determined per run). These calibration factors are applied to the observed area
percent for haemoglobins A2 and F in all subsequent analyses in the run. The calibration corrects
for the resulting differences in the allocation of area to the haemoglobin A2 and F peaks.
EQUIPMENT
Bio-Rad II Variant HPLC analyser, PC, Printer, Sample racks, Automatic pipettes to deliver 5jJ,
250>1, 1 ml and IOml, Micro-vials and micro-vial adapters
REAGENTS
Bio-Rad VARIANT Beta Thalassaemia Short Reorder Pack
E h kac pac contams:
Storage temperature
Elution buffer 1 (A) Room Temperature (I5-30DC)
Elution buffer 2 (B) Room Temperature (I5-30DC)
Whole blood primer 2 - 8DC
Wash solution Room Temperature (IS-30De)
Analytical cartridge - 2 supplied per kit CD Room Temperature (IS-30De)
I ,5ml plastic vials - 500 supplied per kit Room Temperature (IS-30DC)
Haemolysis reagent Room Temperature (IS-30De)
HbA2/F calibrator set/Diluent set 2 - 8DC
ROMeard Room Temperature (I5-30De)
REQUIRED ITEMS
Latex medical gloves
Disposable towelettes
Micropipettes S~L, ImL, 10mL
Transfer pipettes
Deionized water
SJ'riIlges 20mls
ADDITIONAL ITEMS
Haemoglobin A2 control
Autodiluter, for sample preparation
Variant Thermal printer paper ( 12 rolls)
PROCEDURES
Preparation of reagents
General procedures
1. Wear latex gloves during reagent preparation procedures
2. Do not use reagents after their labelled expiration dates or mix different reagent lots
3. Do not use controls, calibrators or prime if the lyophilized pellet is brown or the vial is broken
4. Adherence to the protocol specified is necessary to ensure proper performance of this product
S. If aberrant results are obtained contact Bio-Rad technical services
Elution buffers, wash solution and analytical cartridges
To install or change elution buffers, wash solution and analytical cartridges; follow the procedures
described in the VARIANT operation manual section 3.0
HbAz/F Calibrator
1. Reconstitute the HbA2/F Calibrator by adding 10mL HbA2/F Calibrator diluent per vial
2. Swirl gently to dissolve and ensure complete mixing
3. Allow calibrator to stand for 10 minutes at 15 - 30°C. reconstituted calibrator is stable for 10
days when stored at 2-8°C.
4. When reconstituted, label vial with date of reconstitution, expiry date and sign vial.
Haemoglobin A2 control
The following controls should be run at the beginning and end of each group of patient specimens:
1. EDTA blood from known normal subject (HbF 1-2%, HbA21.8-3.2%)
2. Bio-Rad Lyphocheck HbA2 Control 1
3. Bio-Rad Lyphocheck HbA2 Control2
Each vial is reconstituted with 1ml distilled water. Stand at IS-30DC for 10 minutes.
Reconstituted lyphochecks are stable for 21 days when stored at 2-8DC.
When reconstituted, label vial with date of reconstitution, expiry date and sign vial.
Haemoglobin primer set
Use the whole blood primer at the beginning of each run to condition the cartridge for analysis
1. Add 1 ml of deionized water to vial,
2. Swirl gently to dissolve and ensure complete mixing
3. Allow to stand for 10 minutes at IS-30De.
Reconstituted primer is stable for 21 days when stored at 2-8DC.
When reconstituted, label vial with date of reconstitution, expiry date and sign vial. Note: each
primer used up in one go.
SPECIMEN
EDTA anticoagulated blood sample - SJ.lL
Patients specimens are stable for 7 days when stored at 2-8DC
Sample preparation
1. Pipette SJ.lLwhole blood from each patient sample into separate l.SmL sample vials
2. Add 1.0mL ofhaemolysis reagent to each sample vial
3. Vortex sample at medium speed.
4. Place the sample vial into the VARIANT. Note: This will be in position 5 in variant sample
tray
5. Patient haemolysates are stable for 24 hours when stored at 2-8DC
Method selection
1. Press POWER
a. The system performs a 5-minute warm up program, after which the system enters
IDLE set up. The RUN SETUP screen is then displayed.
2. Press the TEST MENU key followed by' l' to select the ~ thalassemia short program.
3. Press ENTER to confirm the selection
Preparation of analyser prior to run
Check buffer and wash solution reservoir levels and printer paper supply. Note: Do not mix
components of different batches or kits.
1. When the machine is in stand-by mode:
• Flush piston/seal wash port: open port half a tum, counter clockwise
• Insert lOml distilled water using a disposable syringe.
• Close port.
• Check for leaks; tighten any connections showing evidence of leakage.
• Wipe up any spillage.
2. To put the machine into active/ready state click on the top left hand side box which says V2-
BTHAL INACTIVE'. The communication box will appear and one left click on the return
button will put the machine in a ready state and perform the auto warm-up operation. You will
be asked:
Q: Do you want to perform automatic warm-up operation?
A: Yes
3. Each day the maintenance/cleaning log MUST be filled in by the operator
4. Place the laboratory number of the sample onto the micro-vial. Place the sample vials into the
appropriate positions in the sample rack and place the rack on the analyser.
Run Set Up
1. Prepare patient samples as outlined above
2. Transfer 250J..lLof each of the following reconstituted reagents into sample vials and place in
d Istate position on vanant sample tray:
Well# Reagent
STAT well Haemoglobin primer
1 Deionised water
2 HbA2/F Calibrator
3 Normal control
4 Abnormal control
5 to N* Patient haemolysates
N+l Normal control
N+2 Abnormal control
3. Initiate analysis:
The machine will be in the ready state (see preparation of analyser prior to run) so click onto the
box on the left hand side of the screen which says RUN. Make sure you are in the work list screen
and then clear the previous work list. Click onto the start button and click start again then the run
will activate.
4. Post-analysis:
The calibration response factors for HbA2 and F are automatically calculated. The calibration
response factors are used in the calculation of area percentages for HbA2 and F for all subsequent
analyses in the run.
CALIBRATION REPORT
F I Response factor: 0.97
A2 I Response factor: 0.93
If the calibration response factor for either HbA2 or HbF is less than 0.80 or greater than 1.20, the
system prints an error message and automatically aborts the run. In such cases, contact Bio-Rad
technical Service
5. At the completion of each cycle, the system automatically initiates a five-minute WASH
cycle. At the completion of wash cycle, the system enters into IDLE status
INTERPRETATION OF CHROMATOGRAMS
1. Check water blanks show a flat, straight line.
2. Check baselines on samples analysed are flat.
3. Check that controls are within given ranges.
4. Check the total area of each sample analysed is within 1-4 x 106.
Note: If any of the above are unsatisfactory, individual tests or the whole run will have to be
repeated.
5. Record chromatography results against patient's demographics on worksheet. Typical
examples of haemoglobin patterns are recorded as follows:
NAHD
A+S
A+C
A+ fraction co-eluting with A2
A+ A2 variant
Record the percentages found of Hb A2lHb F and any variant fraction.
6. After reading and recording the values, sign the worksheet. The results must be checked by a
senior member of staff. The senior must also sign the worksheet as having checked the data.
EXPECTED RESULTS / RANGE (S)
Normal haemoglobin pattern: No evidence of a haemoglobin variant. (Hb A detected as the major
f ti t)rae Ion presen
Normal levels Variant maximum reportable ranae
Normal Hb Az 2.2 - 3.3% 13%
Normal Hb F Less than 1% 40%
Patient state Hb Azlevel HbF level
Heterozygous f3-thalassemia 4-9% 1-5%
Homozygous f3-thalassemia Normal or increased 80-100%
Heterozygous HPFH <l.5% 10-20%
Homozygous HPFH Absent 100%
INTERPRET ATION
Detection of a haemoglobin variant requires second line testing in either heterozygous, compound
heterozygous or homozygous conditions. Borderline Hb A2 values (3.4 -3.7%) may require
second line testing and results must be referred for comment. Elevation of HbA2 is diagnostic of
J3-thalassaemia trait, but may also be found in unstable p-globin chain variants. If differentiation is
required, heat stability testing must be undertaken. Elevation of Hb F may be indicative of a-
thalassaemia trait and further testing is indicated if the elevation of F is accompanied by
microcytic, hypochromic indices.
REPORTING I VERIFICATION I PRINTING
Enter haemoglobin type, A2 and F results. See reporting SOP -Interpretation and verification is
undertaken by senior personnel.
